"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOU_PERUGIA",2000,8,8,1.625,0.375,0.5,0.375,1,0.75,0.8,0.75,0.125,1,3,2,0,3,0.38,0.25,0,0.38,25.12,0.554256742711635,NA,0.125,0.625,0.44,0,0,0,"GIUSEPPE SCHILLACI;SERGIO PEDE;ANGELO MARTIGNETTI;L. R. PASTORE;CRISTINA CASCIARI;E. BUONCRISTIANI;S. RAGOSA;MOHADDESE SOKUTI NASIMI;CARLA COVARELLI;LEONELLA PASQUALINI;EMANUELA MENCAGLIA;LEONE DE MAGISTRIS C;G. POLICANI;S. CRISTALLINI;F PARLANI;PAOLA DI GIULIO;G BENEMIO;PAOLO G. CASALI;P. VERDECCHIA;PAGANELLI MT","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DEL FAVERO A;GIUSEPPE SCHILLACI;SERGIO PEDE;CARLO PORCELLATI;PAOLO VERDECCHIA;GIANPAOLO REBOLDI;CRISTINA CASCIARI;LEONELLA PASQUALINI;G. POLICANI;S. CRISTALLINI;PAOLO FILIPPONI;GAETANO VAUDO;ELMO MANNARINO;FRANCO EVANGELISTA;M.F SCHIFINI;P. VERDECCHIA;P GARINEI;LEONE DE MAGISTRIS C;G BENEMIO;P. VERDECCHIA","1;0.51;0.34;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14;0.14","P. VERDECCHIA;PAGANELLI MT;DEL FAVERO A;P.M. ANGELA;C. PORCELLATI;ELMO MANNARINO;CARLO PORCELLATI;PAOLO VERDECCHIA;P. VERDECCHIA;P GARINEI;F. ROILA;SIMONETTA BULLETTI;U. BUONCRISTIANÍ","1;1;1;1;1;1;1;1;1;1;1;1;1","DEL FAVERO A;CARLO PORCELLATI;PAOLO VERDECCHIA;ELMO MANNARINO;P. VERDECCHIA;P GARINEI;P. VERDECCHIA;PAGANELLI MT;C. PORCELLATI;U. BUONCRISTIANÍ;P.M. ANGELA;F. ROILA;SIMONETTA BULLETTI","1;0.2;0.2;0.17;0.17;0.17;0.14;0.14;0.14;0.12;0.04;0.04;0.04","GIUSEPPE SCHILLACI;P. VERDECCHIA;ELMO MANNARINO;FRANCO EVANGELISTA;GAETANO VAUDO;LEONELLA PASQUALINI;SERGIO PEDE;ANGELO MARTIGNETTI;B. MASSIDDA;DANIELA DE CANDIS;ELISABETTA CAMPORA;EMANUELA MENCAGLIA;ENRICO CORTESI;ENZO BALLATORI;F. ROILA;GLORIA BARACCO;L. R. PASTORE;L. ZODA;LISA LICITRA;MARCELLO TAMBURINI","136;115;86;86;86;86;50;37;37;37;37;37;37;37;37;37;37;37;37;37","P. VERDECCHIA;ELMO MANNARINO;F. ROILA;P.M. ANGELA;SIMONETTA BULLETTI;C. PORCELLATI;P GARINEI;CARLO PORCELLATI;PAOLO VERDECCHIA;PAGANELLI MT;DEL FAVERO A;U. BUONCRISTIANÍ","115;86;37;37;37;29;25;21;21;3;0;0","P. VERDECCHIA;C. PORCELLATI;CARLO PORCELLATI;ELMO MANNARINO;F. ROILA;P GARINEI;P.M. ANGELA;PAGANELLI MT;PAOLO VERDECCHIA;SIMONETTA BULLETTI;DEL FAVERO A;U. BUONCRISTIANÍ","2;1;1;1;1;1;1;1;1;1;0;0","MEDICINE;BIOLOGY;PSYCHOLOGY","8;2;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;PATHOLOGY;ANESTHESIA;BIOMEDICAL ENGINEERING;CLINICAL PSYCHOLOGY;ECOLOGY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;MICROBIOLOGY;NURSING;RADIOLOGY;UROLOGY","6;3;3;2;1;1;1;1;1;1;1;1;1;1","BLOOD PRESSURE;BODY MASS INDEX;AMBULATORY;ANEURYSM;ANTIBIOTICS;ASYMPTOMATIC;BONE REMODELING;BONE RESORPTION;CANCER;CAROTID ARTERIES;CATHETER;CHEMOTHERAPY;CONFOUNDING;CONTAMINATION;DISEASE;DISINFECTANT;EXTERNAL ILIAC ARTERY;FEMUR;ILIAC ARTERY;INTERNAL ILIAC ARTERY;MUSCLE HYPERTROPHY;OSTEOPOROSIS;PERIOPERATIVE;PERITONEAL CAVITY;PERITONITIS;PUBLIC HEALTH;QUALITY OF LIFE (HEALTHCARE);SUBCLINICAL INFECTION","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DIASTOLE;AMBULATORY BLOOD PRESSURE;BACTEREMIA;BONE DENSITY;BONE MINERAL;COMMON CAROTID ARTERY;CONTINUOUS AMBULATORY PERITONEAL DIALYSIS;ESSENTIAL HYPERTENSION;FEMORAL NECK;INTIMA-MEDIA THICKNESS;LEFT VENTRICULAR HYPERTROPHY;NEUTROPENIA;QUALITY OF LIFE RESEARCH","2;1;1;1;1;1;1;1;1;1;1;1;1","SYSTOLE","2","HYPERTENSION;HUMANS;HYPERTROPHY, LEFT VENTRICULAR;FEMALE;HEART VENTRICLES;MALE;MIDDLE AGED;CLODRONIC ACID;ANEURYSM, RUPTURED;BACTEREMIA;BACTERIA;OSTEOPOROSIS;PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY;ADULT;AGED;ANTIHYPERTENSIVE AGENTS;BLOOD PRESSURE;BLOOD PRESSURE MONITORING, AMBULATORY;BONE DENSITY;CAROTID ARTERIES","11;8;7;5;5;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2","ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;MANAGEMENT OF FEBRILE NEUTROPENIA IN CANCER PATIENTS;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;OSTEOPOROSIS;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY","1;1;1;1;1;1;1;1","HYPERTENSION;BLOOD PRESSURE;SYSTOLE;ANEURYSM RUPTURE;ARTERIAL STIFFNESS;BACTEREMIA;BACTERIAL IDENTIFICATION;BONE MINERAL DENSITY;BONE REMODELING;BONE RESORPTION;CAROTID INTIMA-MEDIA THICKNESS;DIASTOLIC FUNCTION;DISINFECTANT;ESSENTIAL HYPERTENSION;EXTERNAL ILIAC ARTERY;HEALTH-RELATED QUALITY OF LIFE;INTERNAL ILIAC ARTERY;INTIMA-MEDIA THICKNESS;LEFT VENTRICULAR FUNCTION;NEUTROPENIA","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BLOOD PRESSURE;LEFT VENTRICULAR;ARTERIAL WALL;BACTEREMIA MANAGEMENT;BONE MASS;CANCER PATIENTS;CLINICAL RELEVANCE;CLODRONATE ADMINISTRATION;CONTINUOUS CLODRONATE;DEFINING QUALITY;DIAGNOSED ESSENTIAL;ESSENTIAL HYPERTENSION;HOUR BLOOD;ILIAC ARTERY;INTERMITTENT VERSUS;INTERNAL ILIAC;ISOLATED RUPTURE;LIFE DOMAINS;LOW BONE;MULTICENTRE SURVEY;NEUTROPENIA APPROACHES;NEWLY DIAGNOSED;OFFICE UNDERESTIMATION;ONCOLOGY IGEO;POSTMENOPAUSAL WOMEN;SUBCLINICAL LEFT;SYSTEMIC HYPERTENSION;TREATED HYPERTENSION;TWO-WAY CONNECTION;USUAL BLOOD","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LV MASS;FEMORAL IMT;LV HYPERTROPHY;BLOOD PRESSURE;MM HG;PRESSURE MM;AMERICAN JOURNAL;ANALYZED CAROTID;ARTERIAL SITES;ARTERIAL WALL;ARTERIES HIGH-RESOLUTION;B-MODE ULTRASOUND;CAROTID IMT;CLINIC BLOOD;DIAGNOSED NEVER-TREATED;DIFFUSE PROCESS;ESSENTIAL HYPERTENSION;FEMORAL ARTERIES;FEMORAL LEVEL;HDL CHOLESTEROL;HG -H;HIGH-DENSITY LIPOPROTEIN;HIGH-RESOLUTION B-MODE;HYPERTENS AMERICAN;HYPERTENSION ARTERIAL;HYPERTENSIVE SUBJECTS;IMT READINGS;INTERNAL CAROTID;INTIMA-MEDIA THICKNESS;LEFT VENTRICULAR","4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",1,0.12,6,3,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,0,0,11,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,5,3200,7.69,0,0,66,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1","CARDIOVASCULAR;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;PREVENTION","1;1;1;1;1;1","CARDIOVASCULAR","1","2.4 SURVEILLANCE AND DISTRIBUTION","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2001,11,5.72727272727273,1.45454545454545,0.363636363636364,0.0909090909090909,0.363636363636364,1.06666666666667,0.8,0.5,0.8,0,0,2,2,2,5,0.18,0.18,0.18,0.45,41.36,0.905262365098742,NA,0.0909090909090909,0.636363636363636,0.319,0.15,0,0.15,"R. TARDUCCI;S. CENCETTI;G. GOBBI;G.P. PELLICCIOLI;VIRGILIO GALLAI;GRAZIA CELANI;ALESSANDRO FRATTEGIANI;MARCO CATANI;UMBERTO SENIN;FRANCESCO DONATO;LEONELLA PASQUALINI;ERNESTO MARANZANO;ANTONIO CHERUBINI;PATRIZIA MECOCCI;PAOLA SARCHIELLI;GIOVANNA CENACCHI;P CHIARINI;SILVANO MONARCA;GIUSEPPE SCHILLACI;ANTONELLA REPETTO","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","S. CENCETTI;MARIA LETIZIA D’ANNIBALE;TASSONE DD;DANIELE CROTTI;SALVATORE ARENA;ANNALISA ANGELINI;BRUSCO GF;R. TARDUCCI;G. GOBBI;GIOVANNA CENACCHI;F S CORRENTI;U MERCATI;CORRADO CASTRIOTO;PAOLO GIOVENALI;GIOVANNI ANTONINI;FELICE GIANGASPERO;MARIA TERESA PAGANELLI;G.P. PELLICCIOLI;ANTONELLA REPETTO;MASSIMO MARRONI","0.62;0.5;0.5;0.5;0.33;0.33;0.33;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.24;0.17;0.17","S. CENCETTI;G.P. PELLICCIOLI;GRAZIA CELANI;P CHIARINI;ANTONELLA REPETTO;L. PRATTICHIZZO;FRANCESCO MARIA CERAMI;C PORCELLATI;BRUSCO GF;CORRADO CASTRIOTO;PAOLO GIOVENALI;ENRICO RIGHETTI;DANIELE CROTTI;MARIA TERESA PAGANELLI;GIANPIERO PELLICCIOLI","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","S. CENCETTI;DANIELE CROTTI;BRUSCO GF;CORRADO CASTRIOTO;PAOLO GIOVENALI;MARIA TERESA PAGANELLI;G.P. PELLICCIOLI;ANTONELLA REPETTO;L. PRATTICHIZZO;P CHIARINI;FRANCESCO MARIA CERAMI;C PORCELLATI;GIANPIERO PELLICCIOLI;GRAZIA CELANI;ENRICO RIGHETTI","0.62;0.5;0.33;0.25;0.25;0.25;0.24;0.17;0.17;0.14;0.12;0.12;0.11;0.1;0.1","G. GOBBI;R. TARDUCCI;ANTONIO CHERUBINI;G.P. PELLICCIOLI;GIANPIERO PELLICCIOLI;MARCO CATANI;MASSIMO PICCIRILLI;PATRIZIA MECOCCI;ROBERT HOWARD;UMBERTO SENIN;O. PRESCIUTTI;P CHIARINI;PAOLA SARCHIELLI;VIRGILIO GALLAI;CORRADO CASTRIOTO;FELICE GIANGASPERO;GIOVANNA CENACCHI;PAOLO GIOVENALI;ALESSANDRO FRATTEGIANI;BIANCA MOIRA PANIZZA","218;218;137;137;137;137;137;137;137;137;81;81;81;81;61;61;61;61;56;56","GIANPIERO PELLICCIOLI;G.P. PELLICCIOLI;P CHIARINI;CORRADO CASTRIOTO;PAOLO GIOVENALI;ENRICO RIGHETTI;GRAZIA CELANI;C PORCELLATI;FRANCESCO MARIA CERAMI;S. CENCETTI;DANIELE CROTTI;BRUSCO GF;ANTONELLA REPETTO;L. PRATTICHIZZO;MARIA TERESA PAGANELLI","137;81;81;61;61;56;56;55;33;33;18;10;4;4;0","S. CENCETTI;ANTONELLA REPETTO;BRUSCO GF;C PORCELLATI;CORRADO CASTRIOTO;DANIELE CROTTI;ENRICO RIGHETTI;FRANCESCO MARIA CERAMI;G.P. PELLICCIOLI;GIANPIERO PELLICCIOLI;GRAZIA CELANI;L. PRATTICHIZZO;P CHIARINI;PAOLO GIOVENALI;MARIA TERESA PAGANELLI","2;1;1;1;1;1;1;1;1;1;1;1;1;1;0","MEDICINE;BIOLOGY;PHYSICS;BUSINESS;COMPUTER SCIENCE;ECONOMICS;PSYCHOLOGY","10;5;2;1;1;1;1","INTERNAL MEDICINE;ENDOCRINOLOGY;PATHOLOGY;RADIOLOGY;GENETICS;IMMUNOLOGY;MICROBIOLOGY;PSYCHIATRY;SURGERY;ANATOMY;ANESTHESIA;ARTIFICIAL INTELLIGENCE;BOTANY;CARDIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;FINANCE;GENERAL SURGERY;GYNECOLOGY;NEUROSCIENCE;NUCLEAR MEDICINE;OBSTETRICS;OPTICS;PHYSIOLOGY;QUANTUM MECHANICS;TOXICOLOGY;VETERINARY MEDICINE","6;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MAGNETIC RESONANCE IMAGING;CREATINE;DISEASE;ABDOMINAL WALL;ADENOMA;AMERICAN SOCIETY OF ANESTHESIOLOGISTS;ASPERGILLUS;ASPERGILLUS FLAVUS;ATROPHY;BLOOD PRESSURE;BODY MASS INDEX;CANCER;CENTRAL NERVOUS SYSTEM DISEASE;CHOLESTEROL;CHOLINE;CONTROL (MANAGEMENT);DECOMPRESSION;DIABETES MELLITUS;ENDOPLASMIC RETICULUM;ENTERITIS;FECES;FLAGELLATE;GASTROSTOMY;GENE;GIEMSA STAIN;HELMINTHS;HEPATIC STELLATE CELL;HORMONE;HYPOPITUITARISM;HYSTEROSCOPY;IMMUNOHISTOCHEMISTRY;IN VITRO;INCIDENCE (GEOMETRY);INSULIN;LATERALIZATION OF BRAIN FUNCTION;MEDICAL MICROBIOLOGY;NEUROLOGY;NITROUS OXIDE;OCCUPATIONAL EXPOSURE;OUTPATIENT CLINIC;PARASITOLOGY;PARENTERAL NUTRITION;PEG RATIO;PERCUTANEOUS;PITUITARY TUMORS;PREGNANCY;QUALITY (PHILOSOPHY);RADIATION THERAPY;REGIMEN;SPINAL CORD;STAINING;STIMULATION;STOMACH;STROMAL CELL;TOXICITY;ULTRASTRUCTURE;UTERUS","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALZHEIMER'S DISEASE;AMYOTROPHIC LATERAL SCLEROSIS;CERVIX;CHROMOSOME;DEGENERATIVE DISEASE;DIFFUSION MRI;ENTERAL ADMINISTRATION;ENTEROBIUS;ESSENTIAL HYPERTENSION;GASTROPEXY;GOLGI APPARATUS;H&E STAIN;HIGH-DENSITY LIPOPROTEIN;IN VIVO MAGNETIC RESONANCE SPECTROSCOPY;INFERTILITY;INSULIN RESISTANCE;LAMINECTOMY;LEFT VENTRICULAR HYPERTROPHY;MICRONUCLEUS TEST;MOTOR CORTEX;MYELOPATHY;NEURORADIOLOGY;OCCUPATIONAL MEDICINE;PERCUTANEOUS ENDOSCOPIC GASTROSTOMY;PITUITARY ADENOMA;PITUITARY GLAND;PRECENTRAL GYRUS;SISTER CHROMATID EXCHANGE;SPINAL CORD COMPRESSION;STRONGYLOIDES STERCORALIS;STRONGYLOIDIASIS;UTERINE CAVITY;VIMENTIN;WHITE MATTER","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CERVICAL CANAL;CORTICOSPINAL TRACT;HYSTEROSALPINGOGRAPHY;PITUITARY STALK;POSTERIOR PITUITARY;PRIMARY MOTOR CORTEX;SISTER CHROMATIDS;TRICHROME;UPPER MOTOR NEURON","1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ASPERGILLOSIS;DIENTAMOEBIASIS;GLIOMA;HYPERTENSION;PITUITARY NEOPLASMS;PROSTHESIS-RELATED INFECTIONS;AMYOTROPHIC LATERAL SCLEROSIS;ASPARTIC ACID;ASPERGILLUS FLAVUS;BLOOD VESSEL PROSTHESIS;BRAIN;CELL NUCLEUS;DIAGNOSIS, DIFFERENTIAL;HYPERTROPHY, LEFT VENTRICULAR","10;8;7;7;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3","AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CLINICAL IMPLICATIONS OF UTERINE ANOMALIES AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;EPIDEMIOLOGY AND MOLECULAR CHARACTERIZATION OF PARASITIC DISEASES;EVOLUTION OF LEGAL SYSTEMS AND JURISPRUDENCE;LABORATORY SAFETY AND CHEMICAL MANAGEMENT PRACTICES;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MANAGEMENT OF SPINAL METASTATIC TUMORS;MANAGEMENT OF VASCULAR GRAFT INFECTIONS AND ANEURYSMS;PROVISION AND ASSESSMENT OF NUTRITION SUPPORT THERAPY","1;1;1;1;1;1;1;1;1;1;1","CREATINE;ANTIBIOTIC TREATMENT;AORTIC ANEURYSMS;AORTOENTERIC FISTULA;BLOOD PRESSURE;CERVICAL CANAL;CHOLESTEROL;CHOLINE;CORTICOSPINAL TRACT;DIAGNOSIS;DIAGNOSTIC HYSTEROSCOPY;ENTERAL ADMINISTRATION;ENTERAL NUTRITION;ENTEROBIUS;ESSENTIAL HYPERTENSION;FLAGELLATE;GASTROPEXY;GENOTOXICITY TESTING;GIEMSA STAIN;HEPATIC STELLATE CELL","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MAGNETIC RESONANCE;RESONANCE IMAGING;AMYOTROPHIC LATERAL;AORTIC BYPASS;ASPERGILLUS FLAVUS;BRAIN AGING;CHROMATID EXCHANGES;CLINICAL PARASITOLOGY;COGNITIVE IMPAIRMENT;COMPRESSION PATIENTS;CONTRACTED EXTERNAL;CORD COMPRESSION;DIAGNOSTIC HYSTEROSCOPY;DIENTAMOEBA FRAGILIS;DIENTAMOEBIASIS ASPECTS;DIFFERENTIATES MILD;ENDOSCOPIC PERCUTANEOUS;ESSENTIAL HYPERTENSION;EXTERNAL SERVICES;FLAVUS INFECTION;FOLLICULO-STELLATE CELLS;H-MAGNETIC RESONANCE;H-MR SPECTROSCOPY;HIGH-DENSITY LIPOPROTEIN;HYPOFRACTIONATED RADIOTHERAPY;IMAGING ANALYSIS;INFERTILE WOMEN;LABORATORY DIAGNOSIS;LATERAL SCLEROSIS;LEFT VENTRICULAR","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",1,0.09,3,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,4,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,8,15895,13.33,0,0,354,0,0,0,0,1,0,1,0,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Germany","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AGING;CANCER;CARDIOVASCULAR;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE","2;2;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","6.1 PHARMACEUTICALS","2","COLON AND RECTAL CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2002,11,7.90909090909091,1.45454545454545,0.363636363636364,0,0.363636363636364,1.14285714285714,0.8,0,0.8,0,1,3,0,5,3,0.27,0,0.45,0.27,21.45,0.388889739377079,NA,0.181818181818182,0.636363636363636,0.395,0,0,0,"R. TARDUCCI;VIRGILIO GALLAI;MARCO CATANI;UMBERTO SENIN;PATRIZIA MECOCCI;P CHIARINI;MASSIMO MARRONI;LISA MALINCARNE;MARINA VALENTE;G.P. PELLICCIOLI;GIULIANO STAGNI;ANTONIO CHERUBINI;RICCARDO MARIA FAGUGLI;A. P. IORI;FLÁVIA MARIANA VALENTE;AMIR REZA DANESHMAND ESLAMI;ANTONIO CHERUBINI;LUCILLA PARNETTI;PAOLA SARCHIELLI;CLAUDIO SFARA","3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MAURIZIO TONATO;R. TARDUCCI;VIRGILIO GALLAI;AMIR REZA DANESHMAND ESLAMI;C TODISCO;STEFANO BAGLIONI;TOMMASO TODISCO;P CHIARINI;G.P. PELLICCIOLI;MARCO CATANI;UMBERTO SENIN;PATRIZIA MECOCCI;MASSIMO MARRONI;LISA MALINCARNE;MARINA VALENTE;GIULIANO STAGNI;RICCARDO MARIA FAGUGLI;FLÁVIA MARIANA VALENTE;MARIA LETIZIA D’ANNIBALE;PAOLA SANTIROSI","1;0.34;0.29;0.25;0.25;0.25;0.25;0.24;0.22;0.21;0.21;0.21;0.21;0.21;0.21;0.21;0.2;0.2;0.2;0.2","P CHIARINI;G.P. PELLICCIOLI;RICCARDO MARIA FAGUGLI;MAURIZIO TONATO;E. CIORBA;GIAMPIERO GUBBIOTTI;STEFANIA CEPPI;PIERO FLORIDI;STEFANO FIORUCCI;ROBERTO LUCCIOLI;DANIELE CROTTI;TOMMASO TODISCO;MASSIMO COZZARI;GIANPIERO PELLICCIOLI","2;2;1;1;1;1;1;1;1;1;1;1;1;1","MAURIZIO TONATO;TOMMASO TODISCO;P CHIARINI;G.P. PELLICCIOLI;RICCARDO MARIA FAGUGLI;DANIELE CROTTI;E. CIORBA;ROBERTO LUCCIOLI;GIAMPIERO GUBBIOTTI;MASSIMO COZZARI;GIANPIERO PELLICCIOLI;PIERO FLORIDI;STEFANO FIORUCCI;STEFANIA CEPPI","1;0.25;0.24;0.22;0.2;0.2;0.17;0.17;0.11;0.11;0.11;0.1;0.1;0.05","G.P. PELLICCIOLI;R. TARDUCCI;VIRGILIO GALLAI;ANDREA ALBERTI;G. GOBBI;O. PRESCIUTTI;P CHIARINI;PAOLA SARCHIELLI;GIULIANO STAGNI;LISA MALINCARNE;MARINA VALENTE;MASSIMO MARRONI;ANGELA CARDACCIA;BARBARA BELFIORI;CLAUDIO FARINA;GUIDO CAMANNI;PIERO FLORIDI;STEFANO FIORUCCI;ANTONIO CHERUBINI;ANTONIO METASTASIO","115;115;92;80;80;80;80;80;54;54;54;54;52;52;52;52;52;52;35;35","G.P. PELLICCIOLI;P CHIARINI;PIERO FLORIDI;STEFANO FIORUCCI;STEFANIA CEPPI;RICCARDO MARIA FAGUGLI;E. CIORBA;ROBERTO LUCCIOLI;TOMMASO TODISCO;DANIELE CROTTI;GIAMPIERO GUBBIOTTI;MASSIMO COZZARI;GIANPIERO PELLICCIOLI;MAURIZIO TONATO","115;80;52;52;33;15;12;12;5;2;2;2;0;0","G.P. PELLICCIOLI;P CHIARINI;DANIELE CROTTI;E. CIORBA;GIAMPIERO GUBBIOTTI;MASSIMO COZZARI;PIERO FLORIDI;RICCARDO MARIA FAGUGLI;ROBERTO LUCCIOLI;STEFANIA CEPPI;STEFANO FIORUCCI;TOMMASO TODISCO;GIANPIERO PELLICCIOLI;MAURIZIO TONATO","2;2;1;1;1;1;1;1;1;1;1;1;0;0","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PHYSICS","11;3;2;1;1;1;1;1","INTERNAL MEDICINE;RADIOLOGY;SURGERY;CARDIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;DERMATOLOGY;GENETICS;IMMUNOLOGY;MICROBIOLOGY;NEUROSCIENCE;PSYCHIATRY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;ONCOLOGY;OPTICS;PATHOLOGY;PEDIATRICS;PHYSICAL THERAPY;STATISTICS","9;5;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MAGNETIC RESONANCE IMAGING;POPULATION;ADVERSE EFFECT;ANTIBIOTICS;ATROPHY;BACTERIA;CREATINE;ABSCESS;AMBULATORY;ANTIFUNGAL;ASYMPTOMATIC;BLOOD PRESSURE;BONE MARROW;CANCER;CELLULITIS;CEREBRAL CORTEX;CHLAMYDIA;CHOLINE;CLINICAL PRACTICE;COEFFICIENT OF VARIATION;COMPUTED TOMOGRAPHY;CRANIOTOMY;CUFF;DISEASE;EDEMA;EPIDEMIOLOGY;EPILEPSY;FUNCTIONAL MAGNETIC RESONANCE IMAGING;GENE;GROUP A;HELICOBACTER PYLORI;HEMODIALYSIS;INCIDENCE (GEOMETRY);ISCHEMIA;LEISHMANIASIS;LESION;LEUKEMIA;LUNG;LUNG CANCER;MULTIPLE SCLEROSIS;PNEUMONIA;POSTERIOR PARIETAL CORTEX;PROSPECTIVE COHORT STUDY;RESPIRATORY SYSTEM;STROKE (ENGINE);TONSILLITIS;TOXICITY;TRANSPLANTATION","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","WHITE MATTER;AMBULATORY BLOOD PRESSURE;AMPHOTERICIN B;ANTIBACTERIAL AGENT;AZITHROMYCIN;BRAIN ABSCESS;CEREBRAL INFARCTION;CLARITHROMYCIN;CUMULATIVE INCIDENCE;DEMENTIA;DIASTOLE;ERYTHROMYCIN;HEMATOPOIETIC STEM CELL TRANSPLANTATION;ISCHEMIC STROKE;LYMPHOBLASTIC LEUKEMIA;NOCARDIA;PANCYTOPENIA;PHENOTYPE;RESPIRATORY TRACT INFECTIONS;STAPHYLOCOCCUS AUREUS;TOLERABILITY;VISCERAL LEISHMANIASIS","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE LYMPHOCYTIC LEUKEMIA;LACUNAR STROKE;STREPTOCOCCUS PYOGENES","1;1;1","HUMANS;MALE;ASPARTIC ACID;FEMALE;ADULT;MIDDLE AGED;PHARYNGITIS;TONSILLITIS;AGED;BRAIN;BRAIN ABSCESS;BRAIN ISCHEMIA;CEREBRAL INFARCTION;CREATINE;LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;NOCARDIA INFECTIONS;STREPTOCOCCAL INFECTIONS;STROKE;THIAMPHENICOL;ALZHEIMER DISEASE","9;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3","ADVANCEMENTS IN LUNG CANCER RESEARCH;CLINICAL AND MOLECULAR ASPECTS OF NOCARDIOSIS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;GLOBAL BURDEN OF GROUP A STREPTOCOCCAL DISEASES;GLOBAL BURDEN OF LEISHMANIASIS INCIDENCE AND TREATMENT;HEMATOPOIETIC STEM CELL BIOLOGY;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MENTAL HEALTH AND QUALITY OF LIFE;VAGINAL MICROBIOME AND SEXUALLY TRANSMITTED INFECTIONS","1;1;1;1;1;1;1;1;1;1;1","TREATMENT;CREATINE;MAGNETIC RESONANCE IMAGING;ACUTE LYMPHOCYTIC LEUKEMIA;ALZHEIMER'S DISEASE;ANTIBIOTIC SUSCEPTIBILITY;BLOOD PRESSURE;BRAIN ABSCESS;CHOLINE;CLINICAL PRACTICE;COEFFICIENT OF VARIATION;CUFF;CUMULATIVE INCIDENCE;ELDERLY;GROUP A;HEMATOPOIETIC CELL TRANSPLANTATION;HEMODIALYSIS;HEMODYNAMIC MONITORING;INFARCTION TREATMENT;LACUNAR STROKE","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MAGNETIC RESONANCE;RESONANCE SPECTROSCOPY;ACUTE LEUKEMIA;ACUTE LOWER;ACUTE STROKE;AIEOP PROSPECTIVE;ALLOGRAFT PATIENT;ALZHEIMERS DISEASE;AMBULATORY BLOOD;AUSCULTATORY METHODS;BLOOD PRESSURE;BRAIN ABSCESS;BRAIN CT-SCAN;CELL LUNG;CHRONIC HYPERTENSION;COMPARATIVE PILOT;CORTICAL GRAY;CURRENT TREATMENT;DUE TOICHLAMYDIA;ELDERLY SUBJECTS;EPIDEMIOLOGICAL ASPECTS;FUNCTIONAL MAGNETIC;GLYCINATE HYDROCHLORIDE;GRAY MATTER;HEALTHY ELDERLY;HEMODIALYSIS PATIENTS;IMAGING STUDY;IMMUNOCOMPETENT PATIENT;INFECTIONS DUE;KIDNEY ALLOGRAFT","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",2,0.18,3,1.75,0,0,0,0,0,0,0,1.75,0,0,0,0,1.75,0,0,0,0,0,0,24.25,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,4,464.5,14.29,0,0,41.5,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Germany","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3208 MEDICAL PHYSIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEART DISEASE;LUNG","2;2;1;1;1","CARDIOVASCULAR;RESPIRATORY","1;1","6.1 PHARMACEUTICALS","2",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2003,17,7.88235294117647,2.47058823529412,0.647058823529412,0.235294117647059,0.647058823529412,1.13513513513514,1,0.8,1,0.470588235294118,0,8,4,0,4,0.47,0.24,0,0.24,39.41,0.744631157289863,NA,0.0588235294117647,0.823529411764706,0.268,0.212,0.15,0.212,"VIRGILIO GALLAI;A PUXEDDU;LUCILLA PARNETTI;A. FLORIDI;MAURIZIO PACIARONI;VALERIA CASO;PAOLO MILIA;MAURO ZAMPOLINI;LORENZO SPIZZICHINO;GIANCARLO FINALI;MARCO FRANCESCHINI;FRANCESCO GALLI;MOHAMMED HAMAM;MARIA GRAZIA CELANI;STEFANO COACCIOLI;E. PATUCCHI;FRANCESCO COREA;U. BUONCRISTIANÍ;G.P. PELLICCIOLI;MARIA CRISTINA PAGLIACCI","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","A. FLORIDI;A PUXEDDU;STEFANO COACCIOLI;E. PATUCCHI;FRANCESCO GALLI;U. BUONCRISTIANÍ;VIRGILIO GALLAI;GIAN FRANCESCO BRUSCO;ANTONIO ANGELINI;SAVERIO ARENA;GIUSEPPE FATATI;LUCILLA PARNETTI;MAURIZIO PACIARONI;VALERIA CASO;PAOLO MILIA;MOHAMMED HAMAM;FRANCESCO COREA;G.P. PELLICCIOLI;MAURO ZAMPOLINI;LORENZO SPIZZICHINO","0.5;0.42;0.42;0.42;0.38;0.38;0.37;0.33;0.33;0.33;0.25;0.22;0.22;0.22;0.22;0.22;0.22;0.22;0.2;0.2","VIRGILIO GALLAI;GIANCARLO FINALI;FRANCESCO GALLI;MOHAMMED HAMAM;STEFANO COACCIOLI;E. PATUCCHI;U. BUONCRISTIANÍ;G.P. PELLICCIOLI;MARIA CRISTINA PAGLIACCI;RICCARDO MARIA FAGUGLI;MARTA PIRODDI;E. BUONCRISTIANI;MARIA ANTONIETTA COLOZZA;PAOLA SARCHIELLI;SERENA BENEDETTI;CARMELA CONTE;DA COL U;PAOLO PASINI;CARLO PORCELLATI;S. PORROZZI","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","STEFANO COACCIOLI;E. PATUCCHI;FRANCESCO GALLI;U. BUONCRISTIANÍ;VIRGILIO GALLAI;GIAN FRANCESCO BRUSCO;ANTONIO ANGELINI;SAVERIO ARENA;MOHAMMED HAMAM;G.P. PELLICCIOLI;GIANCARLO FINALI;MARIA CRISTINA PAGLIACCI;PIERO COVARELLI;PAOLA SARCHIELLI;ANDREA ALBERTI;FRANCESCA COPPOLA;CRISTIANA ROSSI;BEATRICE GALLAI;GIOVANNI MAZZOTTA;RICCARDO MARIA FAGUGLI","0.42;0.42;0.38;0.38;0.37;0.33;0.33;0.33;0.22;0.22;0.2;0.2;0.17;0.14;0.14;0.14;0.14;0.14;0.14;0.12","GIANCARLO FINALI;LORENZO SPIZZICHINO;MARCO FRANCESCHINI;MARIA CRISTINA PAGLIACCI;MARIA GRAZIA CELANI;MAURO ZAMPOLINI;VIRGILIO GALLAI;FRANCESCO GALLI;U. BUONCRISTIANÍ;FRANCESCO COREA;G.P. PELLICCIOLI;LUCILLA PARNETTI;MAURIZIO PACIARONI;MOHAMMED HAMAM;PAOLO MILIA;VALERIA CASO;A. FLORIDI;GIORDANO GATTA;LUIGI PERDON;SILVANO BARATTA","141;141;141;141;141;141;116;112;112;102;102;102;102;102;102;102;96;90;90;90","GIANCARLO FINALI;MARIA CRISTINA PAGLIACCI;U. BUONCRISTIANÍ;G.P. PELLICCIOLI;MOHAMMED HAMAM;SILVANO BARATTA;DANIELA RICCIARDI;FRANCA PASTICCI;LUIGI VECCHI;PAOLA SANTIROSI;PAOLO PASINI;RICCARDO MARIA FAGUGLI;S. PORROZZI;ARDESIO FLORIDI;CARMELA CONTE;E. BUONCRISTIANI;FRANCESCO GALLI;FRANCO CANESTRARI;MARTA PIRODDI;SERENA BENEDETTI","141;141;112;102;102;90;83;83;83;83;83;83;66;64;64;64;64;64;64;64","G.P. PELLICCIOLI;GIANCARLO FINALI;MARIA CRISTINA PAGLIACCI;MOHAMMED HAMAM;U. BUONCRISTIANÍ;ANDREA ALBERTI;ANTONIO ANGELINI;ARDESIO FLORIDI;BEATRICE GALLAI;CARLO PORCELLATI;CARMELA CONTE;CRISTIANA ROSSI;DANIELA RICCIARDI;E. BUONCRISTIANI;E. PATUCCHI;F. ROILA;FRANCA PASTICCI;FRANCESCA COPPOLA;FRANCESCO GALLI;FRANCO CANESTRARI","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;ENGINEERING;CHEMISTRY;BIOLOGY;ECONOMICS;MATHEMATICS;PHYSICS","17;3;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;MECHANICAL ENGINEERING;PHYSICAL THERAPY;PSYCHIATRY;RADIOLOGY;ANESTHESIA;ONCOLOGY;BIOCHEMISTRY;CELL BIOLOGY;COMBINATORICS;EMERGENCY MEDICINE;ENVIRONMENTAL HEALTH;FOOD SCIENCE;GENERAL SURGERY;GYNECOLOGY;IMMUNOLOGY;MICROECONOMICS;OPTICS;PEDIATRICS;PHARMACOLOGY;UROLOGY","16;8;5;5;3;3;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;BODY MASS INDEX;CHEMOTHERAPY;HEMODIALYSIS;STROKE (ENGINE);ADVERSE EFFECT;BLOOD PRESSURE;DIABETES MELLITUS;DISEASE;HEART FAILURE;ISCHEMIA;LESION;MYOCARDIAL INFARCTION;OBESITY;OCCLUSION;SPINAL CORD;ADJUVANT;ANALGESIC;ANASTOMOSIS;ANGIOGRAPHY;ANTIOXIDANT;ASCORBIC ACID;ATRIAL FIBRILLATION;ATRIAL NATRIURETIC PEPTIDE;BODY WEIGHT;CARDIAC SURGERY;CENTRAL NERVOUS SYSTEM DISEASE;CLINICAL TRIAL;CONFIDENCE INTERVAL;CONFOUNDING;CREATININE;DILATION (METRIC SPACE);DISSECTION (MEDICAL);DIVERTICULUM (MOLLUSC);DRUG;DUMPING;EPILEPSY;ERYTHROCYTE SEDIMENTATION RATE;ETIOLOGY;EXTRACELLULAR;FIBROMYALGIA;HOMOCYSTEINE;HYSTEROSCOPY;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);INTERNAL CAROTID ARTERY;IRRITABLE BOWEL SYNDROME;KIDNEY;LYMPHOCYTE;METHOTREXATE;MIGRAINE;MULTIVARIATE ANALYSIS;NEUROLOGY;POPULATION;REGIMEN;REHABILITATION;RENAL FUNCTION;RESPIRATORY FAILURE;RISK FACTOR;SALINE;STENOSIS;TRAUMATIC BRAIN INJURY;ULTRASOUND;URIC ACID;UTERUS;VENTRICLE;VERTEBRAL ARTERY;VITAMIN;VITAMIN C","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CYCLOPHOSPHAMIDE;AMBULATORY BLOOD PRESSURE;LEFT VENTRICULAR HYPERTROPHY;ADJUVANT THERAPY;AURA;BRAIN NATRIURETIC PEPTIDE;BREAST CANCER;CAROTID ENDARTERECTOMY;CD8;CEREBRAL ANGIOGRAPHY;CEREBRAL INFARCTION;CERVICAL ARTERY;CERVIX;CISPLATIN;COLORECTAL CANCER;DOCETAXEL;DOXORUBICIN;EJECTION FRACTION;END STAGE RENAL DISEASE;EXTRACELLULAR FLUID;FLUOROURACIL;GASTRECTOMY;HYPERHOMOCYSTEINEMIA;INFARCTION;LEVETIRACETAM;MIDDLE CEREBRAL ARTERY;MUCOSITIS;NATRIURETIC PEPTIDE;NEUTROPENIA;OPEN LABEL;OVERWEIGHT;QUARTILE;REVASCULARIZATION;SPINAL CORD DISEASES;SPINAL CORD INJURY;TOLERABILITY;TYPE 2 DIABETES MELLITUS;UNIVARIATE ANALYSIS;UTERINE CAVITY;VASCULITIS;VERTEBRAL ARTERY DISSECTION;VITAMIN E;WEIGHT LOSS","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EPIRUBICIN;CAPECITABINE;CERVICAL CANAL;DUMPING SYNDROME;FEBRILE NEUTROPENIA;GIANT CELL ARTERITIS;LYMPHOCYTE SUBSETS","2;1;1;1;1;1;1","FEMALE;HUMANS;AGED;MALE;MIDDLE AGED;ADULT;ITALY;SPINAL CORD INJURIES;KIDNEY FAILURE, CHRONIC;BREAST NEOPLASMS;STROKE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;HYPERTROPHY, LEFT VENTRICULAR;PRESSURE ULCER;PROSPECTIVE STUDIES;ACUTE KIDNEY INJURY;ARTERIAL OCCLUSIVE DISEASES;BLOOD PRESSURE;CAROTID STENOSIS;EPIRUBICIN","16;16;12;12;11;10;8;8;7;6;6;5;5;5;5;4;4;4;4;4","CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLINICAL IMPLICATIONS OF UTERINE ANOMALIES AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF FIBROMYALGIA SYNDROME;DIAGNOSIS AND MANAGEMENT OF URTICARIA;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIAGNOSIS AND TREATMENT OF HEART FAILURE;GASTRIC CANCER RESEARCH AND TREATMENT;INTUSSUSCEPTION AND MECKEL'S DIVERTICULUM;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;MOLECULAR RESEARCH ON BREAST CANCER;PATHOPHYSIOLOGY AND MANAGEMENT OF CEREBRAL ANEURYSMS;PATHOPHYSIOLOGY AND TREATMENT OF SPINAL CORD INJURY;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;ROLE OF OXIDATIVE STRESS IN HEALTH AND DISEASE;SPINA BIFIDA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","STROKE (ENGINE);EPIRUBICIN;SPINAL CORD INJURY;ADJUVANT THERAPY;ATRIAL NATRIURETIC PEPTIDE;B-TYPE NATRIURETIC PEPTIDE;BLOOD PRESSURE;BRAIN NATRIURETIC PEPTIDE;CARDIOVASCULAR EVALUATION;CAROTID ARTERY STENOSIS;CERVICAL ARTERY;CERVICAL CANAL;CLINICAL FEATURES;DIAGNOSIS;DIAGNOSTIC HYSTEROSCOPY;DILATION (METRIC SPACE);DUMPING;DUMPING SYNDROME;ERYTHROCYTE SEDIMENTATION RATE;ETIOLOGY","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SPINAL CORD;ADJUVANT SYSTEMIC;ADVANCED BREAST;ADVANCED GASTRIC;AGE RESULTS;ANASTOMOTIC FALSE-DIVERTICULUM;ARTERY DISSECTION;ARTERY SEVERE;ATYPICAL DUMPING;AUTHORS ISARE;AUTOIMMUNE INFLAMMATORY;BLOOD PRESSURE;BODY WEIGHT;BRAIN NATRIURETIC;BREAST CANCERAN;BREAST CARCINOMA;CANCERAN AUDIT;CARBON DIOXIDE;CAROTID ARTERY;CERVICAL ARTERY;CHRONIC AUTOIMMUNE;CISPLATIN EPIRUBICIN;CLINICAL PRACTICE;COMMERCIAL PARTY;CORD INJURY;CORD LESION;DIABETES MELLITUS;DIAGNOSTIC HYSTEROSCOPY;DIOXIDE VERSUS;DIRECT FINANCIAL","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PROTEIN-LEAKING DIALYZERS;NORMAL SALINE;BREAST CANCER;CANCER PATIENTS;DELTA HDHCY;GRADE ADVERSE;III DISEASE;NON-PROTEIN-LEAKING DIALYZERS;SCL PATIENTS;STAGE III;ACCEPTABLE SAFETY;ADJUVANT SYSTEMIC;ADVANCED GASTRIC;ADVERSE EVENTS;BREAST CARCINOMA;COMPLETE RESPONSES;ENDOCRINE THERAPY;ESRD PATIENTS;EVIDENCE-BASED GUIDELINES;FU DOXORUBICIN;GASTRIC CARCINOMA;HEADACHE FREQUENCY;ITALIAN BREAST;ITALIAN CENTERS;IV DISEASE;LOCAL ANESTHESIA;MONTHS VERSUS;NT AETIOLOGY;OBJECTIVE RESPONSE;ORAL CAPECITABINE","6;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",5,0.29,3,2,0,0,0,0,0,0,1.25,2,0,0,2,0,0,0,0,2,0,0,0,34,34,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,5,280,2.86,1,1,19,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","AGING;BREAST CANCER;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CONTRACEPTION/REPRODUCTION;ESTROGEN;PREVENTION","1;1;1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS","1","BREAST CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2004,16,5.375,1.8125,0.75,0.125,0.75,1.03571428571429,0.923076923076923,0.666666666666667,0.923076923076923,0.25,4,5,0,1,9,0.31,0,0.06,0.56,48.88,1.03870875854553,NA,0.125,0.3125,0.489,0.119,0,0.119,"STEFANIA GORI;MAURIZIO TONATO;BIANCA POLLO;LYDIA ROMANO;MICHELA CASANOVA;ALESSANDRO FRATTEGIANI;JOHANNES H. M. MERKS;GIOVANNI SCARZELLO;VALENTINO PAGLIUCA;FILIPPO SPREAFICO;FABIO VERZINI;CRISTIANA TODISCO;P. ANASTASI;GIAN LUCA DE SALVO;GUSTAVO IACONO;MAURIZIO STEFANELLI;GIOVANNI RIZZO;PIERINA NAVARRIA;ANDREA MENCARELLI;PAOLA COLLINI","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MAURIZIO TONATO;M. PICCIAFUOCO;DANIELE CROTTI;MARIANTONIETTA COLOZZA;CRISTIANA TODISCO;GIUSEPPE QUINTALIANI;CARMINE ZOCCALI;BONCIARELLI;MARIA PIA ROSITO;TOMMASO TODISCO;E. CORGNA;M. MEACCI;STEFANIA GORI;P. ANASTASI;SERGIO BRACARDA;CLAUDIA CASERTA;FRANCESCA MARROCOLO;GUDRUN BOYSEN;MARIA GRAZIA CELANI;ENRICO RIGHETTI","1.33;1;1;1;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.46;0.33;0.33;0.33;0.33;0.17;0.17;0.17","STEFANIA GORI;MAURIZIO TONATO;LYDIA ROMANO;VALENTINO PAGLIUCA;FABIO VERZINI;GUSTAVO IACONO;MAURIZIO STEFANELLI;GIOVANNI RIZZO;ANDREA MENCARELLI;I MAZZARINO;GIUSEPPE QUINTALIANI;BARBARA RENGA;STEFANO ORLANDI;M. PICCIAFUOCO;STEFANO FIORUCCI;SERGIO BRACARDA;PAOLA DE RANGO;LUISA RICCARDI;TERESA ANNA CANTISANI;DANIELE CROTTI","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MAURIZIO TONATO;M. PICCIAFUOCO;DANIELE CROTTI;MARIANTONIETTA COLOZZA;GIUSEPPE QUINTALIANI;TOMMASO TODISCO;E. CORGNA;M. MEACCI;STEFANIA GORI;SERGIO BRACARDA;TERESA ANNA CANTISANI;LYDIA ROMANO;VALENTINO PAGLIUCA;FABIO VERZINI;GUSTAVO IACONO;PAOLA DE RANGO;PIERGIORGIO CAO;GIANBATTISTA PARLANI;GIOVANNI RIZZO;ANDREA MENCARELLI","1.33;1;1;1;0.5;0.5;0.5;0.5;0.46;0.33;0.17;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.11;0.11","ANDREA MENCARELLI;ANTONIO MORELLI;BARBARA RENGA;ELISABETTA ANTONELLI;GIOVANNI RIZZO;LUISA RICCARDI;ROBERTO PELLICCIARI;STEFANO FIORUCCI;STEFANO ORLANDI;FABIO VERZINI;GIANBATTISTA PARLANI;GUSTAVO IACONO;LYDIA ROMANO;PAOLA DE RANGO;PIERGIORGIO CAO;VALENTINO PAGLIUCA;ANDREA FERRARI;CRISTINA MEAZZA;GIAN LUCA DE SALVO;GIANNI BISOGNO","437;437;437;437;437;437;437;437;437;129;129;129;129;129;129;129;107;107;107;107","ANDREA MENCARELLI;ANTONIO MORELLI;BARBARA RENGA;ELISABETTA ANTONELLI;GIOVANNI RIZZO;LUISA RICCARDI;STEFANO FIORUCCI;STEFANO ORLANDI;FABIO VERZINI;GIANBATTISTA PARLANI;GUSTAVO IACONO;LYDIA ROMANO;PAOLA DE RANGO;PIERGIORGIO CAO;VALENTINO PAGLIUCA;I MAZZARINO;MAURIZIO STEFANELLI;TERESA ANNA CANTISANI;DANIELE CROTTI;E. CORGNA","437;437;437;437;437;437;437;437;129;129;129;129;129;129;129;107;92;15;2;0","ANDREA MENCARELLI;ANTONIO MORELLI;BARBARA RENGA;DANIELE CROTTI;ELISABETTA ANTONELLI;FABIO VERZINI;GIANBATTISTA PARLANI;GIOVANNI RIZZO;GUSTAVO IACONO;I MAZZARINO;LUISA RICCARDI;LYDIA ROMANO;MAURIZIO STEFANELLI;PAOLA DE RANGO;PIERGIORGIO CAO;STEFANO FIORUCCI;STEFANO ORLANDI;TERESA ANNA CANTISANI;VALENTINO PAGLIUCA;E. CORGNA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;0","MEDICINE;BIOLOGY;ENGINEERING;PHILOSOPHY;BUSINESS;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY","15;3;3;3;1;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;INTENSIVE CARE MEDICINE;SURGERY;EPISTEMOLOGY;MECHANICAL ENGINEERING;ALGORITHM;ANESTHESIA;ASTROBIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;ENGINEERING ETHICS;FAMILY MEDICINE;FINANCE;GENETICS;GYNECOLOGY;HUMANITIES;LAW;MEDICAL EDUCATION;MICROBIOLOGY;NURSING;PATHOLOGY;PEDIATRICS;PUBLIC RELATIONS;STATISTICS","11;6;4;4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;RADIATION THERAPY;ADJUVANT;ALTERNATIVE MEDICINE;ANEURYSM;ANTIBIOTICS;BACTERIA;BILE ACID;BRAIN EDEMA;CLINICAL PRACTICE;CLINICAL TRIAL;CONTINUING EDUCATION;EDEMA;EMPIRICISM;ENTERITIS;EPENDYMOMA;GENE;HEPATIC STELLATE CELL;INDEPENDENCE (PROBABILITY THEORY);INTENSIVE CARE UNIT;INTERQUARTILE RANGE;INTUBATION;MECHANICAL VENTILATION;MORTALITY RATE;OBLIGATION;ORDER (EXCHANGE);OVERALL SURVIVAL;POSTMENOPAUSAL WOMEN;QUALITY (PHILOSOPHY);REFRACTORY (PLANETARY SCIENCE);RESPIRATORY FAILURE;RESPIRATORY SYSTEM;STATE (COMPUTER SCIENCE);STROKE (ENGINE);SURVIVAL RATE;TISSUE PLASMINOGEN ACTIVATOR;TRANSFORMING GROWTH FACTOR;URSODEOXYCHOLIC ACID;VENTILATION (ARCHITECTURE)","7;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CISPLATIN;ABDOMINAL AORTIC ANEURYSM;ACUTE RESPIRATORY FAILURE;ACUTE STROKE;AORTIC ANEURYSM;AORTIC REPAIR;CAMPYLOBACTER;CAMPYLOBACTER JEJUNI;CIPROFLOXACIN;CLINICAL ENDPOINT;CLINICAL ONCOLOGY;CONTINUING MEDICAL EDUCATION;CYCLOPHOSPHAMIDE;ENDOTRACHEAL INTUBATION;ERYTHROMYCIN;MINOCYCLINE;NONINVASIVE VENTILATION;OROTRACHEAL INTUBATION;PANCREATIC CANCER;PLACEBO;POSITIVE PRESSURE VENTILATION;PRESSURE SUPPORT VENTILATION;PROSTATE;PROSTATE CANCER;RNA;STOMACH CANCER;TETRACYCLINE;TRANSCRIPTION FACTOR","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ARCOBACTER;AXILLARY LYMPH NODES;CARBOPLATIN;ENDOVASCULAR ANEURYSM REPAIR;MASTECTOMY;METASTATIC BREAST CANCER;NORFLOXACIN;NUCLEAR RECEPTOR;SMALL INTERFERING RNA;SUPRACLAVICULAR FOSSA;SUPRACLAVICULAR LYMPH NODES;TAMOXIFEN;TRASTUZUMAB;VINORELBINE","1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST NEOPLASMS;HUMANS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CLINICAL TRIALS, PHASE III AS TOPIC;CYCLOPHOSPHAMIDE;ANTINEOPLASTIC AGENTS, HORMONAL;FEMALE;AORTIC ANEURYSM, ABDOMINAL;BRAIN NEOPLASMS;EPENDYMOMA;ETOPOSIDE;INFRATENTORIAL NEOPLASMS;MALE;OSTEOPOROSIS, POSTMENOPAUSAL;PROSTATIC NEOPLASMS;RANDOMIZED CONTROLLED TRIALS AS TOPIC;STOMACH NEOPLASMS;SUPRATENTORIAL NEOPLASMS;SURVIVAL ANALYSIS;ADENOCARCINOMA","12;11;10;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3","ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CANCER OF UNKNOWN PRIMARY SITE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;GASTRIC CANCER RESEARCH AND TREATMENT;GLIOMAS;GLOBAL BURDEN OF FOODBORNE PATHOGENS;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER;MOLECULAR RESEARCH ON BREAST CANCER;PEDIATRIC CANCER AND QUALITY OF LIFE;SARCOMA RESEARCH AND TREATMENT;TRANSFORMATION OF MEDICAL EDUCATION AND PROFESSIONALISM","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RADIOTHERAPY;TREATMENT;ACUTE RESPIRATORY FAILURE;ACUTE STROKE;ANAL CANCER;ANASTROZOLE;ANEURYSM RUPTURE;AORTIC ANEURYSMS;AORTIC DISSECTION;AORTIC REPAIR;AORTIC ROOT REPLACEMENT;ARCOBACTER;AXILLARY LYMPH NODES;BIOMARKER ANALYSIS;BRAIN EDEMA;BREAST CANCER;BREAST RECONSTRUCTION;BREAST-CONSERVING SURGERY;CAMPYLOBACTER;CANCER OF UNKNOWN PRIMARY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;DIFFICULT CHOICE;ABDOMINAL AORTIC;ACUTE RESPIRATORY;ACUTE STROKE;ADJUVANT LOCOREGIONAL;ADJUVANT TAMOXIFEN;ADVANCED STOMACH;AIEOP ASSOCIAZIONE;ALCUNI ASPETTI;ANEURYSM ENDOGRAFTING;AORTIC ANEURYSM;ASSOCIAZIONE ITALIANA;AXILLARY LYMPH;BIENNIO DEL;BIOLOGICAL DRUGS;CAMPYLOBACTERIOSI NEL;CHEMOTHERAPY RESULTS;CHILDHOOD EPENDYMOMA;CLINICAL EFFECT;CLINICAL PRACTICE;CLINICAL RESEARCH;CLINICAL TRIALS;CONCURRENT COMPARISON;CONSIDERAZIONI DI;CONTINUOUS MEDICAL;DEL NUOVO;DI EMATOLOGIA-ONCOLOGIA;DI MICROBIOLOGIA;EMATOLOGIA-ONCOLOGIA PEDIATRICA","3;3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GLYCEROL TREATMENT;ACUTE STROKE;LIVER FIBROSIS;SCHEDULED TREATMENT;SECONDARY PROCEDURES;ALPHAI COLLAGEN;COCHRANE LIBRARY;FUNCTIONAL OUTCOME;INTRAVENOUS GLYCEROL;IPI NA;ISCHEMIC STROKE;PERUGIA ITALY;TREATMENT PERIOD;ACUTE ISCHEMIC;AMERICAN SOCIETY;ANESTHESIOLOGISTS IV;ANNA CANTISANI;AORTIC ANEURYSM;BDL RATS;BRAIN EDEMA;CANTISANI ROBERTO;CELANI TERESA;CLINICAL OUTCOME;COMPLETED RANDOMIZED;CONFIDENCE INTERVAL;DISEASE RATE;ENRICO RIGHETTI;FXR LIGAND;FXR LIGANDS;GRAZIA CELANI","6;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",3,0.19,9.5,27.5,0,0,0,1,53,0,1,28.5,0,0,0,0,0,0,0,0,0,0.5,0,81,81.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,20,1294,3.7,1,1,22,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1","AGING;BREAST CANCER;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;ESTROGEN","1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS","1","BREAST CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2005,19,15.1578947368421,2.73684210526316,0.631578947368421,0.31578947368421,0.68421052631579,1.1063829787234,1.09090909090909,0.857142857142857,1.08333333333333,0.263157894736842,0,6,4,3,4,0.32,0.21,0.16,0.21,34.42,0.650144096738903,NA,0.210526315789474,0.736842105263158,0.369,0.15,0.167,0.14,"MARIA LETIZIA D’ANNIBALE;DANIELE CROTTI;JØRN HERRSTEDT;E BUCCIARELLI;MAURIZIO TONATO;R. TARDUCCI;ANGELO SIDONI;STEFANO CASCINU;G. GOBBI;ENZO BALLATORI;F. DE PAOLA;G.P. PELLICCIOLI;M BOTTURI;FURIO POLI;A RUGGIERO;GIULIANA BARDELLI;MODESTO DʼAPRILE;PAOLO ALESSANDRONI;PAOLA COLLECCHI;BARBARA PICCONI","3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MARIA LETIZIA D’ANNIBALE;DANIELE CROTTI;JØRN HERRSTEDT;STEFANO MARCO PAOLO ROSSI;A RICCI;FAUSTO ROILA;MATTI AAPRO;VESA KATAJA;R. TARDUCCI;G. GOBBI;G.P. PELLICCIOLI;GIULIANA BARDELLI;PASQUALINO CIAPPETTA;A PUXEDDU;ROBERTO DELFINI;E LENCI;GIUSEPPE QUINTALIANI;L BENCI;S FIORONI;ANTONINO RACO","0.83;0.83;0.35;0.33;0.33;0.25;0.25;0.25;0.22;0.22;0.22;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2","MARIA LETIZIA D’ANNIBALE;DANIELE CROTTI;E BUCCIARELLI;MAURIZIO TONATO;R. TARDUCCI;ANGELO SIDONI;G. GOBBI;ENZO BALLATORI;G.P. PELLICCIOLI;GIULIANA BARDELLI;PASQUALINO CIAPPETTA;FABIO PARAZZINI;ROBERTA CHERUBINI;CRISTINA SIDOLI;GIUSEPPE PANUCCIO;FABIO VERZINI;STEFANIA GORI;FAUSTO ROILA;MAURA BETTI;GUSTAVO IACONO","3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MARIA LETIZIA D’ANNIBALE;DANIELE CROTTI;FAUSTO ROILA;R. TARDUCCI;G. GOBBI;G.P. PELLICCIOLI;GIULIANA BARDELLI;PASQUALINO CIAPPETTA;GIUSEPPE QUINTALIANI;SERGIO PAOLINI;TEMISTOCLE RAGNI;STEFANO COACCIOLI;GIUSEPPE MINNITI;I DIBELLA;U DACOL;DANIELA ROSSI;G FONZO;FABIO PARAZZINI;CRISTINA SIDOLI;GIUSEPPE PANUCCIO","0.83;0.83;0.25;0.22;0.22;0.22;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.17;0.17;0.14;0.14;0.14","G. GOBBI;G.P. PELLICCIOLI;R. TARDUCCI;ANTONIO CHERUBINI;ANTONIO METASTASIO;ELENA MARIANI;F.T. FELIZIANI;PATRIZIA MECOCCI;PATRIZIA RINALDI;UMBERTO SENIN;ANDREA ALBERTI;GIUSEPPE CAPOCCHI;GIUSEPPE STIPA;O. PRESCIUTTI;PAOLA SARCHIELLI;ANTONIO PISANI;BARBARA PICCONI;CARMELO SGOBIO;ENRICA PASSINO;GIORGIO BERNARDI","195;195;195;100;100;100;100;100;100;100;95;95;95;95;95;89;89;89;89;89","G.P. PELLICCIOLI;G. GOBBI;O. PRESCIUTTI;R. TARDUCCI;PAOLO CALABRESI;D K XANTHOPOULOS;FABIO VERZINI;GIANBATTISTA PARLANI;GIUSEPPE PANUCCIO;GUSTAVO IACONO;PAOLA DE RANGO;PIERGIORGIO CAO;A CHIÀNTERA;ALESSANDRA GRAZIOTTIN;COSTANTE DONATI SARTI;CRISTINA SIDOLI;FABIO PARAZZINI;FERDINANDO OGNISANTI;MILENA MINCIGRUCCI;PASQUALINO CIAPPETTA","195;95;95;95;89;77;77;77;77;77;77;77;60;60;60;60;60;60;60;57","DANIELE CROTTI;FAUSTO ROILA;G.P. PELLICCIOLI;MARIA LETIZIA D’ANNIBALE;MAURIZIO TONATO;A CHIÀNTERA;ALESSANDRA GRAZIOTTIN;ANGELO SIDONI;ANNA MARIA MOSCONI;COSTANTE DONATI SARTI;CRISTINA SIDOLI;D K XANTHOPOULOS;E BUCCIARELLI;ENZO BALLATORI;FABIO PARAZZINI;FABIO VERZINI;FERDINANDO OGNISANTI;FRANCESCA MARROCOLO;G FONZO;G. GOBBI","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY","18;6;3;2;1;1;1;1","INTERNAL MEDICINE;ANESTHESIA;GENETICS;INTENSIVE CARE MEDICINE;NURSING;ONCOLOGY;PATHOLOGY;SURGERY;IMMUNOLOGY;NEUROSCIENCE;PALEONTOLOGY;RADIOLOGY;VETERINARY MEDICINE;ANATOMY;ASTRONOMY;AUDIOLOGY;CANCER RESEARCH;CARDIOLOGY;DEMOGRAPHY;DERMATOLOGY;ECOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;LAW;MEDICAL EDUCATION;MEDICAL PHYSICS;MICROBIOLOGY;NUCLEAR MAGNETIC RESONANCE;OPTICS;PHARMACOLOGY;PHYSICAL THERAPY;PSYCHIATRY;PSYCHOTHERAPIST;PUBLIC RELATIONS;STATISTICS;WORLD WIDE WEB;ZOOLOGY","14;3;3;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;DISEASE;EPIDEMIOLOGY;IMMUNOHISTOCHEMISTRY;NAUSEA;STAGE (STRATIGRAPHY);VOMITING;ADJUVANT;ANEMIA;ANESTHESIOLOGY;ANEURYSM;ANTIBODY;ARGUMENTATIVE;CENTRAL NERVOUS SYSTEM;CHOLINERGIC;CHRONIC RENAL FAILURE;CLINICAL TRIAL;CONCORDANCE;CORTICOSTEROID;DIABETES MELLITUS;DYSPLASIA;ELECTROENCEPHALOGRAPHY;EOSINOPHILIA;ETIOLOGY;FECES;FLOW CYTOMETRY;FLUOROSCOPY;GENE;GIARDIA;GIARDIA LAMBLIA;GIEMSA STAIN;HELMINTHS;HEMODIALYSIS;HEMODYNAMICS;HEMOLYSIS;HEMOLYTIC ANEMIA;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);INFLAMMATION;INSOMNIA;LARVA;LESION;LUMBAR;LYMPHOCYTE;MAGNETIC RESONANCE IMAGING;MENOPAUSE;MIGRAINE;MITRAL VALVE;MORAL RESPONSIBILITY;MYELOID;MYELOID LEUKEMIA;NURSING RESEARCH;OUTPATIENT CLINIC;PARASITE HOSTING;PARASITOLOGY;PERCEPTION;POPULATION;POSTMENOPAUSAL WOMEN;PREDNISOLONE;PREDNISONE;PROFESSIONAL DEVELOPMENT;PROFESSIONAL RESPONSIBILITY;PROTON MAGNETIC RESONANCE;QUALITY OF LIFE (HEALTHCARE);RADIATION THERAPY;RADIOGRAPHY;RECEPTOR;RELEVANCE (LAW);REPRODUCIBILITY;SOCIAL RESPONSIBILITY;SPECTROSCOPY;SPINOUS PROCESS;STIMULATION;STIMULUS (PSYCHOLOGY);TESTOSTERONE (PATCH);THORACIC SPINE;TRANSDERMAL;VERTEBRA;VISUAL CORTEX","4;4;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ABDOMINAL AORTIC ANEURYSM;ADJUVANT THERAPY;ANTIEMETIC;AURA;BASAL GANGLIA;CD8;CHEMOTHERAPY REGIMEN;CHROMOSOME;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;DEFLAZACORT;DEMENTIA;FLUOROURACIL;HORMONE REPLACEMENT THERAPY (FEMALE-TO-MALE);HUNTINGTON'S DISEASE;ICTAL;LONG-TERM POTENTIATION;LUMBAR VERTEBRAE;MICROANGIOPATHY;MITRAL VALVE REPAIR;MONOCLONAL ANTIBODY;MYIASIS;NEURONAVIGATION;PAIN MEDICINE;PREDICTIVE MARKER;SLEEP QUALITY;STRONGYLOIDES STERCORALIS;STRONGYLOIDIASIS;SYNAPTIC PLASTICITY;THROMBOTIC MICROANGIOPATHY;VASCULITIS;VISUAL PERCEPTION","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTHRACYCLINE;BREAST CARCINOMA;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;CHROMOSOME 7 (HUMAN);CHROMOSOME INSTABILITY;ENDOVASCULAR ANEURYSM REPAIR;EPIRUBICIN;FOLINIC ACID;GIANT CELL ARTERITIS;HER2/NEU;HORMONE THERAPY;KARYOTYPE;LYMPHOCYTE SUBSETS;MEDIUM SPINY NEURON;MIGRAINE WITH AURA;OESTRUS OVIS;PHOTIC STIMULATION;THORACIC VERTEBRAE;TRASTUZUMAB","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ASPARTIC ACID;BREAST NEOPLASMS;ADULT;AGED;BIOMARKERS, TUMOR;CHOLINE;COLORECTAL NEOPLASMS;MIDDLE AGED;AMNESIA;COGNITION DISORDERS;CREATINE;DEMENTIA;DIENTAMOEBA;DIENTAMOEBIASIS;FLUOROURACIL;GIARDIA","15;10;10;7;7;7;5;5;5;5;5;5;4;4;4;4;4;4;4;4","HER2 SIGNALING IN BREAST CANCER TREATMENT;PREVENTION AND MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING;AMOEBIASIS: PATHOGENESIS AND CLINICAL MANAGEMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF URTICARIA;EFFECTS OF HORMONES ON MENOPAUSAL WOMEN'S HEALTH;FORENSIC ENTOMOLOGY AND DECOMPOSITION SCIENCE;GENETIC BASIS OF NEUTROPENIA DISORDERS;GLOBAL IMPACT OF HELMINTH INFECTIONS AND CONTROL STRATEGIES;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;MANAGEMENT OF VALVULAR HEART DISEASE;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;MOLECULAR MECHANISMS OF NEURODEGENERATIVE DISEASES;MORAL DISTRESS IN HEALTHCARE PROFESSIONALS;PATHOPHYSIOLOGY OF LUMBAR DISC DEGENERATION AND TREATMENT;RHABDOMYOLYSIS AND COMPARTMENT SYNDROMES","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CHEMOTHERAPY-INDUCED NAUSEA;POSTOPERATIVE NAUSEA;VOMITING PREVENTION;ADJUVANT CHEMOTHERAPY;ADJUVANT THERAPY;ANEURYSM RUPTURE;ANEURYSM SCREENING;ANTIEMETIC THERAPY;ARGUMENTATIVE;BRAIN ACTIVATION;BRAIN METABOLITES;BREAST CARCINOMA;CHEMOTHERAPY REGIMEN;CHROMOSOME INSTABILITY;CHRONIC RENAL FAILURE;CLINICAL FEATURES;CONCORDANCE;DEFLAZACORT;DIAGNOSIS","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;LYMPHOCYTE SUBPOPULATIONS;ABDOMINAL AORTIC;ACUTE RENAL;ADJUVANT CYCLOPHOSPHAMIDEMETHOTREXATE-FLUOROURACIL;ADJUVANT SYSTEMIC;ADULTS ATTENDING;ANALISI DI;AORTIC ANEURYSM;ASSESSED INTERICTALLY;AURA ASSESSED;AUTOIMMUNE INFLAMMATORY;BEHAVIORAL ABNORMALITIES;CANCER LONG-TERM;CARE CENTRE;CASISTICA DECENNALE;CENTRAL ITALY;CHEMOTHERAPY-INDUCED NAUSEA;CHOLINERGIC INTERNEURONS;CHRONIC AUTOIMMUNE;CLINICAL PRACTICE;CLINICAL RECOMMENDATIONS;COLORECTAL CANCER;COMPARING ADJUVANT;CONSENSUS PROPOSALS;CRUCIAL ROLE;DAY CARE;DELAYED VOMITING;DEMENTIA ROLE;DI UNA","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PRIMARY EVAR;LATE CONVERSION;SECONDARY ENDOVASCULAR;STRONGYLOIDES STERCORALIS;ACUTE NAUSEA;AGGRESSIVE ATTITUDE;ANAMNESTICAL SUGGESTIONS;ANEURYSMS ASA;ANGULATED NECK;ANTICIPATORY NAUSEA;ASA SCORE;AUTHORS DESCRIBE;AUTHORS RELATE;AUTHORS REPORT;AVOID FORCING;BAERMANNS METHOD;BIOLOGICAL FEATURES;CALCIFICATION PERI-OPERATIVE;CENTRAL ITALY;CENTRAL UMBRIATHUS;CHEMOTHERAPY ANTICIPATORY;CHEMOTHERAPY DELAYED;CHEMOTHERAPY-INDUCED NAUSEA;CLINICAL RECOMMENDATIONS;COMPLETED EVAR;COMPLICATIONSEARLY CONVERSION;CONSECUTIVE PATIENTS;CONVERSIONS OCCURRED;CORRECT DOSAGE;DEFINITIONS ACUTE","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",4,0.21,8.25,1.75,0,1,0,2,1,0,0,1.75,0,0,0,0,2,0,0,0,0,0,0,76.5,76.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,4.33,1778.33,9.52,1,0.25,21,0,0,1,0,0,0,2,1,0,2,1,0,0,0,0,0,0,4,0,0,3,1,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY","4;3;1;1;1;1;1","CLINICAL RESEARCH;CARDIOVASCULAR;AGING;ATHEROSCLEROSIS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;GENETIC TESTING;GENETICS;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HUMAN GENOME;HYPERTENSION;NEUROSCIENCES;PREVENTION;STROKE","3;2;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;STROKE","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS","1;1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2006,25,6.68,2.96,0.56,0.52,0.68,1.19354838709677,1,1.08333333333333,1,0.28,0,10,4,6,3,0.4,0.16,0.24,0.12,42.6,0.834015176952523,NA,0.16,0.72,0.352,0.211,0.313,0.284,"GIORGIO BERNARDI;DIEGO CENTONZE;BARBARA PICCONI;PAOLO CALABRESI;CHIARA PROSPERETTI;SILVIA ROSSI;TEMISTOCLE RAGNI;UBERTO DA COL;GIULIANA BARDELLI;LUCILLA PARNETTI;GIUSEPPE CAPOCCHI;GIORGIO SILVESTRELLI;PERUGIA STROKE;MARIA LETIZIA D’ANNIBALE;ILARIA BARONE;DAVIDE DI LAZZARO;GINO DI MANICI;NICOLA TAMBASCO;DANIELE CROTTI;ANNE TSCHERTER","6;5;5;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MARIA LETIZIA D’ANNIBALE;DANIELE CROTTI;GIORGIO BERNARDI;BARBARA PICCONI;PAOLO CALABRESI;DIEGO CENTONZE;CHRISTOPHE MATHOULIN;M. MASSARELLA;TEMISTOCLE RAGNI;UBERTO DA COL;CHIARA PROSPERETTI;SILVIA ROSSI;ISIDORO DI BELLA;LUCILLA PARNETTI;GIUSEPPE CAPOCCHI;GIORGIO SILVESTRELLI;PERUGIA STROKE;NICOLA TAMBASCO;DAVIDE DI LAZZARO;GINO DI MANICI","1;1;0.74;0.63;0.63;0.61;0.5;0.5;0.47;0.47;0.45;0.45;0.37;0.31;0.31;0.31;0.31;0.31;0.3;0.3","PAOLO CALABRESI;TEMISTOCLE RAGNI;UBERTO DA COL;GIULIANA BARDELLI;LUCILLA PARNETTI;GIUSEPPE CAPOCCHI;GIORGIO SILVESTRELLI;PERUGIA STROKE;MARIA LETIZIA D’ANNIBALE;DAVIDE DI LAZZARO;GINO DI MANICI;NICOLA TAMBASCO;DANIELE CROTTI;ISIDORO DI BELLA;AGOSTINO MASELLI;ANTONIO RULLI;LUCIO CRINÓ;FRANCESCO GRASSELLI;EDOARDO FARINELLI;GRAEME J. HANKEY","5;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","MARIA LETIZIA D’ANNIBALE;DANIELE CROTTI;PAOLO CALABRESI;CHRISTOPHE MATHOULIN;M. MASSARELLA;TEMISTOCLE RAGNI;UBERTO DA COL;ISIDORO DI BELLA;LUCILLA PARNETTI;GIUSEPPE CAPOCCHI;GIORGIO SILVESTRELLI;PERUGIA STROKE;NICOLA TAMBASCO;DAVIDE DI LAZZARO;GINO DI MANICI;GIULIANA BARDELLI;EDOARDO FARINELLI;GRAEME J. HANKEY;GABRIO BASSOTTI;MARIA GRAZIA CELANI","1;1;0.63;0.5;0.5;0.47;0.47;0.37;0.31;0.31;0.31;0.31;0.31;0.3;0.3;0.27;0.25;0.2;0.2;0.2","ANTONIO MORELLI;GABRIO BASSOTTI;GIUSEPPE CHIARIONI;VINCENZO PEZZA;WILLIAM E. WHITEHEAD;A. TOSONI;ALBA A. BRANDES;ENRICO FRANCESCHI;GIOVANNI CAVALLO;LUCIO CRINÓ;M BISCUOLA;MARIO ERMANI;ROBERTA BERTORELLE;V. BLATT;V. GIOIA;GIORGIO BERNARDI;PAOLO CALABRESI;DIEGO CENTONZE;BARBARA PICCONI;CHIARA PROSPERETTI","427;427;427;427;427;227;227;227;227;227;227;227;227;227;227;147;120;115;102;95","ANTONIO MORELLI;GABRIO BASSOTTI;LUCIO CRINÓ;PAOLO CALABRESI;M D'AJELLO;NICOLA AVENIA;AGOSTINO MASELLI;FABIO VERZINI;GIUSEPPE GIORDANO;LUCIA NORGIOLINI;PAOLA DE RANGO;PIERGIORGIO CAO;ANTONIO ANGELINI;GIAN FRANCESCO BRUSCO;HELMY SELMAN;NICOLETTA BARNOCCHI;CINZIA COSTA;TEMISTOCLE RAGNI;UBERTO DA COL;GIULIANA BARDELLI","427;427;227;120;66;66;52;52;52;52;52;52;47;47;47;47;45;29;29;28","PAOLO CALABRESI;TEMISTOCLE RAGNI;UBERTO DA COL;DAVIDE DI LAZZARO;GINO DI MANICI;GIULIANA BARDELLI;ISIDORO DI BELLA;AGOSTINO MASELLI;ANGELO SIDONI;ANNA MARIA MOSCONI;ANTONIO ANGELINI;ANTONIO MORELLI;ANTONIO RULLI;CHRISTOPHE MATHOULIN;CINZIA COSTA;DANIELE CROTTI;E. PACIFICO;ELIANA RULLI;ENRICA ANGELI;ENRICO RAMONI","5;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;ENGINEERING;CHEMISTRY;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY","25;11;4;3;1;1;1","INTERNAL MEDICINE;SURGERY;NEUROSCIENCE;CARDIOLOGY;GENETICS;MECHANICAL ENGINEERING;PATHOLOGY;BIOCHEMISTRY;PALEONTOLOGY;PEDIATRICS;PHARMACOLOGY;RADIOLOGY;ANESTHESIA;CELL BIOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;OBSTETRICS;ONCOLOGY;PHYSICAL THERAPY;ANDROLOGY;DERMATOLOGY;EMERGENCY MEDICINE;ENDOCRINOLOGY;GASTROENTEROLOGY;GENERAL SURGERY;HUMANITIES;IMMUNOLOGY;INTENSIVE CARE MEDICINE;MATHEMATICS EDUCATION;MICROBIOLOGY;NUCLEAR MEDICINE;PSYCHIATRY;VIROLOGY","15;14;6;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DOPAMINE;RECEPTOR;DISEASE;STROKE (ENGINE);ISCHEMIA;BACTERIA;BLOOD PRESSURE;CANCER;CENTRAL NERVOUS SYSTEM;CHEMOTHERAPY;CONSTIPATION;ETIOLOGY;INHIBITORY POSTSYNAPTIC POTENTIAL;LESION;PROSTHESIS;TISSUE PLASMINOGEN ACTIVATOR;WRIST;ABNORMALITY;ACETYLCHOLINE;ADDICTION;ANGIOGRAPHY;ARTERY;ARTHROSCOPY;ASYMPTOMATIC;BIOFEEDBACK;CARNITINE;CAROTID ARTERIES;COMPUTED TOMOGRAPHY;CONCORDANCE;CUFF;DEFECATION;DENERVATION;ELECTROPHYSIOLOGY;EMBRYO;ENDOGENY;ENDOSCOPY;ENEMA;ENTERITIS;EPIDEMIOLOGY;FISTULA;GENE;HELMINTHS;HUMAN PAPILLOMAVIRUS;IMMUNOHISTOCHEMISTRY;IN VITRO;ISOLATION (MICROBIOLOGY);KINASE;LEAFLET (BOTANY);MITOCHONDRION;MITRAL VALVE;NATURAL HISTORY;NEUROPROTECTION;NODULE (GEOLOGY);OXYURIASIS;PAEDIATRIC SURGERY;PATHOLOGICAL;PELVIC FLOOR;PIRACETAM;POPULATION;POSTERIOR WALL;PREGNANCY;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;REGIMEN;RESECTION;SPERM;SPHINCTER;STAGE (STRATIGRAPHY);STERNUM;THYROID;ULTRASOUND;UNIT (RING THEORY);UPPER LIMB;VAGINA;VEIN","5;5;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","STRIATUM;GLUTAMATE RECEPTOR;PARKINSON'S DISEASE;BASAL GANGLIA;DIASTOLE;EXCITATORY POSTSYNAPTIC POTENTIAL;ISCHEMIC STROKE;NMDA RECEPTOR;ACUTE STROKE;AGAR;AGAR PLATE;ANORECTAL MANOMETRY;ARTIFICIAL INSEMINATION;BREAST CANCER;CAMPYLOBACTER;CAROTID ENDARTERECTOMY;CERVICAL CANCER;CHEMOTHERAPY REGIMEN;CHOREA;CHRONIC CONSTIPATION;COMPUTED TOMOGRAPHY ANGIOGRAPHY;DACARBAZINE;DOPAMINE RECEPTOR D2;DOPAMINERGIC;DYSSYNERGIA;EMBRYO TRANSFER;ENDARTERECTOMY;ENTEROBIUS;FUNCTIONAL CONSTIPATION;GENETIC MODEL;HUNTINGTON'S DISEASE;INSEMINATION;LAXATIVE;LONG-TERM POTENTIATION;MITRAL VALVE REPAIR;MULTIDETECTOR COMPUTED TOMOGRAPHY;NEUROTRANSMISSION;OOCYTE;PHASES OF CLINICAL RESEARCH;PREGNANCY RATE;PROSTATE;PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC;RADIAL ARTERY;REPRODUCTIVE MEDICINE;ROTENONE;SCAPHOLUNATE LIGAMENT;STAPHYLOCOCCUS AUREUS;SYNAPTIC PLASTICITY;TEMOZOLOMIDE;THYROID FUNCTION;THYROID NODULES;WRIST ARTHROSCOPY","5;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DEEP BRAIN STIMULATION;CAROTID STENTING;CERVICAL INTRAEPITHELIAL NEOPLASIA;COLPOSCOPY;DYSKINESIA;EMBRYO QUALITY;EXCITOTOXICITY;HPV INFECTION;INDIRECT PATHWAY OF MOVEMENT;INTRAEPITHELIAL NEOPLASIA;LYN;MEDIUM SPINY NEURON;MODIFIED RANKIN SCALE;SINGLE EMBRYO TRANSFER;SUBSTANTIA NIGRA;TRASTUZUMAB;VANCOMYCIN","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;CORPUS STRIATUM;MIDDLE AGED;AGED;ADULT;ANIMALS;EXCITATORY POSTSYNAPTIC POTENTIALS;ITALY;NEURONS;SYNAPTIC TRANSMISSION;RATS;STROKE;;CONSTIPATION;DACARBAZINE;FOLLOW-UP STUDIES;HUNTINGTON DISEASE;PROSTHESIS-RELATED INFECTIONS","14;13;12;9;9;8;7;7;7;7;7;7;6;6;5;5;5;5;5;5","EPIDEMIOLOGY AND MANAGEMENT OF STROKE;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;MANAGEMENT OF VALVULAR HEART DISEASE;MOLECULAR MECHANISMS OF NEURODEGENERATIVE DISEASES;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIAGNOSIS AND TREATMENT OF SPINAL INFECTIONS;GLIOMAS;GLOBAL BURDEN OF FOODBORNE PATHOGENS;GLOBAL IMPACT OF HELMINTH INFECTIONS AND CONTROL STRATEGIES;HER2 SIGNALING IN BREAST CANCER TREATMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;IMPACT OF ASSISTED REPRODUCTIVE TECHNOLOGY ON PERINATAL OUTCOMES;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;PRINCIPLES AND INTERVENTIONS IN STROKE REHABILITATION","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","STROKE (ENGINE);CONSTIPATION;ETIOLOGY;SUBTHALAMIC NUCLEUS;TRANSCATHETER AORTIC-VALVE REPLACEMENT;TREATMENT;ACUTE STROKE;ANORECTAL MANOMETRY;BACTERIAL CONTAMINATION;BIOFEEDBACK;BLOOD PRESSURE;BREAST CANCER;CAMPYLOBACTER;CARDIOVASCULAR EVENTS;CAROTID ARTERY STENOSIS;CAROTID STENTING;CELL DEATH;CEREBROVASCULAR EVENTS;CHEMOTHERAPY REGIMEN;COMPULSIVE BEHAVIORS","4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GLUTAMATE TRANSMISSION;STROKE UNIT;AAMPD WRIST-CUFF;ACETYL-L-CARNITINE PROTECTS;ACUTE ISCHEMIC;AORTIC PROSTHESIS;ARTERY BYPASS;ASSISTED REPRODUCTIVE;BC PATIENTS;BENIGN THYROID;BLOOD PRESSURE;BOVINE PERICARDIAL;BREAST CANCER;BYPASS GRAFTS;CAMPYLOBACTER UPSALIENSIS;CANCER BC;CAROTID STENTING;CHRONIC COCAINE;CLINICAL-PATHOLOGICAL PARAMETERS;COCAINE PREVENTS;COMPUTED TOMOGRAPHY;CONSTIPATION DUE;CONTROLLED TRIAL;COOPERATIVO DI;CORTICOSTRIATAL SYNAPSES;CSF FISTULA;DA CAMPYLOBACTER;DE CAS;DE LARTHROSCOPIE;DELAYED ADMISSION","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PERUGIA ITALY;RADIAL ARTERY;BOVINE PERICARDIAL;COMPUTED TOMOGRAPHY;UOCD NEUROLOGIA;ACUTE ISCHEMIC;ACUTE STROKE;AZIENDA OSPEDALIERA;DELL UMBRIA;ICTUS USL;NEUROFISIOPATOLOGIA TAC;OSPEDALIERA PERUGIA;TAC AZIENDA;UMBRIA PERUGIA;USL DELL;ARTERY GRAFT;CORONARY ARTERY;ISCHEMIC STROKE;MULTIDETECTOR ROW;PELVIC FLOOR;PERICARDIAL VALVE;ROW COMPUTED;TARGET VESSEL;VEIN GRAFTS;AORTIC VALVE;ASCENDING AORTA;BIZEKIS CS;CARDIOVASC SURG;COLVIN SB;CS STRONG","11;8;7;6;6;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3",8,0.32,6,2,0,1,0,7,2,0,2,2.25,0,1,4.75,0,1,1,1,2.5,1,0,0,55.5,55.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,7.5,825.5,3.33,0,0,165,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","2;2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DRUG ABUSE (NIDA ONLY);EMERGING INFECTIOUS DISEASES;HEMATOLOGY;LUNG;LYMPHOMA;PATIENT SAFETY;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;SUBSTANCE MISUSE","2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","2;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2007,41,8.02439024390244,2.60975609756098,0.658536585365854,0.292682926829268,0.658536585365854,1.50704225352113,1.17391304347826,1.2,1.17391304347826,0.463414634146341,0,20,5,2,6,0.49,0.12,0.05,0.15,89.98,1.70485874644074,NA,0.341463414634146,0.658536585365854,0.463,0.388,0.387,0.395,"LUCIO CRINÓ;STEFANIA GORI;PAOLO CALABRESI;MARIA LETIZIA D’ANNIBALE;DANIELE CROTTI;DIEGO CENTONZE;FEDERICO CAPPUZZO;BARBARA PICCONI;VINCENZO BELCASTRO;CINZIA COSTA;GIUSEPPE AMBROSIO;ENRICO RAMONI;TEMISTOCLE RAGNI;VERENA DE ANGELIS;MARIANTONIETTA COLOZZA;ALESSANDRO TOZZI;GIOVANNA FINOCCHIARO;LUCILLA PARNETTI;GIAMPAOLO BUCANEVE;GIORGIO BERNARDI","9;5;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","MARIA LETIZIA D’ANNIBALE;DANIELE CROTTI;LUCIO CRINÓ;STEFANIA GORI;PAOLO CALABRESI;GIUSEPPE AMBROSIO;MASSIMO E. DOTTORINI;LUIGI MANSI;ENRICO RAMONI;TEMISTOCLE RAGNI;GIAMPAOLO BUCANEVE;FRANCESCO MENICHETTI;VINCENZO BELCASTRO;CINZIA COSTA;PAOLO VERDECCHIA;DIEGO CENTONZE;BARBARA PICCONI;SILVIA CROTTI;ISIDORO DI BELLA;VERENA DE ANGELIS","1.83;1.83;1.17;0.84;0.64;0.57;0.5;0.5;0.44;0.44;0.4;0.4;0.39;0.39;0.37;0.36;0.35;0.33;0.3;0.29","LUCIO CRINÓ;STEFANIA GORI;PAOLO CALABRESI;MARIA LETIZIA D’ANNIBALE;DANIELE CROTTI;BARBARA PICCONI;VINCENZO BELCASTRO;CINZIA COSTA;ENRICO RAMONI;TEMISTOCLE RAGNI;VERENA DE ANGELIS;MARIANTONIETTA COLOZZA;ALESSANDRO TOZZI;LUCILLA PARNETTI;GIAMPAOLO BUCANEVE;VALERIA CASO;P. ANASTASI;ANGELO SIDONI;SERGIO BRACARDA;MICHELA TANTUCCI","9;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MARIA LETIZIA D’ANNIBALE;DANIELE CROTTI;LUCIO CRINÓ;STEFANIA GORI;PAOLO CALABRESI;MASSIMO E. DOTTORINI;ENRICO RAMONI;TEMISTOCLE RAGNI;GIAMPAOLO BUCANEVE;VINCENZO BELCASTRO;CINZIA COSTA;PAOLO VERDECCHIA;BARBARA PICCONI;ISIDORO DI BELLA;VERENA DE ANGELIS;LUCILLA PARNETTI;FABIO ANGELI;GIUSEPPE QUINTALIANI;MARIANTONIETTA COLOZZA;VALERIA CASO","1.83;1.83;1.17;0.84;0.64;0.5;0.44;0.44;0.4;0.39;0.39;0.37;0.35;0.3;0.29;0.28;0.27;0.25;0.24;0.22","SERGIO BRACARDA;A PŁUŻAŃSKA;AGNIESZKA JAGIEŁŁO-GRUSZFELD;ALAIN RAVAUD;BERNARD ESCUDIER;BOHUSLAV MELICHAR;CEZARY SZCZYLIK;CHRISTINE CHEVREAU;EMILIO BAJETTA;I. BODROGI;JACQUES‐OLIVIER BAY;M. FILIPEK;N. MOORE;P. KORALEWSKI;В. А. ГОРБУНОВА;LUCIO CRINÓ;GIANCARLO AGNELLI;FEDERICO CAPPUZZO;C. LIGORIO;ELISA ROSSI","2219;2203;2203;2203;2203;2203;2203;2203;2203;2203;2203;2203;2203;2203;2203;520;356;354;349;349","SERGIO BRACARDA;LUCIO CRINÓ;AJAY K. KAKKAR;ALEXANDER GALLUS;FRANK MISSELWITZ;GIANCARLO AGNELLI;MENNO V. HUISMAN;RUSSEL HULL;SAMUEL Z. GOLDHABER;SEBASTIAN SCHELLONG;SYLVIA HAAS;PAOLO CALABRESI;STEFANIA GORI;CINZIA COSTA;VINCENZO BELCASTRO;MARIANTONIETTA COLOZZA;CARLO BASURTO;P. ANASTASI;LUCILLA PARNETTI;ALESSANDRO TOZZI","2219;520;331;331;331;331;331;331;331;331;331;288;184;178;178;172;146;146;119;94","LUCIO CRINÓ;STEFANIA GORI;PAOLO CALABRESI;MARIA LETIZIA D’ANNIBALE;CINZIA COSTA;MARIANTONIETTA COLOZZA;VINCENZO BELCASTRO;ALESSANDRO TOZZI;ENRICO RAMONI;GIAMPAOLO BUCANEVE;ISIDORO DI BELLA;LUCILLA PARNETTI;MICHELA TANTUCCI;P. ANASTASI;PAOLO VERDECCHIA;SERGIO BRACARDA;TEMISTOCLE RAGNI;VERENA DE ANGELIS;A. CONTU;AJAY K. KAKKAR","9;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1","MEDICINE;BIOLOGY;CHEMISTRY;MATHEMATICS;ART;COMPUTER SCIENCE;ENGINEERING;PHYSICS;PSYCHOLOGY;PHILOSOPHY;POLITICAL SCIENCE","37;12;6;3;2;2;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;CARDIOLOGY;PATHOLOGY;RADIOLOGY;BIOCHEMISTRY;GENETICS;NEUROSCIENCE;CANCER RESEARCH;ENDOCRINOLOGY;GENERAL SURGERY;INTENSIVE CARE MEDICINE;PHARMACOLOGY;ANATOMY;ANESTHESIA;ECOLOGY;HUMANITIES;MECHANICAL ENGINEERING;MEDICAL PHYSICS;MICROBIOLOGY;PEDIATRICS;UROLOGY","32;11;10;8;7;6;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","CHEMOTHERAPY;CANCER;LUNG CANCER;RECEPTOR;ADVERSE EFFECT;RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;BLOOD PRESSURE;CLINICAL TRIAL;GENE;ATRIAL FIBRILLATION;CARCINOMA;CONFIDENCE INTERVAL;DOPAMINE;HEART FAILURE;IMMUNOHISTOCHEMISTRY;ISCHEMIA;MYOCARDIAL INFARCTION;PROSPECTIVE COHORT STUDY;RENAL CELL CARCINOMA;STROKE (ENGINE);THROMBUS","11;10;6;6;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CLINICAL ENDPOINT;EPIDERMAL GROWTH FACTOR RECEPTOR;GLUTAMATE RECEPTOR;PHASES OF CLINICAL RESEARCH;CHROMOSOME;CISPLATIN;COLORECTAL CANCER;EXON;NEUROTRANSMISSION;NMDA RECEPTOR;PLACEBO;PROGRESSIVE DISEASE;STRIATUM;TYROSINE KINASE;A549 CELL;AGONIST;ALKALINE PHOSPHATASE;ALPHA INTERFERON;AMBULATORY BLOOD PRESSURE;ANGINA;ANGIOTENSIN-CONVERTING ENZYME;ANTIBIOTIC PROPHYLAXIS;ANTIEPILEPTIC DRUG;AORTIC ARCH;AORTIC VALVE REPLACEMENT;ASCENDING AORTA;ATENOLOL;BEVACIZUMAB;BONE MINERAL;BRAIN ISCHEMIA;CAMPYLOBACTER;CARDIOTOXICITY;CLINICAL ONCOLOGY;CONTRAINDICATION;CRITICAL APPRAISAL;DEEP VEIN;DIASTOLE;DOCETAXEL;DOPAMINE RECEPTOR D2;DOXAZOSIN;EJECTION FRACTION;EPIDERMAL GROWTH FACTOR;EVIDENCE-BASED MEDICINE;EXCITATORY POSTSYNAPTIC POTENTIAL;GEMCITABINE;GENE EXPRESSION;GENOME;HAZARD RATIO;HEART RATE;HUNTINGTON'S DISEASE;INTENTION-TO-TREAT ANALYSIS;INTERIM ANALYSIS;INTERVENTRICULAR SEPTUM;ISCHEMIC STROKE;LEFT ATRIUM;LEFT VENTRICULAR HYPERTROPHY;LEVETIRACETAM;LONG-TERM POTENTIATION;METASTASIS;MUCOSITIS;MUTATION;MYIASIS;NEPHRECTOMY;NEURODEGENERATION;NEUTROPENIA;PATENT FORAMEN OVALE;PERFORMANCE STATUS;PHARMACODYNAMICS;POSTSYNAPTIC POTENTIAL;QUINOLONE;RADIOACTIVE IODINE;RANDOMIZATION;RECEPTOR TYROSINE KINASE;RENIN–ANGIOTENSIN SYSTEM;REPOLARIZATION;SALMONELLA;SEPTIC SHOCK;SORAFENIB;SYNAPTIC PLASTICITY;THROMBOLYSIS;THYROID CANCER;THYROID DISEASE;TOLERABILITY;TYROSINE-KINASE INHIBITOR;UNSTABLE ANGINA;VALVE REPLACEMENT;VASCULAR ENDOTHELIAL GROWTH FACTOR;VENOUS THROMBOSIS;VULVAR CARCINOMA;WARFARIN","5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","METASTATIC BREAST CANCER;FLUORESCENCE IN SITU HYBRIDIZATION;GLUTAMATERGIC;TRASTUZUMAB;ADENOSINE RECEPTOR;ALISKIREN;ANTHRACYCLINE;BRACHIOCEPHALIC ARTERY;BRAIN METASTASIS;CARBOPLATIN;CETUXIMAB;COPY-NUMBER VARIATION;ELEPHANT TRUNKS;EPIRUBICIN;ERLOTINIB;FEBRILE NEUTROPENIA;FORAMEN OVALE (HEART);FOSSA OVALIS;GEFITINIB;GENE DOSAGE;INTERFERON ALFA;KRAS;LISINOPRIL;MEDIUM SPINY NEURON;MEMANTINE;MISSENSE MUTATION;NON-SMALL CELL LUNG CANCER (NSCLC);OESTRUS OVIS;OSTEOCALCIN;PEMETREXED;PLASMA RENIN ACTIVITY;POINT MUTATION;PROTHROMBIN COMPLEX CONCENTRATE;QUINPIROLE;RADIOIODINE THERAPY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIVAROXABAN;VANDETANIB;VITAMIN K ANTAGONIST","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;AGED;MIDDLE AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;ADULT;AGED, 80 AND OVER;COLORECTAL NEOPLASMS;DEOXYCYTIDINE;HYPERTENSION;TREATMENT OUTCOME;ANTIBODIES, MONOCLONAL;ANTINEOPLASTIC AGENTS;CORPUS STRIATUM;EXCITATORY POSTSYNAPTIC POTENTIALS;CARCINOMA, NON-SMALL-CELL LUNG;INTESTINAL OBSTRUCTION","23;19;15;14;12;12;11;11;10;9;9;8;8;8;7;7;7;7;6;6","ADVANCEMENTS IN LUNG CANCER RESEARCH;MANAGEMENT OF FEBRILE NEUTROPENIA IN CANCER PATIENTS;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;RENAL CELL CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANTHELMINTIC RESISTANCE IN VETERINARY PARASITES;CARDIOTOXICITY OF CANCER TREATMENTS;DEVELOPMENT AND EVALUATION OF CLINICAL GUIDELINES;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;EPILEPSY AND SEIZURES;ETIOLOGY AND MANAGEMENT OF PERITONEAL ADHESIONS;FORENSIC ENTOMOLOGY AND DECOMPOSITION SCIENCE;GASTROINTESTINAL VIRAL INFECTIONS AND VACCINES DEVELOPMENT;GLOBAL IMPACT OF HELMINTH INFECTIONS AND CONTROL STRATEGIES;GYNECOLOGIC ONCOLOGY;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE","5;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;HYPERTENSION;CARDIAC IMAGING;EGFR MUTATIONS;STROKE (ENGINE);TREATMENT;;ADENOSINE A2A RECEPTOR;ADENOSINE RECEPTORS;ALISKIREN;ANTICOAGULANT THERAPY;ANTIEPILEPTIC DRUG;AORTIC ANEURYSMS;AORTIC DISSECTION;AORTIC ROOT REPLACEMENT;ATENOLOL;BETA (PROGRAMMING LANGUAGE);BETA-LACTAM ANTIBIOTICS;BIOMARKER ANALYSIS;BONE MINERAL DENSITY","3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER PATIENTS;LUNG CANCER;BREAST CANCER;CELL LUNG;PHASE II;ADVANCED NON-SMALL;CANCER NSCLC;CELL CARCINOMA;DESCRIZIONE DI;II TRIAL;METASTATIC BREAST;METASTATIC RENAL;NON-SMALL CELL;ORAL DIRECT;PATIENTS TREATED;PHASE III;PREVIOUSLY TREATED;RENAL CELL;AA ADENOSINE;ADDITIONAL COURSES;ADJUVANT CHEMOTHERAPY;ADVANCED NONSMALL;AKT STATUS;AL LAGO;ALZHEIMER PATIENTS;AMBITO UMANO;ANOREXIA NERVOSA;ANTITUMORAL ACTIVITY;ARTERIAL HYPERTENSION;ARTERY THROMBUS","4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","RESPONSE RATE;GENE COPY;GROWTH FACTOR;EGFR MUTATIONS;PHASE III;EPIDERMAL GROWTH;FACTOR RECEPTOR;TYROSINE KINASE;CNS METASTASES;LUNG CANCER;PRIMARY EFFICACY;SITU HYBRIDIZATION;VANDETANIB MG;ADVERSE EVENTS;ALISKIREN MG;EGFR GENE;HAZARD RATIO;RECEPTOR TYROSINE;STANDARD CHEMOTHERAPY;ADVANCED NSCLC;AKT ACTIVATION;CELL LUNG;CNS RELAPSE;DNA SEQUENCING;HER-POSITIVE MBC;MG MG;PHASE II;-SIDED NA;AUTHORS DESCRIBE;CANCER NSCLC","12;10;9;8;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3",5,0.12,9,7,0,0,0,0,10,0,1.75,7,0,3,0,0,2,0,0,0,0,0,0,94,94,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,5.33,542.5,10.94,2,0.29,62.71,0,0,1,0,3,0,2,1,0,6,0,0,0,0,0,0,0,5,2,0,6,1,0,0,0,0,0,0,0,0,"France;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3006 FOOD SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","5;4;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;ATHEROSCLEROSIS;LUNG;LUNG CANCER;RARE DISEASES;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BREAST CANCER;CARDIOVASCULAR;COMPLEMENTARY AND INTEGRATIVE HEALTH;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;ORPHAN DRUG","5;5;4;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","3;2","6.1 PHARMACEUTICALS","5","LUNG CANCER;BLOOD CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2008,34,9.47058823529412,2.58823529411765,0.470588235294118,0.294117647058824,0.5,1.25714285714286,1.23076923076923,1,1.21428571428571,0.264705882352941,0,17,9,2,3,0.5,0.26,0.06,0.09,133.26,2.4286524992049,NA,0.235294117647059,0.794117647058823,0.252,0.276,0.204,0.269,"LORENZA PISTOLA;VIENNA LUDOVINI;LUCIO CRINÓ;IRENE FLORIANI;FRANCESCA ROMANA TOFANETTI;ELIANA RULLI;UMBERTO MORELLI;LORENZO CATTORINI;ROBERTO CIROCCHI;PAOLO CALABRESI;FRANCESCO SCIANNAMEO;RICCARDO MARIA FAGUGLI;STEFANIA GORI;FRANCESCA GALLETTI;MAURIZIO TONATO;LUCIANA DI CARLO;CINZIA COSTA;ANGELO SIDONI;LUCIA STOCCHI;MARCO COCCETTA","4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","RICCARDO MARIA FAGUGLI;PAOLO CALABRESI;SALVATORE NOTARISTEFANO;UMBERTO MORELLI;PAOLO SBARZAGLIA;LORENZO CATTORINI;ROBERTO CIROCCHI;CLAUDIO CAVALLINI;FRANCESCO SCIANNAMEO;LORENZA PISTOLA;VIENNA LUDOVINI;ROSANNA CAPOZZI;MICHELE DEL ZINGARO;CHIARA TAGLIONI;GIORGIO GENTILE;GAETANO FERRARA;RACHELE BRUGNANO;NICCOLÒ DADDI;MARIA ELEONORA ALABISO;ETTORE MEARINI","0.5;0.36;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.28;0.28;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25","LORENZA PISTOLA;VIENNA LUDOVINI;LUCIO CRINÓ;FRANCESCA ROMANA TOFANETTI;ROBERTO CIROCCHI;PAOLO CALABRESI;RICCARDO MARIA FAGUGLI;STEFANIA GORI;FRANCESCA GALLETTI;MAURIZIO TONATO;LUCIANA DI CARLO;CINZIA COSTA;LUCIA STOCCHI;SERGIO BRACARDA;G DADDI;MARIANTONIETTA COLOZZA;SAMIR DARWISH;ANTONIA SEMERARO;SALVATORE NOTARISTEFANO;LUCA COLLEBRUSCO","4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1","RICCARDO MARIA FAGUGLI;PAOLO CALABRESI;SALVATORE NOTARISTEFANO;ROBERTO CIROCCHI;LORENZA PISTOLA;VIENNA LUDOVINI;MICHELE DEL ZINGARO;ETTORE MEARINI;MASSIMO PORENA;CLAUDIO FIORONI;R RIBACCHI;ANTONELLA GIANNANTONI;DANIELA RICCIARDI;FRANCESCA GALLETTI;CINZIA COSTA;STEFANIA GORI;MARIANTONIETTA COLOZZA;LUCIO CRINÓ;FRANCESCA ROMANA TOFANETTI;SALVATORE ARENA","0.5;0.36;0.33;0.33;0.28;0.28;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.24;0.24;0.23;0.23;0.2;0.2;0.2","ALAIN RAVAUD;BERNARD ESCUDIER;SERGIO BRACARDA;ANDREA KAY;CAMILLO PORTA;DAVID LEBWOHL;GLADYS URBANOWITZ;JOHN A. THOMPSON;NORBERT HOLLAENDER;ROBERT A. FIGLIN;ROBERT J. MOTZER;STÉPHANE OUDARD;THOMAS E. HUTSON;VIKTOR GRÜNWALD;WILLIAM J. BERG;ALBERTO BUFFOLI;ANTONINO DE PAOLI;CARLO CAPIRCI;CLAUDIO COCO;CLAUS RÖDEL","3011;3011;3011;2906;2906;2906;2906;2906;2906;2906;2906;2906;2906;2906;2906;430;430;430;430;430","SERGIO BRACARDA;MARCO LUPATTELLI;LORENZA PISTOLA;VIENNA LUDOVINI;FRANCESCA ROMANA TOFANETTI;LUCIO CRINÓ;ANTONELLA GIANNANTONI;ETTORE MEARINI;MASSIMO PORENA;MICHELE DEL ZINGARO;MARIANTONIETTA COLOZZA;LUCA SANTUCCI;C. BASURTO;E. PACIFICO;STEFANIA GORI;TERESA ANNA CANTISANI;PAOLO CALABRESI;LUCIA STOCCHI;MAURIZIO TONATO;SAMIR DARWISH","3011;430;252;252;198;198;148;148;148;148;141;116;111;111;111;108;93;87;87;87","LORENZA PISTOLA;VIENNA LUDOVINI;ROBERTO CIROCCHI;FRANCESCA ROMANA TOFANETTI;LUCIO CRINÓ;LUCIA STOCCHI;MARIANTONIETTA COLOZZA;MAURIZIO TONATO;PAOLO CALABRESI;SAMIR DARWISH;SERGIO BRACARDA;A SPACCATINI;ADELMO TERENZI;ALESSIA AUTUORI;ANDREA ALBERTI;ANNA MARINA LIBERATI;ANTONELLA GIANNANTONI;ANTONELLA REPETTO;ANTONIA SEMERARO;C. BASURTO","4;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;PHYSICS;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY","32;11;4;4;3;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;CARDIOLOGY;ONCOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GENETICS;MECHANICAL ENGINEERING;NURSING;PALEONTOLOGY;PHYSICAL THERAPY;BIOCHEMISTRY;CANCER RESEARCH;GASTROENTEROLOGY;PHARMACOLOGY;PSYCHIATRY;RADIOLOGY;UROLOGY;ANESTHESIA;IMMUNOLOGY;INTENSIVE CARE MEDICINE;ORGANIC CHEMISTRY;PEDIATRICS","26;13;11;7;7;4;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2","CANCER;ALTERNATIVE MEDICINE;CHEMOTHERAPY;DISEASE;MYOCARDIAL INFARCTION;POPULATION;STAGE (STRATIGRAPHY);STROKE (ENGINE);GENE;OBSERVATIONAL STUDY;ADJUVANT;ATRIAL FIBRILLATION;BLOOD PRESSURE;DIALYSIS;HEART FAILURE;HEMODIALYSIS;INFLAMMATION;LESION;LUNG;LUNG CANCER;OBSTRUCTIVE SLEEP APNEA;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;RECEPTOR;RECTUM;RENAL CELL CARCINOMA;STENT","8;5;4;4;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COLORECTAL CANCER;BREAST CANCER;PLACEBO;ADJUVANT THERAPY;ABORTION;ACUTE CARE;AMBULATORY BLOOD PRESSURE;ANAL CANAL;ANGINA;ANTIBACTERIAL AGENT;AORTIC PRESSURE;ARTERIAL DISEASE;B SYMPTOMS;BEVACIZUMAB;BIOFILM;CANCER PAIN;CAROTID ENDARTERECTOMY;CELL CYCLE;CENSUS;CLINICAL ENDPOINT;COLORECTAL SURGERY;CYCLOPHOSPHAMIDE;CYTOPENIA;DACARBAZINE;DETRUSOR MUSCLE;DOWNREGULATION AND UPREGULATION;FIBRINOLYTIC AGENT;HEART RATE;HODGKIN'S LYMPHOMA;HYPOXIA (ENVIRONMENTAL);INFLAMMATORY BOWEL DISEASE;INTERLEUKIN;INTRACRANIAL HAEMORRHAGE;ISCHAEMIC STROKE;ISCHEMIC STROKE;LAMINA PROPRIA;LEFT VENTRICULAR HYPERTROPHY;LEVETIRACETAM;LONG-TERM POTENTIATION;MANUAL THERAPY;MDM2;MENTAL HEALTH CARE;MYELODYSPLASTIC SYNDROMES;NITRIC OXIDE SYNTHASE;NOD;OPIOID;OVERACTIVE BLADDER;PAIN MEDICINE;PARAPLEGIA;PERCUTANEOUS CORONARY INTERVENTION;POLYSOMNOGRAPHY;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;PULMONARY SEQUESTRATION;REFLUX;RESTENOSIS;REVASCULARIZATION;SPINAL CORD DISEASES;SPINAL CORD INJURY;STAPHYLOCOCCUS AUREUS;THROMBOLYSIS;THYROID CANCER;TOLERABILITY;TRANSCRIPTION FACTOR;TUMOR PROGRESSION;VILLOUS ADENOMA","4;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COLONOSCOPY;CAROTID STENTING;DOUBLE BLIND;DRUG-ELUTING STENT;ESTROGEN RECEPTOR;HEMICOLECTOMY;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;LEUCINE ZIPPER;MDMX;METASTATIC BREAST CANCER;MICROCOCCACEAE;MISOPROSTOL;MODIFIED RANKIN SCALE;NEOADJUVANT THERAPY;ONCOGENE;RECTAL EXAMINATION;STAPHYLOCOCCAL INFECTIONS;TRASTUZUMAB;VESICOURETERAL REFLUX;VINCRISTINE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;AGED;ADULT;MIDDLE AGED;SLEEP APNEA, OBSTRUCTIVE;BREAST NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;LUNG NEOPLASMS;AGED, 80 AND OVER;ITALY;ADENOCARCINOMA;CARCINOMA, LARGE CELL;CARCINOMA, SQUAMOUS CELL;CARCINOMA;COLITIS;COLORECTAL NEOPLASMS;DISEASE-FREE SURVIVAL;NEOPLASMS, HORMONE-DEPENDENT","27;20;19;16;14;14;10;9;9;9;8;8;7;7;7;6;6;6;6;6","MANAGEMENT AND TREATMENT OF PERIPHERAL ARTERIAL DISEASE;RENAL CELL CARCINOMA;SLEEP-DISORDERED BREATHING AND HEALTH OUTCOMES;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANORECTAL SURGICAL PROCEDURES;ASSESSMENT OF DECISIONAL CAPACITY IN PSYCHIATRY;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLINICAL IMPLICATIONS OF UTERINE ANOMALIES AND TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;EPILEPSY AND SEIZURES;GASTRIC CANCER RESEARCH AND TREATMENT;HER2 SIGNALING IN BREAST CANCER TREATMENT;HYPERSENSITIVITY REACTIONS TO DRUGS AND MEDICATIONS","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","STROKE (ENGINE);TREATMENT;ADJUVANT THERAPY;BREAST CANCER;HER2;HODGKIN'S LYMPHOMA;OBSTRUCTIVE SLEEP APNEA;PAIN MANAGEMENT;ABVD;ALLOPURINOL;ANASTOMOTIC LEAKS;ANTIMICROBIAL SUSCEPTIBILITY TESTING;AORTIC PRESSURE;B SYMPTOMS;BARIUM ENEMA;BIOMARKER ANALYSIS;BRAIN METASTASES;CANCER PAIN;CAPACITY EVALUATION;CARDIAC SURGERY RISK MODELS","4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CANCER PATIENTS;CELL CARCINOMA;CELL LUNG;LUNG CANCER;MULTIDISCIPLINARY TEAM;NITRIC OXIDE;NON-SMALL CELL;OBSTRUCTIVE SLEEP;PERUGIA MULTIDISCIPLINARY;RADICALLY RESECTED;RENAL CELL;SLEEP APNEA;ABVD TREATED;ACETYL-L-CARNITINE SELECTIVELY;ACUTE CHOLECYSTITIS;ACUTE ISCHAEMIC;ACUTE PSYCHIATRIC;ACUTE RENAL;ADJUVANT THERAPY;ADVANCED RECTAL;ADVANCED RENAL;ALLOPURINOL TREATMENT;ANOMALOUS ARTERIAL;ANTIINFLAMMATORY ACTIVITY;APNEA SYNDROME;ARTERIAL CONNECTION;ARTERIAL DISEASE;BEVACIZUMAB COMBINED;BIOFILM-FORMING STAPHYLOCOCCUS","2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ECD LEVELS;BOWEL DISEASES;BREAST CANCER;CIRCULATING DNA;DINITROBENZENE SULFONIC;GILZ-TG MICE;INFLAMMATORY BOWEL;SCC MEC;STAGE IIII;TUMOR TISSUE;ACIDTREATED WT;ADDITION INHIBITION;ANTI-INFLAMMATORY ACTIVITY;ANTIBIOTIC RESISTANCE;BEVACIZUMAB IFN;BEVACIZUMAB REDUCED-DOSE;BRAIN IMAGING;CANCER PATIENTS;CASSETTE CHROMOSOME;COLITIS DEVELOPMENT;COLITIS INDUCTION;COMMON DISEASES;CONSECUTIVE PATIENTS;CONSEQUENT PRODUCTION;CYTOKINES PREVIOUS;DEXAMETHASONE TREATMENT;DIMINISHED INTESTINAL;DISEASE RECURRENCE;DISEASES RESIDES;DS DS","5;4;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",9,0.26,6,4,0,3,0,1,4,0,2.25,4,0,1,3,0,4,0,1,1.5,2,0,0,116,116,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,6.45,630.5,17.91,3,0.25,48.5,0,0,2,0,5,0,3,2,0,11,1,0,0,0,0,0,0,10,2,0,11,0,0,1,0,0,0,0,0,0,"Italy;Germany","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","12;7;7;3;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;CARDIOVASCULAR;HEART DISEASE;LUNG;RARE DISEASES;BIOMEDICAL IMAGING;LUNG CANCER;OVARIAN CANCER;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;COLO-RECTAL CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;HEALTH SERVICES;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;INFECTIOUS DISEASES;KIDNEY DISEASE","11;9;7;5;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION;RENAL AND UROGENITAL;RESPIRATORY","8;3;1;1;1","6.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY;6.7 PHYSICAL","10;2;1;1;1;1","LUNG CANCER;OVARIAN CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;THYROID CANCER","2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","6;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2009,34,8.58823529411765,3.79411764705882,0.558823529411765,0.470588235294118,0.558823529411765,1.5,1,1.33333333333333,1.11764705882353,0.441176470588235,0,23,4,1,2,0.68,0.12,0.03,0.06,52.09,1.12605627384807,NA,0.176470588235294,0.823529411764706,0.39,0.234,0.357,0.237,"LUCIO CRINÓ;ANDREA MENCARELLI;BARBARA RENGA;ELEONORA DISTRUTTI;STEFANO FIORUCCI;GIAN FRANCESCO BRUSCO;G AFFRONTI;BARBARA PICCONI;ALESSANDRO TOZZI;VINCENZO BELCASTRO;CINZIA COSTA;SILVIA CANONICO;MICHELA TANTUCCI;VIENNA LUDOVINI;PAOLO CALABRESI;G. LUZI;PAOLO PRONTERA;ELISA LUCHETTI;CAMILLO PORTA;SABRINA CIPRIANI","6;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2","ELVIO SCOSCIA;STEFANO BAGLIONI;GIAN FRANCESCO BRUSCO;G AFFRONTI;ANDREA MENCARELLI;BARBARA RENGA;ELEONORA DISTRUTTI;STEFANO FIORUCCI;LUCIO CRINÓ;SILVIA CANONICO;G. LUZI;MARIA LETIZIA D’ANNIBALE;SALVATORE ARENA;MARCO MIGLIORATI;ELISABETTA ANTONELLI;GIORGIO EPICOCO;DANIELE CROTTI;SAVERIO ARENA;PAOLO PRONTERA;EMILIO DONTI","0.75;0.75;0.73;0.73;0.69;0.69;0.69;0.69;0.57;0.57;0.57;0.5;0.4;0.34;0.33;0.33;0.33;0.33;0.31;0.31","LUCIO CRINÓ;ANDREA MENCARELLI;ELEONORA DISTRUTTI;STEFANO FIORUCCI;GIAN FRANCESCO BRUSCO;G AFFRONTI;ALESSANDRO TOZZI;VINCENZO BELCASTRO;CINZIA COSTA;SILVIA CANONICO;MICHELA TANTUCCI;VIENNA LUDOVINI;PAOLO CALABRESI;G. LUZI;ELISA LUCHETTI;CAMILLO PORTA;SABRINA CIPRIANI;LUCILLA PARNETTI;SABRINA SILIQUINI;STEFANIA GORI","6;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2","ELVIO SCOSCIA;STEFANO BAGLIONI;GIAN FRANCESCO BRUSCO;G AFFRONTI;ANDREA MENCARELLI;ELEONORA DISTRUTTI;STEFANO FIORUCCI;LUCIO CRINÓ;SILVIA CANONICO;G. LUZI;MARIA LETIZIA D’ANNIBALE;SALVATORE ARENA;MARCO MIGLIORATI;ELISABETTA ANTONELLI;GIORGIO EPICOCO;SAVERIO ARENA;GABRIELA STANGONI;ALESSANDRO TOZZI;VINCENZO BELCASTRO;CINZIA COSTA","0.75;0.75;0.73;0.73;0.69;0.69;0.69;0.57;0.57;0.57;0.5;0.4;0.34;0.33;0.33;0.33;0.31;0.3;0.3;0.3","CAMILLO PORTA;SERGIO BRACARDA;ALEJANDRA NIETO;CEZARY SZCZYLIK;DANIEL CASTELLANO;EDUARD VRDOLJAK;GEORG A. BJARNASON;HARIHARAN SUBRAMANIAN;JINYU YUAN;JOHN B.A.G. HAANEN;MARTIN GORE;PATRICK SCHÖFFSKI;PAUL N. MAINWARING;RONALD M. BUKOWSKI;SE‐HOON LEE;STÉPHANE OUDARD;ANDREA MENCARELLI;BARBARA RENGA;ELEONORA DISTRUTTI;STEFANO FIORUCCI","586;586;579;579;579;579;579;579;579;579;579;579;579;579;579;579;303;303;303;303","SERGIO BRACARDA;ELEONORA DISTRUTTI;LUCIO CRINÓ;LUCILLA PARNETTI;STEFANIA GORI;VIENNA LUDOVINI;VERENA DE ANGELIS;LUCA SANTUCCI;GIUSEPPE MARIA MILANO;G AFFRONTI;GIORGIO EPICOCO;SAVERIO ARENA;PAOLO GIOVENALI;R RIBACCHI;STEFANO ASCANI;ALESSANDRO TOZZI;CINZIA COSTA;MICHELA TANTUCCI;PAOLO CALABRESI;VINCENZO BELCASTRO","586;303;287;169;159;159;158;146;134;87;87;87;86;86;86;81;81;81;81;81","LUCIO CRINÓ;G AFFRONTI;GIAN FRANCESCO BRUSCO;ELEONORA DISTRUTTI;G. LUZI;SILVIA CANONICO;ALESSANDRO TOZZI;CINZIA COSTA;MICHELA TANTUCCI;PAOLO CALABRESI;VIENNA LUDOVINI;VINCENZO BELCASTRO;ELISA LUCHETTI;ELVIO SCOSCIA;GABRIELA STANGONI;GIORGIO EPICOCO;MARIA LETIZIA D’ANNIBALE;MASSIMILIANO DI FILIPPO;SABRINA SILIQUINI;SAVERIO ARENA","6;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;PSYCHOLOGY;HISTORY;PHILOSOPHY;PHYSICS","30;17;5;2;2;1;1;1","INTERNAL MEDICINE;GENETICS;SURGERY;BIOCHEMISTRY;ONCOLOGY;GYNECOLOGY;OBSTETRICS;PATHOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;NEUROSCIENCE;PEDIATRICS;PHARMACOLOGY;RADIOLOGY;ANESTHESIA;CARDIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;MICROBIOLOGY;PALEONTOLOGY;VETERINARY MEDICINE","22;8;8;7;7;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","GENE;CANCER;CHEMOTHERAPY;DISEASE;PREGNANCY;RECEPTOR;ADVERSE EFFECT;BILE ACID;DOPAMINE;ANEURYSM;CENTRAL NERVOUS SYSTEM;COLITIS;FECES;IMMUNE SYSTEM;INFLAMMATION;INTENSIVE CARE UNIT;LAPAROSCOPY;LUNG CANCER;MITOCHONDRION;NEUROPROTECTION;POPULATION;RANDOMIZED CONTROLLED TRIAL;RENAL CELL CARCINOMA;RESPIRATORY FAILURE","6;5;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;STRIATUM;AGONIST;BASAL GANGLIA;FETUS;GENOTYPE;GESTATION;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;ROTENONE;TRANSCRIPTION FACTOR;ACUTE HEPATITIS;ACUTE RESPIRATORY FAILURE;AGGRESSIVE FIBROMATOSIS;ALZHEIMER'S DISEASE;AMYLOID Β;ANTAGONIST;AORTIC REPAIR;CARDIOTOXICITY;CHENODEOXYCHOLIC ACID;CHROMOSOME;CLINICAL ENDPOINT;DEMENTIA;DEOXYCHOLIC ACID;DISPAR;DNA REPAIR;DOCETAXEL;DOPAMINERGIC;DOXORUBICIN;ECTOPIC PREGNANCY;EJECTION FRACTION;EMBRYO TRANSFER;EUTHYROID;EXCITATORY POSTSYNAPTIC POTENTIAL;GEMCITABINE;GENE EXPRESSION;GESTATIONAL AGE;GLUTAMATE RECEPTOR;HAZARD RATIO;HEART ANEURYSM;IMMUNITY;IN VITRO FERTILISATION;INFERTILITY;INFLAMMATORY BOWEL DISEASE;LAMINA PROPRIA;LITHOCHOLIC ACID;LOCUS (GENETICS);LONG-TERM POTENTIATION;MEDICAL GENETICS;MITOCHONDRIAL RESPIRATORY CHAIN;MYELODYSPLASTIC SYNDROMES;NOCICEPTION;OBSTETRICS AND GYNAECOLOGY;OPIOID;PERFORMANCE STATUS;PI3K/AKT/MTOR PATHWAY;PSEUDOANEURYSM;SORAFENIB;STRONGYLOIDES STERCORALIS;STRONGYLOIDIASIS;SUNITINIB;SYNAPTIC PLASTICITY;T CELL;TRIIODOTHYRONINE;ULCERATIVE COLITIS;VAGINAL BLEEDING;VENTRICULOTOMY;VINBLASTINE","4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","METASTATIC BREAST CANCER;NUCLEAR RECEPTOR;PLACENTA;TRASTUZUMAB;ADENOSINE RECEPTOR;ANTHRACYCLINE;COMPARATIVE GENOMIC HYBRIDIZATION;EPIRUBICIN;EUTHYROID SICK SYNDROME;GESTATIONAL SAC;GSTP1;HYSTEROSALPINGOGRAPHY;KARYOTYPE;LONG ARM;MEDIUM SPINY NEURON;NUCLEOTIDE EXCISION REPAIR;OVARIAN HYPERSTIMULATION SYNDROME;PTEN;RECEPTOR ANTAGONIST;REPORTER GENE;SINGLE-NUCLEOTIDE POLYMORPHISM;SUBSTANTIA NIGRA;TAMOXIFEN;TAU PROTEIN;TWIN PREGNANCY;VASCULAR DEMENTIA","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;;FEMALE;BREAST NEOPLASMS;ANIMALS;LIVER;ADULT;BILE ACIDS AND SALTS;CORPUS STRIATUM;RECEPTORS, CYTOPLASMIC AND NUCLEAR;AGED;COLON;VINBLASTINE;COLITIS;MIDDLE AGED;RATS;ACTION POTENTIALS;ADENOCARCINOMA;ANTINEOPLASTIC AGENTS","17;13;10;10;9;8;8;7;7;7;7;6;6;6;5;5;5;4;4;4","MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER;RENAL CELL CARCINOMA;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLINICAL IMPLICATIONS OF UTERINE ANOMALIES AND TREATMENT;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF APPENDICITIS;DIAGNOSIS AND MANAGEMENT OF ECTOPIC PREGNANCY;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND MOLECULAR CHARACTERIZATION OF PARASITIC DISEASES;FERTILITY PRESERVATION IN CANCER PATIENTS;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GENOMIC REARRANGEMENT DISORDERS IN SKIN DISEASES;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FARNESOID X RECEPTOR;GIARDIA;PLACENTA PREVIA;PROGRESSION-FREE SURVIVAL;RENAL CELL CARCINOMA;ROTENONE;ABDOMINAL COMPARTMENT SYNDROME;ACUTE HEPATITIS;ACUTE RESPIRATORY FAILURE;ADENOSINE A2A RECEPTOR;ADENOSINE RECEPTORS;AGGRESSIVE FIBROMATOSIS;AORTIC REPAIR;AORTIC ROOT REPLACEMENT;AORTOENTERIC FISTULA;BILE ACIDS;BIOMARKER ANALYSIS;BRAIN DEVELOPMENT;BREAST CANCER;CANCER GENOMICS","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ADVANCED NON-SMALL;CELL LUNG;LUNG CANCER;METASTATIC BREAST;NON-SMALL CELL;AA ADENOSINE;ABDOMINAL COMPARTIMENTAL;ACID DERIVATIVE;ACID SENSOR;ACUTE HEPATITIS;ACUTE RESPIRATORY;ADENOSINE RECEPTOR;ADULT PATIENT;ADVANCED UNTREATED;AGGRESSIVE FIBROMATOSIS;ALZHEIMERS DISEASE;AMINO ACID;ANTAGONISTS PROTECT;AORTOBRONCHIAL FISTULA;ATTENUATES INFLAMMATION;ATTENUATES PAIN;BILE ACID;BILE-ACID-ACTIVATED FARNESOID;BLYNCH SUTURE;BOWEL DISEASE;BRONCHIAL CARCINOIDS;CANCER NSCLC;CANCER PATIENTS;CANCER RCC","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PUBMED SCOPUS;OVARIAN HYPERSTIMULATION;CROSSREF PUBMED;EMBRYO TRANSFER;HYPERSTIMULATION SYNDROME;REPROD -CROSSREF;DEVELOPING OHSS;OVARIAN TORSION;ELECTIVE CRYOPRESERVATION;STERIL -ABSTRACT;MULTICENTRIC FORMS;BRONCHIAL CARCINOIDS;EMERGENCY PROCEDURE;ADNEXAL TORSION;BREAST CANCER;CELL CARCINOMA;CLINICAL SIGNIFICANCE;COMPLETE ABSENCE;DEVELOPING OVARIAN;DOPPLER ULTRASOUND;EGFR PMAPK;MITOCHONDRIAL COMPLEX;PMAPK PAKT;SERIAL SECTIONS;VASCULAR FLOW;AA RECEPTOR;ASSIST REPROD;CLINICAL PREGNANCIES;CNS METASTASES;COLON INFLAMMATION","20;17;14;10;9;9;8;8;7;7;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3",7,0.21,8,3,0,0,0,0,2,0,1,3,0,1,0,0,0,0,0,0,0,0,0,75.5,75.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,6,411,11.25,2,0.22,52.44,0,0,3,0,5,0,1,0,0,6,0,0,0,0,0,0,0,5,2,2,6,3,0,0,0,0,0,0,0,0,"Italy;United Kingdom;United States","3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;4204 MIDWIFERY","9;6;5;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;RARE DISEASES;INFECTIOUS DISEASES;LYMPHOMA;PREVENTION;PROSTATE CANCER;UROLOGIC DISEASES;AGING;CERVICAL CANCER;COLO-RECTAL CANCER;CONTRACEPTION/REPRODUCTION;DIGESTIVE DISEASES;GENETICS;HODGKIN'S DISEASE;INFANT MORTALITY;LUNG;LUNG CANCER","7;5;5;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;BLOOD;REPRODUCTIVE HEALTH AND CHILDBIRTH","5;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","7;1;1","NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LUNG CANCER;MYELOMA;OVARIAN CANCER","2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2010,32,10.375,2.46875,0.375,0.25,0.5,1.21538461538462,0.923076923076923,0.888888888888889,0.941176470588235,0.625,1,17,9,4,1,0.53,0.28,0.12,0.03,56.09,1.24127048357611,NA,0.34375,1,0.328,0.241,0.271,0.271,"PAOLO CALABRESI;LUCIO CRINÓ;SABRINA CIPRIANI;LUCILLA PARNETTI;ANDREA MENCARELLI;BARBARA RENGA;ELEONORA DISTRUTTI;STEFANO FIORUCCI;BARBARA PICCONI;CARMELO SGOBIO;FRANCO BALDELLI;ALESSANDRO TOZZI;MARIO BOCCADORO;KAJ BLENNOW;VINCENZA BAGETTA;ANNA CASTRIOTO;SILVIA GENTILI;VERONICA GHIGLIERI;MARCO MIGLIORATI;GIUSEPPE PALLADINO","4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","D'ANGELI;PAOLO CALABRESI;SABRINA CIPRIANI;ANDREA MENCARELLI;BARBARA RENGA;ELEONORA DISTRUTTI;STEFANO FIORUCCI;FRANCO BALDELLI;ENRICO CIERI;PIERGIORGIO CAO;ANNA CASTRIOTO;MARCO MIGLIORATI;PAOLA DE RANGO;LUCIO CRINÓ;BARBARA PICCONI;CARMELO SGOBIO;VINCENZA BAGETTA;VERONICA GHIGLIERI;VALENTINA PENDOLINO;ALESSIO SGRELLI","1;0.4;0.39;0.39;0.39;0.39;0.39;0.38;0.29;0.29;0.28;0.27;0.27;0.27;0.26;0.26;0.26;0.26;0.26;0.25","PAOLO CALABRESI;LUCIO CRINÓ;LUCILLA PARNETTI;ELEONORA DISTRUTTI;FRANCO BALDELLI;ALESSANDRO TOZZI;ANNA CASTRIOTO;ENRICO CIERI;ANNA MARINA LIBERATI;PAOLA DE RANGO;PIERGIORGIO CAO;ANTHONY E. LANG;STEFANIA ASCIUTTI;GIACOMO ISERNIA;ALESSIO SGRELLI;VINCENZO BELCASTRO;AIK CHOON TAN;UBERTO DA;PAOLA SARCHIELLI;FABIO VERZINI","4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","D'ANGELI;PAOLO CALABRESI;ELEONORA DISTRUTTI;FRANCO BALDELLI;ENRICO CIERI;PIERGIORGIO CAO;ANNA CASTRIOTO;PAOLA DE RANGO;LUCIO CRINÓ;ALESSIO SGRELLI;L MARTINELLI;MAURIZIO RADICIONI;DANIELA FRANCISCI;LUCILLA PARNETTI;ANTHONY E. LANG;ELENA MORO;SARA HULLIGER;YU‐YAN POON;UBERTO DA;ALESSANDRO AFFRONTI","1;0.4;0.39;0.38;0.29;0.29;0.28;0.27;0.27;0.25;0.25;0.25;0.25;0.22;0.2;0.2;0.2;0.2;0.17;0.17","LUCIO CRINÓ;ANNA MARINA LIBERATI;ANTONIO PALUMBO;MARIO BOCCADORO;SILVIA GENTILI;ALESSANDRA LAROCCA;ANDREA EVANGELISTA;ANNA LEVI;ANTONIETTA FALCONE;CHIARA NOZZOLI;CLOTILDE CANGIALOSI;DAVIDE ROSSI;FRANCESCA PATRIARCA;GIANLUCA GAÏDANO;GIULIA BENEVOLO;LUCA DE ROSA;MAIDE CAVALLI;MARIELLA GENUARDI;MARIELLA GRASSO;MICHÈLE CAVO","530;376;376;376;376;370;370;370;370;370;370;370;370;370;370;370;370;370;370;370","LUCIO CRINÓ;ANNA MARINA LIBERATI;AIK CHOON TAN;ANTONELLA FLACCO;D. ROSS CAMIDGE;MARILEILA VARELLA‐GARCIA;QING ZHOU;ROBERT C. DOEBELE;SCOTT A. KONO;WILBUR A. FRANKLIN;PAOLO CALABRESI;ALESSANDRO TOZZI;ELEONORA DISTRUTTI;JENNIFER FOGLIETTA;LUCIA STOCCHI;STEFANIA GORI;MASSIMILIANO DI FILIPPO;MICHELA TANTUCCI;LUCILLA PARNETTI;PAOLA DE RANGO","530;376;335;335;335;335;335;335;335;335;319;264;166;164;164;164;134;130;90;75","PAOLO CALABRESI;LUCIO CRINÓ;ELEONORA DISTRUTTI;LUCILLA PARNETTI;ALESSANDRO TOZZI;ANNA CASTRIOTO;ANNA MARINA LIBERATI;ENRICO CIERI;PAOLA DE RANGO;A SPIZZIRRI;AIK CHOON TAN;ALESSANDRO AFFRONTI;ALESSANDRO ROSSI;ALESSIA ROSSI;ALESSIO SGRELLI;ANTHONY E. LANG;ANTONELLA FLACCO;C. MATTIACCI;C. MENICHETTI;D'ANGELI","4;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;BUSINESS;ENGINEERING;SOCIOLOGY","31;13;7;2;1;1;1","INTERNAL MEDICINE;BIOCHEMISTRY;PHARMACOLOGY;SURGERY;ENDOCRINOLOGY;PATHOLOGY;RADIOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;NEUROSCIENCE;ONCOLOGY;CANCER RESEARCH;CARDIOLOGY;ENVIRONMENTAL HEALTH;MICROBIOLOGY;PEDIATRICS;VIROLOGY;ANIMAL SCIENCE;ASTROBIOLOGY;BIOINFORMATICS;BIOPHYSICS;CELL BIOLOGY;CLINICAL PSYCHOLOGY;ECOLOGY;ECONOMIC POLICY;EMERGENCY MEDICINE;GENDER STUDIES;GYNECOLOGY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;PALEONTOLOGY;PHYSICAL MEDICINE AND REHABILITATION;PHYSICAL THERAPY;VETERINARY MEDICINE","27;9;7;7;5;5;5;4;4;4;4;4;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENE;DISEASE;RECEPTOR;CANCER;ANEURYSM;DOPAMINE;MULTIPLE MYELOMA;ANTIBIOTICS;AORTA;ASYMPTOMATIC;CHEMOTHERAPY;DISSECTION (MEDICAL);ENZYME;ISCHEMIA;PERIOPERATIVE;PLATELET;POPULATION;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;VIRUS","8;7;6;5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;PARKINSON'S DISEASE;STRIATUM;ABDOMINAL AORTA;CHROMOSOME;COLORECTAL CANCER;LENALIDOMIDE;SYNAPTIC PLASTICITY;TRANSCRIPTION FACTOR;VIRAL LOAD;ABDOMINAL AORTIC ANEURYSM;ACETYLCHOLINESTERASE;AGONIST;ALZHEIMER'S DISEASE;AMOXICILLIN;AORTIC ANEURYSM;AORTIC DISSECTION;BORTEZOMIB;BRACHYTHERAPY;CAROTID ENDARTERECTOMY;CD36;CHEMOTHERAPY REGIMEN;CHENODEOXYCHOLIC ACID;CLARITHROMYCIN;CYCLIC GUANOSINE MONOPHOSPHATE;CYCLOPHOSPHAMIDE;DEGENERATIVE DISEASE;DEMENTIA;DETOXIFICATION (ALTERNATIVE MEDICINE);DOCETAXEL;DOPAMINERGIC;DOWNREGULATION AND UPREGULATION;DOXORUBICIN;DYSLIPIDEMIA;EUROPEAN COMMISSION;EXCITATORY POSTSYNAPTIC POTENTIAL;EXON;EZETIMIBE;GENE EXPRESSION;GENE REARRANGEMENT;GLYCATION;HEART RUPTURE;HEPATITIS C VIRUS;HEPATOCYTE;HEPATOCYTE GROWTH FACTOR;HISTONE;IMMUNE THROMBOCYTOPENIA;INTERVENTRICULAR SEPTUM;LEUKOREDUCTION;LONG-TERM POTENTIATION;LYSINE;MALIGNANT PLEURAL EFFUSION;MELPHALAN;MENSTRUAL CYCLE;METASTASIS;MISCARRIAGE;MONOCLONAL ANTIBODY;MOVEMENT DISORDERS;MUTATION;NEURODEGENERATION;NEUTROPENIA;NOCICEPTION;OPIOID;ORGASM;PANCREATIC DISEASE;PANCREATIC DUCT;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PHOSPHODIESTERASE;PI3K/AKT/MTOR PATHWAY;PLATELET TRANSFUSION;PROSTATE;PROTEOMICS;PSEUDOANEURYSM;PULMONARY SEQUESTRATION;RESTENOSIS;RIFAXIMIN;RNA;SEXUAL DESIRE;SEXUAL INTERCOURSE;STUNNING;THALIDOMIDE;VIREMIA;VISCERAL LEISHMANIASIS;WHITE MATTER","3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIRETROVIRAL THERAPY;MEDIUM SPINY NEURON;METASTATIC BREAST CANCER;NUCLEAR RECEPTOR;TRASTUZUMAB;(+)-NALOXONE;ACHÉ;ADVANCED GLYCATION END-PRODUCT;ALPHA-SYNUCLEIN;ANAPLASTIC LYMPHOMA KINASE;BIOMARKER DISCOVERY;BRAIN METASTASIS;BREAST CARCINOMA;BRONCHOPULMONARY SEQUESTRATION;CAPECITABINE;CARFILZOMIB;CAROTID STENTING;CRIZOTINIB;DOPAMINE TRANSPORTER;DYSKINESIA;ENKEPHALIN;EXTERNAL BEAM RADIOTHERAPY;FLUORESCENCE IN SITU HYBRIDIZATION;GREY MATTER;HEPACIVIRUS;HISTONE DEACETYLASE;KRAS;LEVODOPA;MASTECTOMY;MONOCLONAL;MTORC1;OPIOID RECEPTOR;PENETRANCE;RECTAL EXAMINATION;SUBSTANTIA NIGRA;VINCRISTINE;VISCERAL PAIN;ZAPRINAST;Μ-OPIOID RECEPTOR","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CORPUS STRIATUM;ADULT;ANIMALS;MULTIPLE MYELOMA;EPENDYMOMA;INFRATENTORIAL NEOPLASMS;SUPRATENTORIAL NEOPLASMS;ANTIBODIES, MONOCLONAL;AORTIC ANEURYSM, ABDOMINAL;CARCINOMA, NON-SMALL-CELL LUNG;ITALY;LUNG NEOPLASMS;LYSINE","24;19;17;13;11;11;9;9;7;7;7;6;6;6;5;5;5;5;5;5","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;BIOCHEMISTRY OF DIABETIC COMPLICATIONS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLINESTERASE INHIBITORS IN NEURODEGENERATIVE DISEASES;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;EFFECTS OF BRAIN STIMULATION ON MOTOR CORTEX;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;EPIDEMIOLOGY AND PATHOGENESIS OF PNEUMOCYSTIS PNEUMONIA;FACTORS AFFECTING MEAT QUALITY AND PRESERVATION;GLIOMAS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEPATITIS C INFECTION AND TREATMENT;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABDOMINAL AORTA;INTERNATIONAL MYELOMA WORKING GROUP;MEDIUM SPINY NEURON;NEURODEGENERATION;RADIOTHERAPY;ABDOMINAL WALL DEFECTS;ADVANCED GLYCATION END PRODUCTS;ADVANCED GLYCATION END-PRODUCT;ALK INHIBITOR;ALK INHIBITORS;AORTIC ANEURYSMS;AORTIC DISSECTION;AORTIC ROOT REPLACEMENT;AORTIC STIFFNESS;ARTERIAL STIFFNESS;BILE ACIDS;BIOMARKER ANALYSIS;BRAIN METASTASES;BREAST CANCER;BREAST CARCINOMA","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;MULTIPLE MYELOMA;ACHE INHIBITORS;ACID SENSOR;ACUTE PANCREATITIS;ADVANCED GLYCATION;ADVANCED PARKINSONS;AIEOP ASSOCIAZIONE;ALK INHIBITOR;ALZHEIMERS DISEASE;ANAPLASTIC LYMPHOMA;ANATOMICAL PATTERN;ANEURYSMAL AORTIC;ANTI-INFLAMMATORY ACTIVITIES;AORTIC BRANCH;AORTIC GRAFT;AORTIC PLAQUES;AORTIC REPAIR;ASSOCIAZIONE ITALIANA;AT-ALPHA-SYNUCLEIN OVEREXPRESSION;BILE ACID;BRAIN METASTASES;BREAST CONSERVING;BUTYRYLCHOLINESTERASE ACTIVITY;CANCER PATIENTS;CANCER TREATED;CARBOXYMETHYL LYSINE;CAROTID STENTING;CHRONIC IMMUNE;CHRONIC KIDNEY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PULMONARY SEQUESTRATION;FEEDING VESSEL;PATIENTS UNDERGOING;INTRALOBAR SEQUESTRATION;LOWER LOBE;PUBMED SCOPUS;SYNAPTIC PLASTICITY;ABDOMINAL AORTA;BREAST CANCER;GENES INVOLVED;MOVEMENT DISORDERS;PATIENTS TREATED;UNDERGOING CAS;AORTIC PLAQUES;CAROTID STENOSIS;COX REGRESSION;DECREASED PERIOPERATIVE;EPITHELIAL CELLS;HR CI;INTRALOBAR PULMONARY;LATE ISCHEMIC;LEFT LOWER;LEVODOPA-INDUCED DYSKINESIA;MULTIVARIABLE ANALYSIS;PROPENSITY SCORE;RELIGIOUS SLAUGHTER;RISK HR;S-INDUCED ANALGESIA;WHITE MATTER;ABERRANT AORTIC","9;8;8;7;7;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3",8,0.25,3.5,4.25,2.5,1,0,0,8.5,0,1,4.25,0,1,2,0,0,0,1,2,1,0,0,128.25,128.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,5.64,300.73,17.46,3,0.27,69.09,0,0,7,0,2,0,0,2,0,9,2,0,0,0,0,0,0,9,2,0,11,0,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","11;7;3;2;2;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;PREVENTION;DIGESTIVE DISEASES;LYMPHOMA;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;BIOENGINEERING;BIOTECHNOLOGY;BREAST CANCER;CARDIOVASCULAR;GENETICS;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;INFECTIOUS DISEASES;LIVER DISEASE","9;6;6;5;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH","6;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES","11;4;1;1","NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;BREAST CANCER;HODGKIN'S DISEASE;LEUKEMIA / LEUKAEMIA;LIVER CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;STOMACH CANCER","2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","8;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"PUBLIC LIBRARY OF SCIENCE","2","32 BIOMEDICAL AND CLINICAL SCIENCES;52 PSYCHOLOGY;3207 MEDICAL MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;5202 BIOLOGICAL PSYCHOLOGY","4;2;1;1;1","ACQUIRED COGNITIVE IMPAIRMENT;AGING;ATHEROSCLEROSIS;BRAIN DISORDERS;CARDIOVASCULAR;DEMENTIA;DIGESTIVE DISEASES;GENETICS;HIV/AIDS;LIVER DISEASE;NEURODEGENERATIVE;NEUROSCIENCES;PARKINSON'S DISEASE","1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;NEUROLOGICAL","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","2;1;1","BIOMEDICAL","2","BASIC SCIENCE","2",NA,NA,NA,NA
"AOU_PERUGIA",2011,62,9.43548387096774,2.67741935483871,0.435483870967742,0.370967741935484,0.435483870967742,1.72916666666667,1.28571428571429,1.35294117647059,1.28571428571429,0.451612903225806,1,28,15,12,6,0.45,0.24,0.19,0.1,44.95,1.05683240737375,NA,0.241935483870968,0.887096774193548,0.397,0.373,0.433,0.406,"PAOLO CALABRESI;LUCIO CRINÓ;STEFANIA GORI;ANDREA MENCARELLI;BARBARA RENGA;ELEONORA DISTRUTTI;STEFANO FIORUCCI;ALESSANDRO TOZZI;SABRINA CIPRIANI;MICHELA TANTUCCI;GIUSEPPE PALLADINO;MARCO VENTURINI;PAOLO PRONTERA;FRANCO BALDELLI;VITTORIO GEBBIA;OSCAR ALABISO;CINZIA COSTA;EMILIO DONTI;CLAUDIO D’AMORE;ANNAMARIA MOLINO","9;7;7;7;7;7;7;6;6;5;5;5;4;4;4;4;4;4;4;4","LUCIO CRINÓ;PAOLO CALABRESI;NICOLA RAMACCIATI;ANDREA MENCARELLI;BARBARA RENGA;ELEONORA DISTRUTTI;STEFANO FIORUCCI;SABRINA CIPRIANI;ALESSANDRO TOZZI;MICHELA TANTUCCI;FRANCO BALDELLI;G AFFRONTI;GIUSEPPE PALLADINO;ELVIO SCOSCIA;STEFANO BAGLIONI;MAURIZIO DOTTORINI;ORONZO PENZA;GIULIO METRO;STEFANIA GORI;PAOLO PRONTERA","1.01;1.01;1;0.83;0.83;0.83;0.83;0.72;0.7;0.64;0.6;0.58;0.58;0.58;0.58;0.58;0.58;0.57;0.57;0.52","PAOLO CALABRESI;LUCIO CRINÓ;STEFANIA GORI;ELEONORA DISTRUTTI;STEFANO FIORUCCI;ALESSANDRO TOZZI;MICHELA TANTUCCI;PAOLO PRONTERA;CINZIA COSTA;EMILIO DONTI;BARBARA PICCONI;LUCILLA PARNETTI;SABRINA SILIQUINI;ELISA BALDELLI;DAVIDE CHIASSERINI;ANTONELLA FLACCO;VIENNA LUDOVINI;ELVIO SCOSCIA;STEFANO BAGLIONI;MAURIZIO DOTTORINI","9;7;7;7;7;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3","LUCIO CRINÓ;PAOLO CALABRESI;NICOLA RAMACCIATI;ELEONORA DISTRUTTI;STEFANO FIORUCCI;ALESSANDRO TOZZI;MICHELA TANTUCCI;ELVIO SCOSCIA;STEFANO BAGLIONI;MAURIZIO DOTTORINI;ORONZO PENZA;GIULIO METRO;STEFANIA GORI;PAOLO PRONTERA;EMILIO DONTI;RICCARDO MARIA FAGUGLI;CHIARA TAGLIONI;CINZIA COSTA;FRANCESCO PUMA;JACOPO VANNUCCI","1.01;1.01;1;0.83;0.83;0.7;0.64;0.58;0.58;0.58;0.58;0.57;0.57;0.52;0.52;0.5;0.5;0.42;0.42;0.42","ANDREA MENCARELLI;BARBARA RENGA;ELEONORA DISTRUTTI;STEFANO FIORUCCI;SABRINA CIPRIANI;FRANCO BALDELLI;ANNIBALE DONINI;LUCIO CRINÓ;PAOLO CALABRESI;GIUSEPPE BIFULCO;MARIA GIOVANNA CHINI;GIUSEPPE PALLADINO;CLAUDIO D’AMORE;ANTONELLA FLACCO;ELISA BALDELLI;VIENNA LUDOVINI;AGOSTINA SINISCALCHI;ALESSANDRA LAROCCA;ALESSANDRA ROMANO;ANNA MARINA LIBERATI","719;719;719;719;613;485;419;414;410;329;329;322;297;271;271;271;263;263;263;263","ELEONORA DISTRUTTI;LUCIO CRINÓ;PAOLO CALABRESI;ANTONELLA FLACCO;ELISA BALDELLI;VIENNA LUDOVINI;ANNA MARINA LIBERATI;ALESSANDRO TOZZI;ANNAMARIA SIGGILLINO;FRANCESCA ROMANA TOFANETTI;LORENZA PISTOLA;RITA CHIARI;VINCENZO MINOTTI;MICHELE DURANTI;STEFANIA GORI;CINZIA COSTA;DANIELA IACONO;MICHELA TANTUCCI;ANTONELLA GIANNANTONI;MASSIMO PORENA","719;414;410;271;271;271;263;231;227;227;227;227;227;222;210;194;171;156;111;111","PAOLO CALABRESI;ELEONORA DISTRUTTI;STEFANIA GORI;LUCIO CRINÓ;ALESSANDRO TOZZI;MICHELA TANTUCCI;CINZIA COSTA;ANTONELLA FLACCO;ELISA BALDELLI;VIENNA LUDOVINI;DAVIDE CHIASSERINI;EMILIO DONTI;LUCILLA PARNETTI;PAOLO PRONTERA;SABRINA SILIQUINI;ANNAMARIA SIGGILLINO;FABIO ANGELI;FRANCESCA ROMANA TOFANETTI;FRANCESCO PUMA;GABRIELA STANGONI","9;7;7;7;6;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;ART;ENGINEERING;GEOGRAPHY;POLITICAL SCIENCE;PSYCHOLOGY","58;32;9;4;3;3;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;BIOCHEMISTRY;GENETICS;ENDOCRINOLOGY;PHARMACOLOGY;SURGERY;IMMUNOLOGY;NEUROSCIENCE;PATHOLOGY;CARDIOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;CELL BIOLOGY;FAMILY MEDICINE;PALEONTOLOGY;ANESTHESIA;BIOINFORMATICS;PEDIATRICS;ANATOMY;COMPUTER SECURITY;GASTROENTEROLOGY;PHYSICAL THERAPY;PSYCHIATRY","46;15;12;11;9;9;9;7;7;7;6;6;6;5;5;5;4;4;4;3;3;3;3;3","GENE;CANCER;DISEASE;RECEPTOR;CHEMOTHERAPY;LUNG CANCER;BLOOD PRESSURE;INFLAMMATION;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;AUTHORIZATION;BILE ACID;COLITIS;FORMULARY;IMMUNE SYSTEM;INTENSIVE CARE UNIT;ISCHEMIA;MARKETING AUTHORIZATION;NITRIC OXIDE;PRIOR AUTHORIZATION;STAGE (STRATIGRAPHY)","14;12;10;10;7;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;TRANSCRIPTION FACTOR;COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;DEMENTIA;LONG-TERM POTENTIATION;PARKINSON'S DISEASE;CARDIOTOXICITY;CHENODEOXYCHOLIC ACID;CISPLATIN;COLORECTAL CANCER;GEMCITABINE;GESTATIONAL AGE;INSULIN RESISTANCE;NMDA RECEPTOR;PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR;PHENOTYPE;PROINFLAMMATORY CYTOKINE;ABORTION;ACUTE HEPATITIS;ACUTE RESPIRATORY FAILURE;ADHESIVE;AMBULATORY BLOOD PRESSURE;APACHE II;ARTERIAL STIFFNESS;ATAXIC GAIT;AZITHROMYCIN;BEVACIZUMAB;BONE DENSITY;BONE MINERAL;CANDIDATE GENE;CARDIOMYOPATHY;CD14;CEREBELLAR ATAXIA;CERVIX;CHEMOKINE;CHOLIC ACID;CINAHL;CLINICAL ENDPOINT;COCHRANE LIBRARY;CRYOPRECIPITATE;CYCLIC GUANOSINE MONOPHOSPHATE;CYCLOPHOSPHAMIDE;CYTIDINE DEAMINASE;DIASTOLE;DNA REPAIR;DOPAMINERGIC;DOWNREGULATION AND UPREGULATION;ENDOTRACHEAL INTUBATION;EXCITATORY POSTSYNAPTIC POTENTIAL;FETUS;FIBRINOLYTIC AGENT;FINE-NEEDLE ASPIRATION;FLUCONAZOLE;FLUOROURACIL;FRESH FROZEN PLASMA;G PROTEIN-COUPLED BILE ACID RECEPTOR;GAIT ATAXIA;GENOTYPE;GESTATION;GLUTAMATE RECEPTOR;GROWTH FACTOR;HAZARD RATIO;HEAT SHOCK PROTEIN;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS;HEPATITIS A VIRUS;HEPATITIS B VIRUS;HYPERALDOSTERONISM;HYPOFIBRINOGENEMIA;IN SILICO;INFLAMMATORY BOWEL DISEASE;INNATE IMMUNE SYSTEM;ISCHAEMIC STROKE;LAMINA PROPRIA;LEFT VENTRICULAR HYPERTROPHY;LEPTIN;LOCUS (GENETICS);MAPK/ERK PATHWAY;MASS/LESION;MEDICAL GENETICS;MEMORY IMPAIRMENT;METASTASIS;MIDDLE CEREBRAL ARTERY;MULTIDETECTOR COMPUTED TOMOGRAPHY;MUTATION;NEURORADIOLOGY;NEUROTRANSMISSION;NEUTROPENIA;NITRIC OXIDE SYNTHASE;NONINVASIVE VENTILATION;NURSING INTERVENTIONS CLASSIFICATION;OCCLUDIN;OVARIAN CANCER;PHOSPHODIESTERASE;PI3K/AKT/MTOR PATHWAY;POSITIVE PRESSURE VENTILATION;PRAVASTATIN;PRIMARY ALDOSTERONISM;PROGRESSION-FREE SURVIVAL;PROMOTION (CHESS);PROTEINURIA;PULSE PRESSURE;RESPIRATORY ACIDOSIS;RIFAXIMIN;ROTENONE;SECONDARY HYPERTENSION;SORAFENIB;SPINAL CORD INJURY;SPINOCEREBELLAR ATAXIA;STRIATUM;STUNNING;SUMMARY OF PRODUCT CHARACTERISTICS;SUNITINIB;SYNAPTIC PLASTICITY;THROMBOLYSIS;TRANSGENE;TRANSPORTER;TYPE 2 DIABETES;TYROSINE KINASE;UNIVARIATE ANALYSIS;URETHROPLASTY;WESTERN BLOT;WHITE ADIPOSE TISSUE","5;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NUCLEAR RECEPTOR;ERLOTINIB;DYSKINESIA;TRASTUZUMAB;ABSOLUTE NEUTROPHIL COUNT;ADIPOKINE;ADIPONECTIN;ADJUVANT CHEMOTHERAPY;ASPIRATION BIOPSY;ATP-BINDING CASSETTE TRANSPORTER;BREAST CARCINOMA;CARBOPLATIN;CERVICAL CANAL;CERVICAL DILATION;CETUXIMAB;CYANOACRYLATE;DIABETIC CARDIOMYOPATHY;DOPAMINE TRANSPORTER;ENOS;EPIRUBICIN;EXOME SEQUENCING;GEFITINIB;GENETICALLY MODIFIED MOUSE;GLUTAMATERGIC;HBSAG;HYPERINSULINEMIA;INSULIN-LIKE GROWTH FACTOR;INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR;INTRAVENTRICULAR HEMORRHAGE;INVASIVE CANDIDIASIS;KRAS;LAMIVUDINE;LIPOTOXICITY;LTP INDUCTION;MASKED HYPERTENSION;MEDIASTINAL LYMPH NODE;METASTATIC BREAST CANCER;MISOPROSTOL;MISSENSE MUTATION;NUCLEOTIDE EXCISION REPAIR;OVARIAN CARCINOMA;PTEN;PULSATILITY INDEX;TAU PROTEIN;UMBILICAL ARTERY;VINCRISTINE;XERODERMA PIGMENTOSUM","5;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;LUNG NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;ADULT;AGED;MIDDLE AGED;BREAST NEOPLASMS;ANIMALS;INTESTINAL MUCOSA;COLITIS;RECEPTORS, CYTOPLASMIC AND NUCLEAR;;ANTINEOPLASTIC AGENTS;SIGNAL TRANSDUCTION;ADENOCARCINOMA;ITALY;AGED, 80 AND OVER;CISPLATIN","41;27;24;22;18;17;16;16;15;14;14;13;13;12;12;12;11;11;9;9","ADVANCEMENTS IN LUNG CANCER RESEARCH;MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER;MECHANISMS OF ALZHEIMER'S DISEASE;DEVELOPMENT AND EVALUATION OF CLINICAL GUIDELINES;ECONOMIC BURDEN OF CANCER TREATMENT;EPIDEMIOLOGY AND TREATMENT OF MENINGIOMAS;HER2 SIGNALING IN BREAST CANCER TREATMENT;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA;AMINO ACID TRANSPORT AND METABOLISM IN HEALTH AND DISEASE;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CHOLESTEROL-LOWERING TREATMENT;CLINICAL IMPLICATIONS OF UTERINE ANOMALIES AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND TREATMENT OF SPINAL INFECTIONS;ECONOMICS OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT;EFFECTS OF D-GALACTOSE ON AGING AND NEURODEGENERATION","4;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","DRUG PRICING;FARNESOID X RECEPTOR;FORMULARY;MARKETING AUTHORIZATION;PRIOR AUTHORIZATION;AVAILABILITY OF MEDICINES;BREAST CANCER;BREAST CANCER SCREENING;CARDIOTOXICITY;CHENODEOXYCHOLIC ACID;CLINICAL PRACTICE;CONCORDANCE;EGFR MUTATIONS;FATTY ACID-BINDING PROTEINS;HYPERTENSION;INFLAMMATION;MENINGIOMAS;NMDA RECEPTORS;PREGNANE X RECEPTOR;REGIMEN","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LUNG CANCER;BREAST CANCER;ANTI-CANCER DRUGS;CELL LUNG;CLINICAL PRACTICE;ITALIAN SOCIETY;MEDICAL ONCOLOGY;NON-SMALL CELL;ONCOLOGY AIOM;REGIONS RESULTS;ADJUVANT CHEMOTHERAPY;ADVANCED NON-SMALL;CANCER CLINICAL;CANCER PATIENTS;EXPERIENCE AIOM;FATTY ACID;ITALIAN EXPERIENCE;ITALIAN REGIONS;PARKINSONS DISEASE;PATIENT ACCESS;SURVEY CONDUCTED;ACID BINDING;ACID METABOLISM;ACID RECEPTOR;ACROFRONTOFACIONASAL DYSOSTOSIS;ACTIVATION IMPROVES;ACUTE HEPATITIS;ACUTE ISCHAEMIC;ACUTE PULMONARY;AD MOUSE","6;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","COGNITIVE IMPAIRMENT;BREAST CARCINOMA;HYPERTENSIVE DISORDERS;PARKINSONS DISEASE;PROGRESSION-FREE SURVIVAL;ADVANCED NSCLC;CROHNS DISEASE;INJURY CAUSED;NSCLC TREATED;SYNAPTIC PLASTICITY;TTP IPI;ACUTE ISCHAEMIC;ADIPOSE TISSUE;AΒ OLIGOMERS;CANCER NSCLC;CDA CT;CELL LUNG;CV EVENTS;IKRASI MUTATION;ISCHAEMIC STROKE;LUNG CANCER;LYSGLN AC;MULTIVARIATE ANALYSIS;NEUTROPHIL COUNT;NON-SMALL CELL;SURVIVAL OS;TG MICE;TGCRND MICE;VERSUS MONTHS;ACUTE HEPATITIS","8;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3",18,0.29,4.44,2.75,1,1.5,0,1,2,1,1,2.75,0,1,2,0,0,1,0,2,0,0,0,91.25,91.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,8.43,707,8.99,2,0.25,96.25,0,0,5,1,2,0,0,0,0,8,0,0,0,0,0,0,0,6,2,0,8,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES","8;8;3","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;RARE DISEASES;BREAST CANCER;LUNG;LUNG CANCER;PATIENT SAFETY;COLO-RECTAL CANCER;OVARIAN CANCER;PEDIATRIC RESEARCH INITIATIVE","8;7;6;3;3;2;2;2;2;1;1;1","CANCER","6","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","8;1","LUNG CANCER;BREAST CANCER;COLON AND RECTAL CANCER;GASTROINTESTINAL TRACT;OVARIAN CANCER;PANCREATIC CANCER","3;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","7;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"PUBLIC LIBRARY OF SCIENCE","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","3;1;1;1","AUTOIMMUNE DISEASE;CROHN'S DISEASE;DIGESTIVE DISEASES;INFLAMMATORY BOWEL DISEASE;BIOTECHNOLOGY;LIVER DISEASE;NUTRITION","2;2;2;2;1;1;1","ORAL AND GASTROINTESTINAL;CANCER","2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2","BIOMEDICAL","2","BASIC SCIENCE","2","COLON AND RECTAL CANCER","2",NA,NA
"AOU_PERUGIA",2012,77,10.3376623376623,3.48051948051948,0.415584415584416,0.402597402597403,0.402597402597403,2,1.68421052631579,2.06666666666667,1.82352941176471,0.428571428571429,0,45,15,8,5,0.58,0.19,0.1,0.06,21.96,0.525782008122294,7.6588785046729,0.233766233766234,0.831168831168831,0.492,0.415,0.524,0.394,"LUCIO CRINÓ;VIENNA LUDOVINI;PAOLA DE RANGO;RITA CHIARI;GIULIO METRO;ANTONELLA FLACCO;PAOLO CALABRESI;ANNAMARIA SIGGILLINO;FORTUNATO BIANCONI;ELISA BALDELLI;ANGELO SIDONI;GIOELE SIMONTE;CHIARA BENNATI;GUIDO BELLEZZA;VINCENZO MINOTTI;FEDERICO CAPPUZZO;BARBARA PICCONI;CARMELA GIAMPÀ;FABIO VERZINI;STEFANIA GORI","24;11;8;7;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4","LUCIO CRINÓ;PAOLA DE RANGO;GIULIO METRO;VIENNA LUDOVINI;GIOELE SIMONTE;MIRKO BERTOZZI;STEFANIA TROIANI;MAURIZIO RADICIONI;ANTONINO APPIGNANI;VINCENZO MINOTTI;FABIO VERZINI;PAOLO CALABRESI;RITA CHIARI;GIUSEPPE GIORDANO;ENRICO CIERI;MASSIMO LENTI;ANTONELLA FLACCO;FEDERICA PIERGENTILI;VALENTINO PAGLIUCA;GIAN DOMENICO GIUSTI","2.68;1.72;1.15;0.95;0.68;0.67;0.67;0.67;0.67;0.61;0.56;0.55;0.55;0.52;0.52;0.52;0.51;0.5;0.5;0.5","LUCIO CRINÓ;VIENNA LUDOVINI;PAOLA DE RANGO;RITA CHIARI;GIULIO METRO;ANTONELLA FLACCO;PAOLO CALABRESI;ANNAMARIA SIGGILLINO;ELISA BALDELLI;ANGELO SIDONI;GIOELE SIMONTE;CHIARA BENNATI;VINCENZO MINOTTI;FABIO VERZINI;STEFANIA GORI;GIUSEPPE GIORDANO;FRANCESCA ROMANA TOFANETTI;ENRICO CIERI;VERENA DE ANGELIS;MASSIMO LENTI","24;11;8;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4","LUCIO CRINÓ;PAOLA DE RANGO;GIULIO METRO;VIENNA LUDOVINI;GIOELE SIMONTE;MIRKO BERTOZZI;STEFANIA TROIANI;MAURIZIO RADICIONI;ANTONINO APPIGNANI;VINCENZO MINOTTI;FABIO VERZINI;PAOLO CALABRESI;RITA CHIARI;GIUSEPPE GIORDANO;ENRICO CIERI;MASSIMO LENTI;ANTONELLA FLACCO;GIAN DOMENICO GIUSTI;A BALDONI;ROBERTO CIACCARINI","2.68;1.72;1.15;0.95;0.68;0.67;0.67;0.67;0.67;0.61;0.56;0.55;0.55;0.52;0.52;0.52;0.51;0.5;0.5;0.44","LUCIO CRINÓ;ANDREA NOZZA;ANGELO MICHELE CARELLA;ANNA BARALDI;ANNA FURLAN;ANNALISA PEZZI;ANNAMARIA BRIOLI;ANTONIETTA FALCONE;ANTONIO PALUMBO;CATELLO CALIFANO;CHIARA NOZZOLI;CLAUDIA CRIPPA;DANIELA DONNARUMMA;DANIELE DERUDAS;ELENA ZAMAGNI;FELICETTO FERRARA;FRANCESCA PATRIARCA;GIULIA PERRONE;LUCIA PANTANI;LUCIANO MASINI","443;305;305;305;305;305;305;305;305;305;305;305;305;305;305;305;305;305;305;305","LUCIO CRINÓ;STELVIO BALLANTI;PAOLO CALABRESI;ELEONORA DISTRUTTI;RITA CHIARI;ANNAMARIA SIGGILLINO;VIENNA LUDOVINI;ALESSANDRA PUCCIARINI;ALESSIA TABARRINI;BARBARA BIGERNA;ENRICO TIACCI;FLAVIO FALCINELLI;MARIA PAOLA MARTELLI;ROBERTA PACINI;ALESSANDRO TOZZI;GIULIO METRO;STEFANIA GORI;CHIARA BENNATI;LUCA MARCOMIGNI;SIMONA DURANTI","436;305;165;162;110;109;109;105;105;105;105;105;105;105;97;78;78;71;70;70","LUCIO CRINÓ;VIENNA LUDOVINI;RITA CHIARI;ANTONELLA FLACCO;PAOLO CALABRESI;GIULIO METRO;ANNAMARIA SIGGILLINO;CHIARA BENNATI;ELISA BALDELLI;PAOLA DE RANGO;FABIO VERZINI;FRANCESCA ROMANA TOFANETTI;STEFANIA GORI;VERENA DE ANGELIS;VINCENZO MINOTTI;ELEONORA DISTRUTTI;JENNIFER FOGLIETTA;LORENZA PISTOLA;SIMONA DURANTI;ALESSANDRO TOZZI","23;11;7;6;6;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;ENGINEERING;ECONOMICS;PHYSICS;POLITICAL SCIENCE;COMPUTER SCIENCE;ART;GEOGRAPHY;MATERIALS SCIENCE;SOCIOLOGY","68;24;7;6;5;4;4;3;2;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;CANCER RESEARCH;GASTROENTEROLOGY;BIOCHEMISTRY;GENETICS;CARDIOLOGY;PHARMACOLOGY;PSYCHIATRY;IMMUNOLOGY;PALEONTOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;CLINICAL PSYCHOLOGY;MECHANICAL ENGINEERING;NEUROSCIENCE;NURSING;CELL BIOLOGY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;OPTICS;PSYCHOTHERAPIST;SOCIAL PSYCHOLOGY;UROLOGY","61;27;23;11;10;10;9;8;7;7;7;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3","CANCER;LUNG CANCER;RECEPTOR;CHEMOTHERAPY;GENE;DISEASE;DOPAMINE;IMMUNOHISTOCHEMISTRY;LUNG;POPULATION;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;STENOSIS;ALTERNATIVE MEDICINE;PERIOPERATIVE;STAGE (STRATIGRAPHY);STROKE (ENGINE);ADVERSE EFFECT;ANTIBODY;ASYMPTOMATIC;HEMODYNAMICS;HEPATOCELLULAR CARCINOMA;INCIDENCE (GEOMETRY);RETROSPECTIVE COHORT STUDY;VOMITING","28;15;13;10;8;7;6;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3","COLORECTAL CANCER;BREAST CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;AGONIST;MALIGNANT PLEURAL EFFUSION;CAROTID ENDARTERECTOMY;GLUTAMATE RECEPTOR;GROWTH FACTOR;MAPK/ERK PATHWAY;PARKINSON'S DISEASE;SORAFENIB;STRIATUM;TOLERABILITY;TYROSINE KINASE;ADENOCARCINOMA;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BIG FIVE PERSONALITY TRAITS;CD34;CHROMOSOME;CLINICAL ENDPOINT;DOCETAXEL;ENDARTERECTOMY;ERBB;GENE EXPRESSION;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HOSPITAL ANXIETY AND DEPRESSION SCALE;INSULIN RESISTANCE;MUTATION;NEUROTRANSMISSION;NMDA RECEPTOR;PHENOTYPE;PLACEBO;PROGRESSIVE DISEASE;RANDOMIZATION;REVASCULARIZATION;SPINAL CORD INJURY;TEMPERAMENT;WARFARIN","12;8;8;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","KRAS;CRIZOTINIB;ERLOTINIB;TRASTUZUMAB;CETUXIMAB;CAROTID STENTING;GEFITINIB;MEDIUM SPINY NEURON;ADENOSINE RECEPTOR;AMPA RECEPTOR;DABIGATRAN;DYSKINESIA;EGFR INHIBITORS;HARM AVOIDANCE;INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR;LEVODOPA;METASTATIC BREAST CANCER;MICROARRAY;NOVELTY SEEKING;RIVAROXABAN;TEMPERAMENT AND CHARACTER INVENTORY","7;5;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;MALE;FEMALE;LUNG NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;MIDDLE AGED;ADULT;AGED;BREAST NEOPLASMS;AGED, 80 AND OVER;CORPUS STRIATUM;ANTINEOPLASTIC AGENTS;TREATMENT OUTCOME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ANTIBODIES, MONOCLONAL, HUMANIZED;ANIMALS;PROTEIN KINASE INHIBITORS;RETROSPECTIVE STUDIES;ANGIOGENESIS INHIBITORS","35;34;26;25;21;18;18;16;15;15;13;12;11;11;10;9;8;8;8;7","ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;HER2 SIGNALING IN BREAST CANCER TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ATRIAL FIBRILLATION;IMPACT OF PARENTAL ILLNESS ON CHILDREN AND FAMILIES;PATHOPHYSIOLOGY AND TREATMENT OF SPINAL CORD INJURY;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;RENAL CELL CARCINOMA;ROLE OF NITRIC OXIDE IN HEALTH AND DISEASE;UROTRAUMA AND GENITOURINARY DEVELOPMENT;CARDIOTOXICITY OF CANCER TREATMENTS;CLASSIFICATION AND TREATMENT OF VASCULAR ANOMALIES;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV","16;4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","EGFR MUTATIONS;CAROTID ARTERY STENOSIS;STROKE (ENGINE);ALK INHIBITORS;BREAST CANCER;CAROTID STENTING;CEREBROVASCULAR EVENTS;EGFR;MEDIUM SPINY NEURON;TOLERABILITY;TRASTUZUMAB;ADENOSINE A2A RECEPTOR;AFATINIB;ALK INHIBITOR;ANTICOAGULANT THERAPY;APIXABAN;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BIOMARKER ANALYSIS;CANCER;CANCER CELL METABOLISM","7;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","LUNG CANCER;CELL LUNG;NON-SMALL CELL;CANCER NSCLC;CANCER PATIENTS;ADVANCED NON-SMALL;COLORECTAL CANCER;ANTI-EGFR MONOCLONAL;BREAST CANCER;CANCER MCRC;CELL CARCINOMA;CLINICAL OUTCOME;METASTATIC COLORECTAL;MONOCLONAL ANTIBODIES;NSCLC PATIENTS;PHASE II;ADJUVANT CHEMOTHERAPY;ADVANCED ALK-POSITIVE;ALK-POSITIVE NON-SMALL;ASYMPTOMATIC PATIENTS;CELL LINES;CHARACTER TRAITS;CORD INJURY;ECHOCARDIOGRAPHIC ASSESSMENT;EGFR WILD;ERBB FAMILY;FAMILY RECEPTORS;FINAL RESULTS;HEALTH-RELATED QUALITY;HER- STATUS","14;11;11;6;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADVISORY RELATIONSHIP;CELL LINES;RESEARCH FUNDING;BLOOD PRESSURE;BP SURGE;CLINICAL FEATURES;HEAD WIDTH;SPINE HEAD;SPINY NEURONS;VERSUS MONTHS;ADJUVANT CHEMOTHERAPY;ADVISORY RELATIONSHIPS;CANINE MAMMARY;CORTICOSTRIATAL SLICES;DARTOS FL;FAILED HYPOSPADIAS;IGFR PATHWAYS;INJURY CAUSED;MEDIAN FOLLOW-UP;MORNING BLOOD;PFIZER HONORARIA;PRESSURE SURGE;ANTAGONIST NVP-AAM;BAYER-SCHERING HOFFMAN;CAROTID STENOSIS;DE-EPITHELISED DARTOS;DENDRITIC SPINES;DOUBLE DE-EPITHELISED;DR AGONISTS;ELI LILLY","12;10;10;8;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4",17,0.22,3.95,3,1,0,1,1,3.5,0,1.75,3,0,0,2,0,0,1,1.25,2,1.5,0,0,67,71,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,7.57,1363.77,11.02,5,0.36,109.93,0,0,2,1,6,0,1,4,0,11,3,0,0,0,0,0,0,11,3,0,14,0,0,0,0,0,0,0,0,0,"Italy;Germany","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;44 HUMAN SOCIETY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4403 DEMOGRAPHY;4409 SOCIAL WORK;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","13;9;6;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LYMPHOMA;AGING;ORPHAN DRUG;STEM CELL RESEARCH;BRAIN DISORDERS;BREAST CANCER;GENETICS;LUNG;MENTAL HEALTH;NEUROSCIENCES;PEDIATRIC;PREVENTION;REGENERATIVE MEDICINE;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION","13;10;9;6;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","9;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.1 INDIVIDUAL CARE NEEDS","10;4;1;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;MYELOMA;OVARIAN CANCER","4;2;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","10;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"PUBLIC LIBRARY OF SCIENCE","1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY","2;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2013,63,12.5396825396825,2.04761904761905,0.285714285714286,0.222222222222222,0.365079365079365,1.46590909090909,1.05882352941176,1.16666666666667,1.04545454545455,0.380952380952381,1,32,14,7,7,0.51,0.22,0.11,0.11,70.56,2.02207995260461,7.83846153846153,0.317460317460317,0.920634920634921,0.383,0.401,0.416,0.381,"LUCIO CRINÓ;SABRINA CIPRIANI;STEFANIA GORI;FRANCESCO PUMA;ANDREA MENCARELLI;BARBARA RENGA;ELEONORA DISTRUTTI;STEFANO FIORUCCI;RITA CHIARI;VIENNA LUDOVINI;VITTORIO BINI;FABIO PUGLISI;FORTUNATO BIANCONI;MASSIMO E. DOTTORINI;GIUSEPPE SCHILLACI;NICCOLÒ DADDI;ANGELO SIDONI;ANNIBALE DONINI;VERENA DE ANGELIS;GUIDO BELLEZZA","10;5;5;5;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3","GIANPAOLO REBOLDI CRISTINA POLTRONIERI;LUCIO CRINÓ;MASSIMO E. DOTTORINI;SABRINA CIPRIANI;ANDREA MENCARELLI;BARBARA RENGA;ELEONORA DISTRUTTI;STEFANO FIORUCCI;MASSIMO SALVATORI;ENRICO RAMONI;UBERTO DA COL;VITTORIO BINI;ELVIO SCOSCIA;STEFANO BAGLIONI;AMIR ESLAMI;MAURIZIO DOTTORINI;FRANCESCO PUMA;GIAN CARLO DI RENZO;RITA CHIARI;VIENNA LUDOVINI","1;0.93;0.68;0.61;0.61;0.61;0.61;0.61;0.61;0.5;0.5;0.45;0.42;0.42;0.42;0.42;0.4;0.39;0.38;0.38","LUCIO CRINÓ;STEFANIA GORI;FRANCESCO PUMA;ELEONORA DISTRUTTI;RITA CHIARI;VIENNA LUDOVINI;MASSIMO E. DOTTORINI;GIUSEPPE SCHILLACI;ANNIBALE DONINI;VERENA DE ANGELIS;GUIDO BELLEZZA;GIAN CARLO DI RENZO;GIACOMO PUCCI;LUCIO CRINÒ;ELISA BALDELLI;ANTONELLA REPETTO;GIULIO METRO;GIUSEPPE VITTORIO DE SOCIO;CHIARA BENNATI;STELVIO BALLANTI","10;5;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","GIANPAOLO REBOLDI CRISTINA POLTRONIERI;LUCIO CRINÓ;MASSIMO E. DOTTORINI;ELEONORA DISTRUTTI;UBERTO DA COL;ELVIO SCOSCIA;STEFANO BAGLIONI;AMIR ESLAMI;MAURIZIO DOTTORINI;FRANCESCO PUMA;GIAN CARLO DI RENZO;RITA CHIARI;VIENNA LUDOVINI;ELISABETTA COSTANTINI;MASSIMO LAZZERI;MASSIMO PORENA;GIUSEPPE SCHILLACI;GIACOMO PUCCI;ANNIBALE DONINI;VERENA DE ANGELIS","1;0.93;0.68;0.61;0.5;0.42;0.42;0.42;0.42;0.4;0.39;0.38;0.38;0.33;0.33;0.33;0.32;0.32;0.29;0.28","LUCIO CRINÓ;D. ROSS CAMIDGE;ALICE T. SHAW;ANNA POLLI;BENJAMIN BESSE;BENJAMIN SOLOMON;DENIS MORO‐SIBILOT;DONG‐WAN KIM;FIONA BLACKHALL;GREGORY J. RIELY;KAZUHIKO NAKAGAWA;KEITH D. WILNER;KENNETH J. O’BYRNE;MICHAEL THOMAS;MYUNG‐JU AHN;PASI A. JÄNNE;SHRIVIDYA IYER;TAKASHI SETO;TOMMASO DE PAS;TONY MOK","3367;3211;3201;3201;3201;3201;3201;3201;3201;3201;3201;3201;3201;3201;3201;3201;3201;3201;3201;3201","LUCIO CRINÓ;ELEONORA DISTRUTTI;ANNIBALE DONINI;MICHELA BONCOMPAGNI;PIERO FLORIDI;VIENNA LUDOVINI;G. GOBBI;R. TARDUCCI;MASSIMO E. DOTTORINI;RITA CHIARI;PAOLO CALABRESI;STELVIO BALLANTI;ANTONELLA FLACCO;VERENA DE ANGELIS;CHIARA BENNATI;ALBERTO REBONATO;BIAGIO RICCIUTI;FRANCESCO PUMA;GIULIO METRO;GUIDO BELLEZZA","3367;251;179;179;98;72;70;70;67;65;62;59;58;55;51;41;41;41;41;41","LUCIO CRINÓ;ELEONORA DISTRUTTI;STEFANIA GORI;VIENNA LUDOVINI;MASSIMO E. DOTTORINI;RITA CHIARI;AMIR ESLAMI;ANTONELLA FLACCO;ANTONELLA REPETTO;CHIARA BENNATI;ELISA BALDELLI;ELVIO SCOSCIA;GIACOMO PUCCI;GIAN CARLO DI RENZO;GIUSEPPE SCHILLACI;KATIA PERRUCCIO;LUCIO CRINÒ;MAURIZIO DOTTORINI;PAOLO CALABRESI;PIERO FLORIDI","10;5;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;MATHEMATICS","57;27;6;4;3;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;IMMUNOLOGY;RADIOLOGY;ANESTHESIA;CANCER RESEARCH;ENDOCRINOLOGY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;OBSTETRICS;PHARMACOLOGY;UROLOGY;CARDIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;NEUROSCIENCE;OPTICS;PALEONTOLOGY","47;21;20;13;11;9;8;8;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3","CANCER;GENE;CHEMOTHERAPY;LUNG CANCER;RECEPTOR;DISEASE;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;THROMBOSIS;ADVERSE EFFECT;BACTERIA;COHORT;CONCOMITANT;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);INFLAMMATION;MULTIVARIATE ANALYSIS;RADIATION THERAPY;THYROID","21;13;10;9;7;6;6;6;4;3;3;3;3;3;3;3;3;3;3;3","COLORECTAL CANCER;BREAST CANCER;DOCETAXEL;CISPLATIN;EPIDERMAL GROWTH FACTOR RECEPTOR;G PROTEIN-COUPLED BILE ACID RECEPTOR;PHASES OF CLINICAL RESEARCH;TOLERABILITY;TRANSCRIPTION FACTOR;VIRAL LOAD;ADENOCARCINOMA;ALZHEIMER'S DISEASE;BORTEZOMIB;CLINICAL ENDPOINT;DEMENTIA;GENOTYPE;GESTATION;HAZARD RATIO;IMMUNOTHERAPY;MALIGNANT PLEURAL EFFUSION;NEUTROPENIA;PHARMACIST;PROSTATE CANCER;REIMBURSEMENT;RITUXIMAB;STAPHYLOCOCCUS AUREUS;THYROID CANCER","7;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","KRAS;NUCLEAR RECEPTOR;PEMETREXED;ANAPLASTIC LYMPHOMA KINASE;ANTIRETROVIRAL THERAPY;BENDAMUSTINE;ERLOTINIB;METASTATIC BREAST CANCER;NIVOLUMAB;ROS1;TRASTUZUMAB;ANDROGEN RECEPTOR;ANTHRACYCLINE;AQUAPORIN 1;AXILLA;BIVALIRUDIN;CAPECITABINE;CETUXIMAB;CHROMOSOME 17 (HUMAN);COGNITIVE DECLINE;COMPARATIVE GENOMIC HYBRIDIZATION;CRIZOTINIB;CTL*;CYP8B1;DESMIN;DNA GYRASE;DNA METHYLATION;ELEPHANT TRUNKS;FGF19;FIRST TRIMESTER;FLUORESCENCE IN SITU HYBRIDIZATION;GESTATIONAL DIABETES;GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HORMONAL THERAPY;HYPERALGESIA;INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR;KARYOTYPE;LTP INDUCTION;MEK INHIBITOR;MEMORY CLINIC;MICROSATELLITE;MISOPROSTOL;NEOADJUVANT THERAPY;NEURAL FACILITATION;NEUROACTIVE STEROID;NITROGEN MUSTARD;NORFLOXACIN;NPR1;PATTERN RECOGNITION RECEPTOR;PLACENTA;PRIMARY MOTOR CORTEX;PROSTATECTOMY;PULSED-FIELD GEL ELECTROPHORESIS;RADIOIODINE THERAPY;RIBAVIRIN;RIBOSOME;SANGER SEQUENCING;SCHISTOCYTE;SECOND TRIMESTER;SENTINEL LYMPH NODE;SMALL FOR GESTATIONAL AGE;STAPHYLOCOCCAL INFECTIONS;STREPTOCOCCUS PYOGENES;TAU PROTEIN;TAXANE;TLR2;TOLL-LIKE RECEPTOR;VANCOMYCIN;VISCERAL PAIN","4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;LUNG NEOPLASMS;ADULT;AGED;MIDDLE AGED;CARCINOMA, NON-SMALL-CELL LUNG;ANTINEOPLASTIC AGENTS;PROTEIN KINASE INHIBITORS;AGED, 80 AND OVER;ITALY;ALZHEIMER DISEASE;TREATMENT OUTCOME;VENOUS THROMBOEMBOLISM;BREAST NEOPLASMS;PROGNOSIS;RECEPTORS, CYTOPLASMIC AND NUCLEAR;SIGNAL TRANSDUCTION","33;28;24;23;21;19;17;17;16;13;10;9;8;7;7;7;6;6;6;6","ADVANCEMENTS IN LUNG CANCER RESEARCH;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;CANCER IMMUNOTHERAPY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;HER2 SIGNALING IN BREAST CANCER TREATMENT;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;MATERNAL MORBIDITY ASSOCIATED WITH PREGNANCY AND CHILDBIRTH;MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER;OCCUPATIONAL EXPOSURE TO ANTINEOPLASTIC DRUGS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;AORTIC ATHEROSCLEROTIC DISEASE AND EMBOLIC EVENTS;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CARDIOTOXICITY OF CANCER TREATMENTS;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;EFFECTS OF BLOOD TRANSFUSION IN CLINICAL PRACTICE","4;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CONCOMITANT;FARNESOID X RECEPTOR;INTESTINAL PERMEABILITY;PEMETREXED;TOLERABILITY;BENDAMUSTINE;BREAST CANCER;CELL DEATH;CLINICAL ENDPOINT;DEEP VEIN THROMBOSIS;EGFR MUTATIONS;HIV;HIV INFECTION;INTERNATIONAL MYELOMA WORKING GROUP;METASTATIC BREAST CANCER;POSTPARTUM HEMORRHAGE;RADIOACTIVE IODINE THERAPY;REFRACTORY (PLANETARY SCIENCE);REGIMEN;REIMBURSEMENT","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LUNG CANCER;BREAST CANCER;CANCER NSCLC;CANCER PATIENTS;PHASE III;ANTI-PD- BMS-;ANTICANCER DRUGS;ATYPICAL PULMONARY;BENDAMUSTINE BORTEZOMIB;BILE ACID;BMS- ONO-;CELL LUNG;CLINICAL OUTCOME;COMPARATIVE STUDY;ELEPHANT TRUNK;GENE COPY;HIV INFECTION;III COMPARATIVE;ITALIAN ONCOLOGY;ITALIAN SOCIETY;LYMPH NODE;MEDICAL ONCOLOGY;MULTICENTRE STUDY;MULTIPLE MYELOMA;NIVOLUMAB ANTI-PD-;NON-SMALL CELL;NON-SMALL-CELL LUNG;ONCOLOGY AIOM;ONCOLOGY PRACTICES;ONO- VERSUS","6;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ITALIAN RO;IGFREGFR FISH;IGFREGFR IHC;NATRIURETIC PEPTIDE;PD PATIENTS;PROSTATE CANCER;BAKRI BALLOON;BILE ACIDS;CONCOMITANT IGFREGFR;CTL SUBJECTS;HAZARD RATIO;HIGHLY EXPRESSED;IGFREGFR FISHIHC;MULTIVARIATE ANALYSIS;RESPONSE RATE;RODENT MODELS;SYNAPTIC PLASTICITY;AMERICAN SOCIETY;ANDROGENIC NEUROSTEROIDS;ART VERSUS;BILE ACID;BILE ACID-ACTIVATED;BIOMOLECULAR PROGNOSTIC;BRAIN NATRIURETIC;CANCER PATIENTS;CARDIOVASCULAR RISK;COMPLEXITY PLANNING;COX REGRESSION;DIFFERENTIATING INDIVIDUALS;EGFR FISH","8;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2",18,0.29,5.81,4.75,2,2.5,0,4.5,9.75,0,2.75,7.25,0,1,5.5,0,2,1.25,8.25,4.5,5,0,0,89.75,90.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,5.92,4313.42,15.12,7,0.54,230.62,0,1,0,0,8,0,0,4,0,9,4,0,0,0,0,0,0,12,1,0,13,0,0,0,0,0,0,0,0,0,"United States;Belgium;Germany;Hungary;Israel;Poland;United Kingdom","3;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;4205 NURSING;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","11;5;5;4;3;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;CARDIOVASCULAR;ATHEROSCLEROSIS;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;LUNG;LUNG CANCER;RARE DISEASES;AGING;BREAST CANCER;NEUROSCIENCES;PREVENTION;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;CHILDHOOD LEUKEMIA;DIGESTIVE DISEASES;ESTROGEN","11;7;6;5;4;3;3;3;3;3;3;2;2;2;2;1;1;1;1;1","CANCER;CARDIOVASCULAR;INJURIES AND ACCIDENTS;NEUROLOGICAL","6;2;1;1","6.1 PHARMACEUTICALS","9","LUNG CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA","3;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","5;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"PUBLIC LIBRARY OF SCIENCE","10","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3207 MEDICAL MICROBIOLOGY;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;51 PHYSICAL SCIENCES","15;4;4;3;2;1;1;1","DIGESTIVE DISEASES;BRAIN DISORDERS;CLINICAL RESEARCH;EMERGING INFECTIOUS DISEASES;GENETICS;HEPATITIS;HEPATITIS - B;LIVER DISEASE;NEURODEGENERATIVE;NEUROSCIENCES;PARKINSON'S DISEASE;PREVENTION;AGING;AUTOIMMUNE DISEASE;BIODEFENSE;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;HEMATOLOGY;HEPATITIS - C;HIV/AIDS","3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","NEUROLOGICAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","3;2;2;1;1","CLINICAL;BIOMEDICAL","2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","7;1","COLON AND RECTAL CANCER;KIDNEY CANCER;LIVER CANCER","1;1;1",NA,NA
"AOU_PERUGIA",2014,54,15.6666666666667,2.90740740740741,0.37037037037037,0.259259259259259,0.592592592592593,1.55445544554455,1.25,1.27272727272727,1.28,0.425925925925926,0,34,10,3,3,0.63,0.19,0.06,0.06,45.69,1.20886818765691,8.08070175438596,0.351851851851852,0.944444444444444,0.412,0.305,0.511,0.449,"LUCIO CRINÓ;PAOLO CALABRESI;ROLF A. STAHEL;SOLANGE PETERS;ENRIQUETA FELIP;GIULIO METRO;SILVIA NOVELLO;GAETANO ROCCO;C. FAIVRE‐FINN;EGBERT F. SMIT;RITA CHIARI;STEFANIA GORI;BENJAMIN BESSE;CHRISTOPHE DOOMS;PETER MELDGAARD;KENNETH J. O’BYRNE;MARTIN RECK;JEAN-YVES DOUILLARD;PAUL BAAS;CHIARA BENNATI","12;10;6;6;6;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","MIRKO BERTOZZI;ANTONINO APPIGNANI;PAOLO CALABRESI;LUCIO CRINÓ;ELISA BALDELLI;FRANCESCA MATTOZZI;STEFANO CAPRONI;VITTORIO BINI;PIERA BERTOLDI;GIUSEPPE QUINTALIANI;SARA BATTISTONI;GIULIO METRO;VERONICA GHIGLIERI;NICOLA TAMBASCO;ELISA MAGRINI;FORTUNATO BIANCONI;PAOLO VALIGI;SARA RICCIONI;RITA CHIARI;CHIARA BENNATI","1.17;1.17;0.98;0.68;0.47;0.45;0.44;0.44;0.42;0.42;0.37;0.36;0.36;0.34;0.33;0.33;0.33;0.33;0.3;0.3","LUCIO CRINÓ;PAOLO CALABRESI;GIULIO METRO;RITA CHIARI;STEFANIA GORI;CHIARA BENNATI;STEFANO CAPRONI;VIENNA LUDOVINI;ANNAMARIA SIGGILLINO;MIRKO BERTOZZI;ELISA BALDELLI;LORENZA PISTOLA;FRANCESCA ROMANA TOFANETTI;DANIELA IACONO;NICOLA TAMBASCO;JENNIFER FOGLIETTA;ANTONINO APPIGNANI;VINCENZO MINOTTI;ILENIA CORBELLI;ALESSANDRO TOZZI","12;10;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2","MIRKO BERTOZZI;ANTONINO APPIGNANI;PAOLO CALABRESI;LUCIO CRINÓ;ELISA BALDELLI;FRANCESCA MATTOZZI;STEFANO CAPRONI;PIERA BERTOLDI;SARA BATTISTONI;GIULIO METRO;NICOLA TAMBASCO;ELISA MAGRINI;RITA CHIARI;CHIARA BENNATI;VIENNA LUDOVINI;LUIGI VECCHI;STEFANIA GORI;DANIELA IACONO;ANNAMARIA SIGGILLINO;LORENZA PISTOLA","1.17;1.17;0.98;0.68;0.47;0.45;0.44;0.42;0.37;0.36;0.34;0.33;0.3;0.3;0.28;0.25;0.24;0.23;0.23;0.23","ENRIQUETA FELIP;ROLF A. STAHEL;SOLANGE PETERS;C. FAIVRE‐FINN;CHRISTOPHE DOOMS;ERIC LIM;GAETANO ROCCO;JEAN-YVES DOUILLARD;JOHAN VANSTEENKISTE;PAUL VAN SCHIL;SURESH SENAN;LUCIO CRINÓ;SILVIA NOVELLO;KENNETH J. O’BYRNE;MARTIN J. EDELMAN;TONY MOK;ALEX A. ADJEI;BENJAMIN BESSE;EGBERT F. SMIT;KONSTANTINOS SYRIGOS","1882;1882;1882;1381;1381;1381;1381;1381;1381;1381;1381;1315;1246;1215;1215;1215;1168;1168;1168;1168","LUCIO CRINÓ;PAOLO CALABRESI;LUCIO CRINÒ;ELEONORA DISTRUTTI;ALESSANDRO TOZZI;MASSIMILIANO DI FILIPPO;STEFANO CAPRONI;CLAUDIO CAVALLINI;PIERO FLORIDI;ILENIA CORBELLI;PAOLA SARCHIELLI;DILETTA LOSCHI;FABIO VERZINI;VINCENZO MINOTTI;FRANCESCA MILANO;MARTA ROSSI;STEFANIA GORI;CINZIA COSTA;NICOLA TAMBASCO;BRUNANGELO FALINI","1313;280;274;200;105;105;101;91;89;69;69;66;66;66;64;63;62;58;53;45","LUCIO CRINÓ;PAOLO CALABRESI;CHIARA BENNATI;RITA CHIARI;STEFANO CAPRONI;JENNIFER FOGLIETTA;ANTONINO APPIGNANI;GIULIO METRO;MIRKO BERTOZZI;VINCENZO MINOTTI;ANNAMARIA SIGGILLINO;DANIELA IACONO;FRANCESCA ROMANA TOFANETTI;LORENZA PISTOLA;NICOLA TAMBASCO;VIENNA LUDOVINI;ALESSANDRO TOZZI;CINZIA COSTA;ELISA BALDELLI;ILENIA CORBELLI","8;7;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;MATHEMATICS;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY","49;23;7;6;4;4;3;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;GENETICS;SURGERY;BIOCHEMISTRY;PATHOLOGY;NEUROSCIENCE;CARDIOLOGY;PALEONTOLOGY;RADIOLOGY;CANCER RESEARCH;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;PSYCHIATRY;ANESTHESIA;CELL BIOLOGY;GASTROENTEROLOGY;PHYSICAL THERAPY;ARTIFICIAL INTELLIGENCE;COMPUTATIONAL BIOLOGY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;IMMUNOLOGY;OPTICS;PEDIATRICS;UROLOGY","37;20;12;11;10;10;8;7;7;6;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2","CANCER;GENE;LUNG CANCER;CHEMOTHERAPY;DISEASE;RECEPTOR;STAGE (STRATIGRAPHY);RANDOMIZED CONTROLLED TRIAL;REGIMEN;ADVERSE EFFECT;ALTERNATIVE MEDICINE;CONSENSUS CONFERENCE;DOPAMINE;HIPPOCAMPUS;BLOOD PRESSURE;CLINICAL TRIAL;DEXAMETHASONE;EPILEPSY;FUNCTIONAL MAGNETIC RESONANCE IMAGING;HEPATOCELLULAR CARCINOMA;HIPPOCAMPAL FORMATION;LAPAROSCOPY;LUNG;LYMPHOMA;MAGNETIC RESONANCE IMAGING;MULTIPLE MYELOMA;MYOCARDIAL INFARCTION;NEPHROLOGY;NEUROLOGY;POPULATION;PREGNANCY;RADIATION THERAPY;RETROSPECTIVE COHORT STUDY;SIGNAL TRANSDUCTION;THYROID","16;16;12;9;8;7;6;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;LONG-TERM POTENTIATION;PARKINSON'S DISEASE;ADENOCARCINOMA;BREAST CANCER;COLORECTAL CANCER;GENE EXPRESSION;NMDA RECEPTOR;PLACEBO;SUNITINIB;BEVACIZUMAB;BORTEZOMIB;DENTATE GYRUS;DOCETAXEL;DOPAMINERGIC;GENOTYPE;MALIGNANT PLEURAL EFFUSION;NEUTROPENIA;SORAFENIB;SYNAPTIC PLASTICITY;TOLERABILITY","5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","AMPA RECEPTOR;KRAS;LASER CAPTURE MICRODISSECTION;METASTATIC BREAST CANCER;PAZOPANIB;ROS1;TRASTUZUMAB;ANAPLASTIC LYMPHOMA KINASE;BENDAMUSTINE;BIVALIRUDIN;CATECHOL-O-METHYL TRANSFERASE;CETUXIMAB;CIRCULATING TUMOR CELL;COMPARATIVE GENOMIC HYBRIDIZATION;CRIZOTINIB;CYCLIN-DEPENDENT KINASE 2;DIRECT PATHWAY OF MOVEMENT;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DYSKINESIA;ERLOTINIB;EXCITOTOXICITY;FLUORESCENCE IN SITU HYBRIDIZATION;FRACTIONAL ANISOTROPY;GESTATIONAL DIABETES;HOMEOBOX;INTRAVENTRICULAR HEMORRHAGE;LEVODOPA;LOSS FUNCTION;MEDIAL FOREBRAIN BUNDLE;MEDIUM SPINY NEURON;MEMANTINE;MICROARRAY;MICRODELETION SYNDROME;PAPILLARY THYROID CANCER;PERFORANT PATH;PHARMACOGENETICS;POLYMORPHISM (COMPUTER SCIENCE);RNA SPLICING;SAPS II;SINGLE-NUCLEOTIDE POLYMORPHISM;SUBSTANTIA NIGRA;SYNAPTIC VESICLE;THORACIC AORTIC ANEURYSM;VANDETANIB","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;LUNG NEOPLASMS;MALE;MIDDLE AGED;AGED;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOMA, NON-SMALL-CELL LUNG;NEOPLASM RECURRENCE, LOCAL;ADULT;ANTIBODIES, MONOCLONAL, HUMANIZED;NEURONS;AGED, 80 AND OVER;ANGIOGENESIS INHIBITORS;ANIMALS;BREAST NEOPLASMS;HIPPOCAMPUS;LONG-TERM POTENTIATION;ANTINEOPLASTIC AGENTS","31;26;25;22;19;18;17;17;15;11;10;9;9;8;8;8;8;8;8;7","ADVANCEMENTS IN LUNG CANCER RESEARCH;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;CARDIAC REHABILITATION AND CARDIOVASCULAR HEALTH INTERVENTIONS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;CLINICAL AND PATHOLOGICAL ASPECTS OF URACHAL CARCINOMA;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DIFFUSION MAGNETIC RESONANCE IMAGING;DIVERSITY AND FUNCTION OF GUT MICROBIOME;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;FLUID RESUSCITATION IN TRAUMA AND CRITICAL CARE","6;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;NON-SMALL CELL LUNG CANCER;REGIMEN;CONSENSUS CONFERENCE;LUNG CANCER;METASTATIC BREAST CANCER;BIOMARKER ANALYSIS;BREAST CANCER;CANCER;CANCER THERAPY;DEEP BRAIN STIMULATION;LASER CAPTURE MICRODISSECTION;NEPHROLOGY;PAZOPANIB;TOLERABILITY;TRASTUZUMAB;TREATMENT;TUMOR MARKERS;ACUTE KIDNEY INJURY;ALTERNATIVE SPLICING","5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1","LUNG CANCER;BREAST CANCER;CONSENSUS CONFERENCE;ESMO CONSENSUS;NON-SMALL-CELL LUNG;PHASE III;AORTIC REPAIR;CANCER PATIENTS;CELL CARCINOMA;CELL LUNG;ENDOVASCULAR AORTIC;FIRST-LINE TREATMENT;HER-POSITIVE METASTATIC;LUNG ADENOCARCINOMA;MEDICATION OVERUSE;METASTATIC BREAST;MULTICENTER PHASE;MYOCARDIAL INFARCTION;NEVER-SMOKER NS;NSCLC PATIENTS;OVARIAN CANCER;OVERUSE HEADACHE;PATIENTS PTS;PHASE II;RANDOMIZED PHASE;RANDOMIZED STUDY;RETROSPECTIVE ANALYSIS;UNSELECTED PATIENTS;ABERRANT CDK;ABSTRACT PP-","11;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","LUNG CANCER;PD PATIENTS;SODIUM VALPROATE;ADVANCED DISEASE;INTESTINAL MICROBIOTA;NON-SMALL-CELL LUNG;AGED RATS;CANCER NSCLC;CTC PREPARATIONS;EGFR MUTATIONS;MAJOR BLEEDING;MOLECULAR BIOMARKERS;BAILOUT GPI;CARDIAC REHABILITATION;CHRONIC ISCHEMIC;CONSENSUS CONFERENCE;CONSENSUS CONFERENCES;CONSENSUS PAPER;EARLY-STAGE DISEASE;ELDERLY PATIENTS;ESMO CONSENSUS;ESMO ORGANISES;EXISTING TREATMENT;EXPERTS MET;INCLUDING REFERENCE;ISCHEMIC MITRAL;LOCALLY ADVANCED;LONG-TERM POTENTIATION;MEDICATION OVERUSE;MITRAL REGURGITATION","12;9;7;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",21,0.39,13.25,5,1.75,1,3,2,4.75,0,1,6,2,0,4,0,1,1,2,3,2.5,0,0,116,116,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,4.56,842.81,16,11,0.69,90.88,0,0,7,0,5,0,1,3,0,14,2,0,0,0,0,0,0,14,2,0,16,0,0,0,0,0,0,0,0,0,"Germany;Italy;United States","3;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY","16;11;5;3;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;LUNG;RARE DISEASES;GENETICS;HEMATOLOGY;LUNG CANCER;AGING;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;NEUROSCIENCES;ORPHAN DRUG;PEDIATRIC;PEDIATRIC CANCER;ACUTE RESPIRATORY DISTRESS SYNDROME;ARTHRITIS;ASSISTIVE TECHNOLOGY;BIOENGINEERING","16;11;8;7;5;5;4;4;3;2;2;2;2;2;2;2;1;1;1;1","CANCER;RESPIRATORY;BLOOD;CARDIOVASCULAR;EYE;INFECTION;MUSCULOSKELETAL;STROKE","5;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","11;3;3;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;BLOOD CANCER;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;SKIN CANCER","3;3;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","6;3;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,"PUBLIC LIBRARY OF SCIENCE","9","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3202 CLINICAL SCIENCES;3208 MEDICAL PHYSIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4202 EPIDEMIOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","12;3;2;2;2;1;1;1;1;1;1;1","AGING;CLINICAL RESEARCH;BRAIN DISORDERS;CANCER;CARDIOVASCULAR;DIABETES;GENETICS;HEART DISEASE;NEURODEGENERATIVE;NEUROSCIENCES;NUTRITION;PARKINSON'S DISEASE;PREVENTION;STROKE","2;2;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;NEUROLOGICAL;STROKE","1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","1;1","CLINICAL;HEALTH SERVICES & SYSTEMS","1;1","CLINICAL MEDICINE AND SCIENCE","3","LUNG CANCER;NOT SITE-SPECIFIC CANCER","1;1",NA,NA
"AOU_PERUGIA",2015,74,14.2432432432432,2.28378378378378,0.324324324324324,0.216216216216216,0.297297297297297,2.0609756097561,1.5,1.33333333333333,1.46666666666667,0.5,2,42,16,5,4,0.57,0.22,0.07,0.05,143.2,3.84248964109701,7.93134328358209,0.405405405405405,0.918918918918919,0.537,0.363,0.456,0.368,"LUCIO CRINÓ;VIENNA LUDOVINI;RITA CHIARI;GIULIO METRO;ELISA BALDELLI;SIMONE CESARO;STEFANIA GORI;ANGELO SIDONI;CHIARA BENNATI;MAURIZIO CANIGLIA;FABIO ANGELI;FORTUNATO BIANCONI;PAOLA SARCHIELLI;PIERO FLORIDI;KATIA PERRUCCIO;PAOLO VERDECCHIA;MARIAELENA PIEROBON;GUIDO BELLEZZA;PAOLO CALABRESI;ANNAMARIA SIGGILLINO","21;9;8;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3","LUCIO CRINÓ;PAOLA SARCHIELLI;FABIO ANGELI;GIANPAOLO REBOLDI;BIAGIO RICCIUTI;VIENNA LUDOVINI;PAOLO VERDECCHIA;ELISA BALDELLI;ENRICO RAMONI;SIMONE PERTICONI;UBERTO DA COL;RITA CHIARI;GIULIO METRO;FORTUNATO BIANCONI;PAOLO CALABRESI;PAOLO VALIGI;MARIAELENA PIEROBON;MAURIZIO CANIGLIA;CHIARA BENNATI;GIUSEPPE QUINTALIANI","2.02;1.37;1.34;1.17;1.16;0.89;0.84;0.82;0.67;0.67;0.67;0.63;0.57;0.55;0.51;0.48;0.46;0.42;0.41;0.37","LUCIO CRINÓ;VIENNA LUDOVINI;RITA CHIARI;GIULIO METRO;ELISA BALDELLI;ANGELO SIDONI;CHIARA BENNATI;MAURIZIO CANIGLIA;FABIO ANGELI;PAOLA SARCHIELLI;PIERO FLORIDI;KATIA PERRUCCIO;PAOLO CALABRESI;ANNAMARIA SIGGILLINO;PAOLO PRONTERA;LUCILLA PARNETTI;BIAGIO RICCIUTI;STEFANO CAPRONI;CLAUDIO CAVALLINI;ILENIA CORBELLI","21;9;8;7;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;2","LUCIO CRINÓ;PAOLA SARCHIELLI;FABIO ANGELI;BIAGIO RICCIUTI;VIENNA LUDOVINI;ELISA BALDELLI;ENRICO RAMONI;SIMONE PERTICONI;UBERTO DA COL;RITA CHIARI;GIULIO METRO;PAOLO CALABRESI;MAURIZIO CANIGLIA;CHIARA BENNATI;GIUSEPPE QUINTALIANI;STEFANO CAPRONI;ANGELO SIDONI;MARCO LUPIDI;KATIA PERRUCCIO;CLAUDIO CAVALLINI","2.02;1.37;1.34;1.16;0.89;0.82;0.67;0.67;0.67;0.63;0.57;0.51;0.42;0.41;0.37;0.37;0.35;0.33;0.33;0.32","ENRIQUETA FELIP;DAVID R. SPIGEL;CHARLES M. RUDIN;CHRISTOPHER HARBISON;CÉCILE DORANGE;DAVID E. GERBER;ELENA PODDUBSKAYA;ESTHER HOLGADO;EVERETT E. VOKES;F. GRAF FINCKENSTEIN;FABRICE BARLÉSI;GEORGE R. BLUMENSCHEIN;H. BORGHAEI;H. LENA;JULIE R. BRAHMER;JÉRÔME FAYETTE;L. CRINA;L. PAZ-ARES;LAURA Q.M. CHOW;LEORA HORN","8614;8607;8531;8531;8531;8531;8531;8531;8531;8531;8531;8531;8531;8531;8531;8531;8531;8531;8531;8531","L. CRINA;LUCIO CRINÓ;VIENNA LUDOVINI;RITA CHIARI;MAGDOLNA DANK;GIULIO METRO;CECILIA BECATTINI;PIERO FLORIDI;PAOLO PRONTERA;GIANLUCA ZINGARINI;LUCA MARCOMIGNI;ERIBERTO FARINELLA;LUCILLA PARNETTI;CHIARA BENNATI;GABRIELA STANGONI;GIAN CARLO DI RENZO;VINCENZO MINOTTI;ANNAMARIA SIGGILLINO;ELISA BALDELLI;PAOLA SARCHIELLI","8531;552;363;341;227;220;194;155;151;127;99;91;90;86;79;75;66;60;57;57","LUCIO CRINÓ;VIENNA LUDOVINI;RITA CHIARI;GIULIO METRO;CHIARA BENNATI;FABIO ANGELI;KATIA PERRUCCIO;MAURIZIO CANIGLIA;PAOLA SARCHIELLI;PAOLO CALABRESI;PAOLO PRONTERA;ANNAMARIA SIGGILLINO;CLAUDIO CAVALLINI;PIERO FLORIDI;STEFANO CAPRONI;ANNA MARIA MOSCONI;BIAGIO RICCIUTI;C PIERSANTI;CARLA CERRI;ELEONORA DISTRUTTI","20;9;8;7;5;5;4;4;4;3;3;3;3;3;3;2;2;2;2;2","MEDICINE;BIOLOGY;MATHEMATICS;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;PSYCHOLOGY;SOCIOLOGY;BUSINESS","68;29;6;5;5;3;2;2;2;2;1","INTERNAL MEDICINE;ONCOLOGY;PATHOLOGY;SURGERY;GASTROENTEROLOGY;GENETICS;BIOCHEMISTRY;CANCER RESEARCH;CARDIOLOGY;PALEONTOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;OPTICS;RADIOLOGY;COMPUTATIONAL BIOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;PEDIATRICS;STATISTICS","57;28;17;16;12;12;11;10;8;8;6;6;5;5;4;4;4;3;3;3;3","CANCER;GENE;LUNG CANCER;CHEMOTHERAPY;DISEASE;CONFIDENCE INTERVAL;POPULATION;ALTERNATIVE MEDICINE;INCIDENCE (GEOMETRY);MYOCARDIAL INFARCTION;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);MIGRAINE;ADJUVANT;BLOOD PRESSURE;MULTIVARIATE ANALYSIS;NEUROLOGY;PROSPECTIVE COHORT STUDY;RECEPTOR;RENAL FUNCTION;REPRODUCIBILITY;RETROSPECTIVE COHORT STUDY","24;17;17;13;7;6;6;5;5;5;5;5;5;4;3;3;3;3;3;3;3;3;3","COLORECTAL CANCER;GENE EXPRESSION;EPIDERMAL GROWTH FACTOR RECEPTOR;MALIGNANT PLEURAL EFFUSION;BREAST CANCER;TYROSINE-KINASE INHIBITOR;ADENOCARCINOMA;CLINICAL ENDPOINT;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MICRODISSECTION;MUTATION;PERCUTANEOUS CORONARY INTERVENTION;PLACEBO;PROGRESSION-FREE SURVIVAL;TRANSCRIPTION FACTOR;A549 CELL;ACUTE CORONARY SYNDROME;CERVICAL CANCER;CISPLATIN;DEMENTIA;DOCETAXEL;ETOPOSIDE;GENOTYPE;HAZARD RATIO;IMMUNOTHERAPY;MESSENGER RNA;MICRORNA;NEUTROPENIA;OVARIAN CANCER;PROTEOMICS;RANDOMIZATION;STAPHYLOCOCCUS AUREUS;TARGETED THERAPY;TYROSINE KINASE","7;6;5;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANAPLASTIC LYMPHOMA KINASE;ERLOTINIB;CRIZOTINIB;GEFITINIB;KRAS;LASER CAPTURE MICRODISSECTION;MICROARRAY;CARBOPLATIN;CETUXIMAB;NON-SMALL CELL LUNG CANCER (NSCLC);NUCLEAR RECEPTOR;TRASTUZUMAB;ALPHA-SYNUCLEIN;ALVEOLAR RHABDOMYOSARCOMA;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIPLATELET DRUG;BIVALIRUDIN;BONE MARROW TRANSPLANT;CAPECITABINE;CASPOFUNGIN;CATECHIN;CYP2C19;CYTOGENETICS;DEMENTIA WITH LEWY BODIES;DIROFILARIA;DIROFILARIA REPENS;EMBRYONAL RHABDOMYOSARCOMA;ESTROGEN RECEPTOR;FLUORESCENCE IN SITU HYBRIDIZATION;FRONTOTEMPORAL DEMENTIA;GASTROINTESTINAL CANCER;HEART-TYPE FATTY ACID BINDING PROTEIN;HEMATOPOIETIC CELL;HEME OXYGENASE;MACROLIDE ANTIBIOTICS;MAMMOGRAPHY;MASTECTOMY;METASTATIC BREAST CANCER;METHYLMALONIC ACIDURIA;MISSENSE MUTATION;MITRAL ANNULUS;MITRAL VALVE ANNULOPLASTY;MYELOPROLIFERATIVE NEOPLASM;NIVOLUMAB;P2Y12;PAX3;POSACONAZOLE;PRASUGREL;PRIMARY TUMOR;PROPHYLACTIC CRANIAL IRRADIATION;PROTEIN PHOSPHORYLATION;PULSED-FIELD GEL ELECTROPHORESIS;RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS;REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;STREPTOCOCCUS PYOGENES;SUBICULUM;SYSTEMIC THERAPY;TELOMERASE REVERSE TRANSCRIPTASE;TICAGRELOR;VINCRISTINE","5;4;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;LUNG NEOPLASMS;;CARCINOMA, NON-SMALL-CELL LUNG;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;BREAST NEOPLASMS;ANTINEOPLASTIC AGENTS;ITALY;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BIOMARKERS, TUMOR;ERBB RECEPTORS;ACUTE CORONARY SYNDROME;BRAIN NEOPLASMS","43;37;30;27;27;27;25;21;17;17;16;12;11;10;9;9;9;9;8;8","ADVANCEMENTS IN LUNG CANCER RESEARCH;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;LYMPHOID NEOPLASMS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF VALVULAR HEART DISEASE;REAL-TIME POLYMERASE CHAIN REACTION;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANALYSIS OF GENE INTERACTION NETWORKS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CANCER IMMUNOTHERAPY;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DISEASES RELATED TO BLOOD GROUP VARIANTS","9;4;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","ALK INHIBITOR;ADJUVANT THERAPY;ALECTINIB;BIOMARKER ANALYSIS;CERITINIB;CLINICAL ENDPOINT;EGFR MUTATIONS;LASER CAPTURE MICRODISSECTION;MICRODISSECTION;MIGRAINE;MIGRAINE PREVENTION;PROGRESSION-FREE SURVIVAL;TREATMENT GUIDELINES;ALK INHIBITORS;B CELL ABNORMALITIES;BIOCHEMICAL MODELING;BREAST CANCER;CARBOPLATIN;CERVICAL CANCER;CONCORDANCE","4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","LUNG CANCER;CELL LUNG;NON-SMALL CELL;CANCER PATIENTS;BREAST CANCER;CANCER NSCLC;II STUDY;PHASE II;RETROSPECTIVE ANALYSIS;ACUTE CORONARY;ADVANCED ANDOR;ANDOR RECURRENT;CANCER CERV;CAPTURE MICRODISSECTION;CERVICAL CANCER;CETUXIMAB NA;CLINICAL OUTCOME;CORONARY INTERVENTION;CORONARY SYNDROME;EGFR MUTATIONS;ELLIPTICAL POSTERIOR;HEALTHY ELDERLY;ITALIAN ASSOCIATION;ITALIAN TRIALS;KINASE INHIBITORS;LASER CAPTURE;LONGITUDINAL REPRODUCIBILITY;LOW-IMPACT REPARATIVE;MITO MULTICENTRE;MITRAL VALVE","13;7;7;6;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LUNG CANCER;ADJUVANT SYSTEMIC;SYSTEMIC THERAPY;CNS METASTASES;MOH PATIENTS;CELL LUNG;BRAIN METASTASES;BREAST CANCER;PATIENTS RECEIVED;CSF-TO-SERUM RATIO;NON-SMALL CELL;CLINICAL OUTCOME;DYSKERIN EXPRESSION;EMM TYPES;KRAS MT;LUNG CANCERS;PUBMED SCOPUS;ST ALK-TKI;ALK-POSITIVE ADVANCED;CANCER NSCLC;CLINICAL TRIALS;DISEASE PROGRESSION;EPIDERMAL GROWTH;FACTOR RECEPTOR;GENE AMPLIFICATION;GROWTH FACTOR;HER-POSITIVE BREAST;HIPPOCAMPAL SUBFIELDS;I- ITALY;ITALY DEPARTMENT","13;12;12;10;9;8;7;7;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4",27,0.36,5.5,5,3,3,1,10,48.5,0,2.5,5,1.25,1,3,0,4.75,1,2.75,4,3.75,0,0,89.5,89.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,6.95,1324,25.64,11,0.55,132.15,1,0,5,0,8,0,1,5,0,17,3,0,0,0,0,0,0,18,2,0,20,0,0,0,0,0,0,0,0,0,"Japan;Italy;United States;Australia;Germany","3;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;40 ENGINEERING","19;10;7;2;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;LUNG;LUNG CANCER;RARE DISEASES;PATIENT SAFETY;HEMATOLOGY;CARDIOVASCULAR;BRAIN DISORDERS;HEART DISEASE;LYMPHOMA;NEUROSCIENCES;ORPHAN DRUG;PEDIATRIC;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION;ACQUIRED COGNITIVE IMPAIRMENT;AGING","19;16;13;6;6;6;5;4;3;2;2;2;2;2;2;2;2;2;1;1","CANCER;CARDIOVASCULAR;INFECTION;BLOOD;NEUROLOGICAL","10;2;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.4 SURGERY","17;3;2;1;1;1;1","LUNG CANCER;LEUKEMIA / LEUKAEMIA;BREAST CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER","6;4;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","11;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,"PUBLIC LIBRARY OF SCIENCE","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","4;2","ESTROGEN","1",NA,NA,"6.1 PHARMACEUTICALS","1",NA,NA,"CLINICAL MEDICINE AND SCIENCE","2",NA,NA,NA,NA
"AOU_PERUGIA",2016,91,14.6813186813187,2.41758241758242,0.362637362637363,0.241758241758242,0.373626373626374,1.66666666666667,1.32,1.22222222222222,1.36,0.472527472527473,3,52,15,6,8,0.57,0.16,0.07,0.09,16.87,0.519290909403876,9.22383720930233,0.274725274725275,0.923076923076923,0.496,0.487,0.518,0.494,"LUCIO CRINÓ;RITA CHIARI;GIULIO METRO;VIENNA LUDOVINI;PAOLA DE RANGO;FILIPPO DE MARINIS;FRANCESCO GROSSI;CHIARA BENNATI;ANGELO DELMONTE;MARCELLO TISEO;LUCILLA PARNETTI;R. TARDUCCI;BIAGIO RICCIUTI;GIOELE SIMONTE;MICHELE MASSIMO GULIZIA;PIERO FLORIDI;ANNA MARINA LIBERATI;CLAUDIO DAZZI;FABRICE BARLÉSI;PAOLO CALABRESI","18;12;7;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","PAOLA DE RANGO;RITA CHIARI;LUCIO CRINÓ;GIULIO METRO;GIUSEPPE QUINTALIANI;BEATRICE FIORUCCI;GIOELE SIMONTE;VIENNA LUDOVINI;RICCARDO MARIA FAGUGLI;LAURA RASERO;GIOVANNI TRIPEPI;RICCARDO GIAMPAOLI;NIKOLAOS TSILIMPARIS;GIANNI ASCIONE;SARA BATTISTONI;NICOLA RAMACCIATI;FRANCESCO PATERA;FABIO VERZINI;PAOLO CALABRESI;ALESSANDRO D’ARPINO","3.46;1.33;1.22;1.04;1;0.7;0.66;0.54;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.46;0.45;0.44","LUCIO CRINÓ;RITA CHIARI;GIULIO METRO;VIENNA LUDOVINI;PAOLA DE RANGO;CHIARA BENNATI;LUCILLA PARNETTI;R. TARDUCCI;BIAGIO RICCIUTI;GIOELE SIMONTE;PIERO FLORIDI;ANNA MARINA LIBERATI;PAOLO CALABRESI;FRANCO BALDELLI;P CHIARINI;GIUSEPPE VITTORIO DE SOCIO;NICOLA TAMBASCO;ENRICO SEBASTIANI;ANNAMARIA SIGGILLINO;RICCARDO MARIA FAGUGLI","18;12;7;7;6;5;4;4;4;4;4;4;4;3;3;3;3;2;2;2","PAOLA DE RANGO;RITA CHIARI;LUCIO CRINÓ;GIULIO METRO;GIUSEPPE QUINTALIANI;BEATRICE FIORUCCI;GIOELE SIMONTE;VIENNA LUDOVINI;RICCARDO MARIA FAGUGLI;GIOVANNI TRIPEPI;RICCARDO GIAMPAOLI;GIANNI ASCIONE;SARA BATTISTONI;NICOLA RAMACCIATI;FRANCESCO PATERA;PAOLO CALABRESI;ALESSANDRO D’ARPINO;BIAGIO RICCIUTI;NICOLA TAMBASCO;P CHIARINI","3.46;1.33;1.22;1.04;1;0.7;0.66;0.54;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.45;0.44;0.39;0.38;0.37","LUCIO CRINÓ;ANDREA DI LENARDA;GIOVANNI CIOFFI;GIOVANNI PULIGNANO;DONATELLA DEL SINDACO;GIANFRANCO ALUNNI;GIOVANNI MINARDI;LUIGI TARANTINI;MARIA DENITZA TINTI;MASSIMO UGUCCIONI;MICHELE SENNI;LUCILLA PARNETTI;RITA CHIARI;PIERO FLORIDI;AGNESE PICCO;ALBERTO BELTRAMELLO;ANDREA SORICELLI;ANTONIO FERRETTI;ANTONIOS DREVELEGAS;BEATRÍZ BOSCH","227;207;206;206;204;204;204;204;204;204;204;200;184;147;122;122;122;122;122;122","LUCIO CRINÓ;GIANFRANCO ALUNNI;RITA CHIARI;PIERO FLORIDI;SIMONE DONNARI;GIULIO METRO;GIUSEPPE VITTORIO DE SOCIO;ELEONORA DISTRUTTI;PAOLO CALABRESI;CINZIA COSTA;LUCILLA PARNETTI;MASSIMILIANO DI FILIPPO;MICHELA TANTUCCI;PAOLO EUSEBI;PETRA MAZZOCCHETTI;SABRINA SILIQUINI;P CHIARINI;BIAGIO RICCIUTI;ANNA MARIA MOSCONI;VIENNA LUDOVINI","227;204;184;147;110;109;106;102;79;77;77;77;77;77;77;77;73;70;69;69","LUCIO CRINÓ;RITA CHIARI;VIENNA LUDOVINI;GIULIO METRO;PAOLA DE RANGO;CHIARA BENNATI;BIAGIO RICCIUTI;PIERO FLORIDI;ANNA MARINA LIBERATI;P CHIARINI;GIUSEPPE VITTORIO DE SOCIO;NICOLA TAMBASCO;ANNAMARIA SIGGILLINO;BEATRICE FIORUCCI;ELEONORA DISTRUTTI;FRANCESCO PATERA;FRANCO BALDELLI;GIACOMO ISERNIA;GIANBATTISTA PARLANI;GIANFRANCO ALUNNI","18;12;7;7;6;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;MATHEMATICS;POLITICAL SCIENCE;BUSINESS;ART;ECONOMICS;ENGINEERING;PHILOSOPHY;CHEMISTRY;GEOGRAPHY;MATERIALS SCIENCE","88;22;8;8;8;6;4;3;2;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;PATHOLOGY;GENETICS;RADIOLOGY;CANCER RESEARCH;FAMILY MEDICINE;IMMUNOLOGY;PALEONTOLOGY;CARDIOLOGY;ENDOCRINOLOGY;NEUROSCIENCE;NURSING;OPTICS;BIOCHEMISTRY;LAW;PEDIATRICS;PHYSICAL MEDICINE AND REHABILITATION;PSYCHIATRY;STATISTICS","64;32;26;13;11;10;10;9;9;7;7;7;7;6;5;5;5;5;4;4;4;4;4;4","CANCER;LUNG CANCER;DISEASE;POPULATION;CHEMOTHERAPY;CLINICAL TRIAL;COHORT;ADVERSE EFFECT;GENE;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;HUMAN IMMUNODEFICIENCY VIRUS (HIV);ANEURYSM;COHORT STUDY;CONTEXT (ARCHAEOLOGY);INCIDENCE (GEOMETRY);OBSERVATIONAL STUDY;RECEPTOR;ARTERY;DISCONTINUATION;EXPANDED ACCESS;HEALTH CARE;HEART FAILURE;LYMPHOMA;PROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);STENT;THROMBOSIS","23;19;13;12;11;9;9;8;7;7;7;7;6;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","IMMUNOTHERAPY;CLINICAL ENDPOINT;EPIDERMAL GROWTH FACTOR RECEPTOR;ABDOMINAL AORTIC ANEURYSM;COLORECTAL CANCER;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;DOCETAXEL;ETOPOSIDE;MALIGNANT PLEURAL EFFUSION;PHASES OF CLINICAL RESEARCH;PROGRESSIVE DISEASE;REVASCULARIZATION;VIRAL LOAD;ADENOCARCINOMA;ANAPLASTIC LARGE-CELL LYMPHOMA;AORTIC ANEURYSM;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BEVACIZUMAB;BORTEZOMIB;BREAST CANCER;CISPLATIN;CUMULATIVE INCIDENCE;DIAGNOSIS OF SCHIZOPHRENIA;EXON;GRANDIOSITY;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HODGKIN LYMPHOMA;INTEROCEPTION;LENALIDOMIDE;MELPHALAN;METASTASIS;MUTATION;MYOCARDIAL REVASCULARIZATION;PARKINSON'S DISEASE;POSITIVE AND NEGATIVE SYNDROME SCALE;SAPHENOUS VEIN GRAFT;T CELL;TYROSINE KINASE","7;6;6;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","NIVOLUMAB;GEFITINIB;ANTIRETROVIRAL THERAPY;CRIZOTINIB;ENDOVASCULAR ANEURYSM REPAIR;ERLOTINIB;BRENTUXIMAB VEDOTIN;CARBOPLATIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;REVERSE TRANSCRIPTASE;ADOPTIVE CELL TRANSFER;ANAPLASTIC LYMPHOMA KINASE;ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY;BRAIN METASTASIS;CAPECITABINE;CHEMOKINE RECEPTOR;COGNITIVE DECLINE;CRYOGLOBULINEMIA;DEMENTIA WITH LEWY BODIES;DIGITAL POLYMERASE CHAIN REACTION;EGFR INHIBITORS;ENDODERMAL SINUS TUMOR;EPITHELIAL–MESENCHYMAL TRANSITION;FANCONI ANEMIA;FRACTIONAL ANISOTROPY;GENE EXPRESSION PROFILING;GP41;HAPLOINSUFFICIENCY;IMMATURE TERATOMA;INTERLEUKIN 21;JAG1;KRAS;LEUKOCYTE TRAFFICKING;LEVODOPA;METASTATIC BREAST CANCER;METATARSALGIA;NATURAL KILLER CELL;NON-SMALL CELL LUNG CANCER (NSCLC);PD-L1;PEMBROLIZUMAB;PENETRANCE;POSACONAZOLE;PROPHYLACTIC CRANIAL IRRADIATION;TAU PROTEIN;TRASTUZUMAB;TUMOR-INFILTRATING LYMPHOCYTES","7;5;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;AGED;LUNG NEOPLASMS;MIDDLE AGED;ADULT;CARCINOMA, NON-SMALL-CELL LUNG;ITALY;AGED, 80 AND OVER;BRAIN;HIV INFECTIONS;ADOLESCENT;MYOCARDIAL INFARCTION;TREATMENT OUTCOME;YOUNG ADULT;CENTRAL NERVOUS SYSTEM NEOPLASMS;CHEST PAIN;CHILD","49;41;33;30;25;22;22;18;17;13;12;10;10;9;9;8;8;7;7;7","ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER IMMUNOTHERAPY;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;MANAGEMENT OF VALVULAR HEART DISEASE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;INTEROCEPTION AND SOMATIC SYMPTOMS;LYMPHOID NEOPLASMS;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;MANAGEMENT OF FEBRILE NEUTROPENIA IN CANCER PATIENTS;NATURAL KILLER CELLS IN IMMUNITY;SMALL CELL LUNG CANCER;ACCURACY OF CLINICAL CODING IN HEALTHCARE DATA;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;ANKLE INJURIES AND DISORDERS IN SPORTS MEDICINE","8;6;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","CLINICAL ENDPOINT;EGFR MUTATIONS;ALECTINIB;ANTIRETROVIRAL THERAPY;BIOMARKERS FOR IMMUNOTHERAPY;BRAIN METASTASES;CARDIOVASCULAR EVALUATION;DISCONTINUATION;ENDOVASCULAR ANEURYSM REPAIR;ENDOVASCULAR REPAIR;EXPANDED ACCESS;SMALL-CELL LUNG CANCER;T790M;TREATMENT GUIDELINES;ACUTE KIDNEY INJURY;AFATINIB;ALK INHIBITOR;ALK INHIBITORS;ANAPLASTIC LARGE-CELL LYMPHOMA;ANEURYSM RUPTURE","6;6;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","LUNG CANCER;CELL LUNG;NON-SMALL CELL;PHASE III;ACCESS PROGRAMME;CNS METASTASES;EXPANDED ACCESS;ITALIAN COHORT;ITALIAN MULTICENTER;MULTICENTER PHASE;NIVOLUMAB EXPANDED;NSCLC PATIENTS;OBSERVATIONAL STUDY;PATIENTS PTS;PATIENTS UNDERGOING;PEER REVIEW;PROGRAMME EAP;REVIEW REPORT;STEM CELL;ACUTE KIDNEY;ADVANCED NON-SMALL;ADVANCED NSCLC;ANMCO POSITION;BRAIN METASTASES;BRENTUXIMAB VEDOTIN;CANCER NSCLC;CANCER PATIENTS;CANCER SCLC;CART-EXPERIENCED SUBJECTS;CELL TRANSPLANTATION","10;9;6;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","LUNG CANCER;GAIT SPEED;HR CI;INTEROCEPTIVE ACCURACY;CELL LUNG;BRAIN METASTASES;CONFIDENCE INTERVAL;IMPAIRED NS;NK CELL;RADIATION THERAPY;ADVERSE EVENTS;CLINICAL PRACTICE;EGFR MUTANT;GROIN PAIN;MEDIAN FOLLOW-UP;YOLK SAC;CLINICAL EVALUATION;CONSENSUS CONFERENCE;EGFR TKIS;HAZARD RATIO;HEART FAILURE;MKN CELLS;NONCRITICALLY ILL;PATIENTS DIED;PATIENTS PTS;PPC PATTERN;PROGRESSION-FREE SURVIVAL;RPNC METHODS;STEM CELL;SURGICAL STAGING","11;9;9;9;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4",27,0.3,6.3,4.5,2,0,1,1,2,0,1,5,1,0,5.25,1,1,1,1,3,2.5,0,0,102.5,102.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,4.83,781.67,9.84,8,0.67,84.67,0,0,0,0,6,0,0,6,0,9,3,0,0,0,0,0,0,11,1,0,12,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","11;6;5;3;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;BRAIN DISORDERS;LUNG;NEURODEGENERATIVE;PREVENTION;RARE DISEASES;AUTOIMMUNE DISEASE;BIOENGINEERING;CARDIOVASCULAR;CONTRACEPTION/REPRODUCTION;HEMATOLOGY;INFANT MORTALITY;LUNG CANCER;MULTIPLE SCLEROSIS;NEUROSCIENCES;PATIENT SAFETY;UROLOGIC DISEASES;ACQUIRED COGNITIVE IMPAIRMENT","12;10;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1","CANCER;NEUROLOGICAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;CARDIOVASCULAR;STROKE","5;2;2;2;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.7 PHYSICAL","7;1;1","LUNG CANCER;BREAST CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"PUBLIC LIBRARY OF SCIENCE","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","4;2",NA,NA,NA,NA,NA,NA,NA,NA,"CLINICAL MEDICINE AND SCIENCE","2","KIDNEY CANCER","1",NA,NA
"AOU_PERUGIA",2017,93,16.505376344086,2.10752688172043,0.301075268817204,0.172043010752688,0.290322580645161,1.63333333333333,1.16666666666667,1.06666666666667,1.17391304347826,0.634408602150538,0,50,19,9,4,0.54,0.2,0.1,0.04,26.94,0.913840851795281,9.40153452685422,0.419354838709677,0.967741935483871,0.426,0.506,0.594,0.512,"LUCIO CRINÓ;RITA CHIARI;GIULIO METRO;ANGELO DELMONTE;VIENNA LUDOVINI;FILIPPO DE MARINIS;HÉCTOR SOTO PARRÀ;GIUSEPPE VITTORIO DE SOCIO;D. TURCI;FRANCESCO GROSSI;ANGELO SIDONI;CHUN‐MING TSAI;DIANA GIANNARELLI;ANNAMARIA SIGGILLINO;FEDERICO CAPPUZZO;GIOVANNI GUARALDI;SABRINA CIPRIANI;DOMENICO GALETTA;BIAGIO RICCIUTI;ANDREA ARDIZZONI","17;15;9;9;8;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4","LUCIO CRINÓ;RITA CHIARI;BEATRICE FIORUCCI;GIULIO METRO;VIENNA LUDOVINI;ANGELO DELMONTE;GIUSEPPE VITTORIO DE SOCIO;TILO KÖLBEL;NIKOLAOS TSILIMPARIS;ANGELO SIDONI;SABRINA CIPRIANI;ADRIANA CARINO;ELEONORA DISTRUTTI;STEFANO FIORUCCI;TITO FIORE;CARLO CAGINI;FILIPPO DE MARINIS;BIAGIO RICCIUTI;GIUSEPPE SCHILLACI;CLAUDIO CAVALLINI","1.11;1.04;1;0.71;0.63;0.54;0.54;0.5;0.5;0.45;0.43;0.43;0.43;0.43;0.42;0.42;0.4;0.39;0.38;0.38","LUCIO CRINÓ;RITA CHIARI;GIULIO METRO;VIENNA LUDOVINI;GIUSEPPE VITTORIO DE SOCIO;ANNAMARIA SIGGILLINO;BIAGIO RICCIUTI;FRANCESCA ROMANA TOFANETTI;ELEONORA DISTRUTTI;GIUSEPPE AMBROSIO;TITO FIORE;KATIA PERRUCCIO;CARLO CAGINI;SARA BAGLIVO;JENNIFER FOGLIETTA;STEFANO MINISTRINI;CARLA COVARELLI;FRANCO BALDELLI;BEATRICE FIORUCCI;LORENZA PISTOLA","17;15;9;8;6;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2","LUCIO CRINÓ;RITA CHIARI;BEATRICE FIORUCCI;GIULIO METRO;VIENNA LUDOVINI;GIUSEPPE VITTORIO DE SOCIO;ELEONORA DISTRUTTI;TITO FIORE;CARLO CAGINI;BIAGIO RICCIUTI;CLAUDIO CAVALLINI;FRANCO BALDELLI;MAURIZIO DEL PINTO;ANNAMARIA SIGGILLINO;GIUSEPPE AMBROSIO;ALESSIO CERQUAGLIA;MARCO LUPIDI;FRANCESCA ROMANA TOFANETTI;STEFANO MINISTRINI;S PUGLIESE","1.11;1.04;1;0.71;0.63;0.54;0.43;0.42;0.42;0.39;0.38;0.33;0.32;0.31;0.31;0.29;0.29;0.28;0.25;0.25","CHUN‐MING TSAI;RITA CHIARI;YI‐LONG WU;DIEGO CORTINOVIS;ALEXIS B. CORTOT;CHONG‐JEN YU;DENIS MORO‐SIBILOT;FABRICE BRANLE;GILBERTO DE CASTRO;JEAN‐CHARLES SORIA;LUÍS PAZ-ARES;PARAMITA SEN;ROSARIO GARCÍA CAMPELO;SARAYUT LUCIEN GEATER;TRACEY MCCULLOCH;CRISTIAN MASSACESI;DANIEL S.W. TAN;JUERGEN WOLF;MARGARET DUGAN;MAXIMILLIAN HOCHMAIR","1278;1085;1042;1034;1026;1026;1026;1026;1026;1026;1026;1026;1026;1026;1026;1012;1012;1012;1012;1012","RITA CHIARI;LUCIO CRINÓ;GIUSEPPE VITTORIO DE SOCIO;KATIA PERRUCCIO;VINCENZO MINOTTI;ELEONORA DISTRUTTI;STELVIO BALLANTI;VIENNA LUDOVINI;GIULIO METRO;ELISA PALAZZARI;MARCO LUPATTELLI;CARLO CAGINI;TITO FIORE;ALESSIO CERQUAGLIA;BARBARA IACCHERI;GIOVANNI TORRONI;MARCO LUPIDI;CINZIA COSTA;CRISTINA TRANFAGLIA;M. E. DOTTORINI","1085;305;156;125;113;106;70;64;58;57;57;52;52;49;49;49;49;47;43;43","LUCIO CRINÓ;RITA CHIARI;GIULIO METRO;VIENNA LUDOVINI;GIUSEPPE VITTORIO DE SOCIO;BIAGIO RICCIUTI;ELEONORA DISTRUTTI;FRANCESCA ROMANA TOFANETTI;KATIA PERRUCCIO;ANNAMARIA SIGGILLINO;CARLO CAGINI;GIUSEPPE AMBROSIO;JENNIFER FOGLIETTA;SARA BAGLIVO;TITO FIORE;ALESSIO CERQUAGLIA;DANIELA FRANCISCI;ERBERTO CARLUCCIO;LORENZA PISTOLA;MARCO LUPIDI","14;13;8;7;6;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATHEMATICS;COMPUTER SCIENCE;PSYCHOLOGY;ECONOMICS;SOCIOLOGY;ENGINEERING;ENVIRONMENTAL SCIENCE;HISTORY;POLITICAL SCIENCE","88;28;11;9;6;5;5;2;2;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;CARDIOLOGY;PATHOLOGY;BIOCHEMISTRY;PALEONTOLOGY;CANCER RESEARCH;GENETICS;NUCLEAR MEDICINE;INTENSIVE CARE MEDICINE;ASTROBIOLOGY;IMMUNOLOGY;NURSING;PHARMACOLOGY;PSYCHIATRY;STATISTICS","72;39;24;18;14;12;11;11;10;10;8;8;8;6;5;5;5;5;5;5","CANCER;LUNG CANCER;CHEMOTHERAPY;CLINICAL TRIAL;GENE;ADVERSE EFFECT;COHORT;DISEASE;POPULATION;STAGE (STRATIGRAPHY);RADIATION THERAPY;EXPANDED ACCESS;LUNG;MYOCARDIAL INFARCTION;RECEPTOR;REFRACTORY (PLANETARY SCIENCE);COHORT STUDY;CONFIDENCE INTERVAL;HUMAN IMMUNODEFICIENCY VIRUS (HIV);LYMPHOMA;MAGNETIC RESONANCE IMAGING;REGIMEN","29;20;17;11;11;9;9;9;9;7;6;5;5;5;5;5;4;4;4;4;4;4","EPIDERMAL GROWTH FACTOR RECEPTOR;IMMUNOTHERAPY;MALIGNANT PLEURAL EFFUSION;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;ADENOCARCINOMA;BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;CISPLATIN;DOCETAXEL;HAZARD RATIO;MUTATION;PHASES OF CLINICAL RESEARCH;PROGRESSIVE DISEASE;GENE EXPRESSION;PARKINSON'S DISEASE;PROGRESSION-FREE SURVIVAL;TYROSINE KINASE;VIRAL LOAD;ANAPLASTIC LARGE-CELL LYMPHOMA;AORTIC ANEURYSM;COMPUTED TOMOGRAPHY ANGIOGRAPHY;EXON;GEMCITABINE;HYPERINTENSITY;SALVAGE THERAPY;TRANSCRIPTION FACTOR","8;8;8;7;6;6;6;5;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2","NIVOLUMAB;CRIZOTINIB;ERLOTINIB;GEFITINIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ANAPLASTIC LYMPHOMA KINASE;KRAS;PEMETREXED;ROS1;ANTIRETROVIRAL THERAPY;TAXANE;CARBOPLATIN;METASTATIC BREAST CANCER;NUCLEAR RECEPTOR;TRANSACTIVATION;TRASTUZUMAB;ACROMEGALY;ADENOCARCINOMA OF THE LUNG;ADJUVANT CHEMOTHERAPY;ANTHRACYCLINE;BRAIN METASTASIS;BRENTUXIMAB VEDOTIN;DABIGATRAN;DEMENTIA WITH LEWY BODIES;DIGITAL POLYMERASE CHAIN REACTION;DISEASE MANAGEMENT;EGFR INHIBITORS;ERBB4;EXTERNAL BEAM RADIOTHERAPY;EXTRAMEDULLARY HEMATOPOIESIS;FRAMINGHAM HEART STUDY;GASTRIC BYPASS;GLYCATED HEMOGLOBIN;GP41;HEPATOPULMONARY SYNDROME;MICROARRAY;MORAXELLA CATARRHALIS;NEOADJUVANT THERAPY;NUCLEOTIDE EXCISION REPAIR;PARS PLANA;POINT MUTATION;POSACONAZOLE;PROPHYLACTIC CRANIAL IRRADIATION;PURE AUTONOMIC FAILURE;PURINE ANALOGUE;REVERSE TRANSCRIPTASE;RIBAVIRIN;SYK;TARGET LESION;TAU PROTEIN;THORACIC AORTIC ANEURYSM;THYMIDYLATE SYNTHASE;TRIPLE-NEGATIVE BREAST CANCER;UMBILICAL ARTERY;VEMURAFENIB","8;6;6;6;6;5;4;4;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;HIV INFECTIONS;LUNG NEOPLASMS;TREATMENT OUTCOME;CARCINOMA, NON-SMALL-CELL LUNG;ANTINEOPLASTIC AGENTS;ITALY;AGED, 80 AND OVER;MYCOSES;ANTIFUNGAL AGENTS;ANTI-HIV AGENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;HEMATOLOGIC NEOPLASMS;RETROSPECTIVE STUDIES","52;41;35;35;23;21;20;20;19;17;15;13;13;12;12;10;9;9;9;9","ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER IMMUNOTHERAPY;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND MANAGEMENT OF OCULAR INFECTIONS;EPILEPSY AND SEIZURES;;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ANTERIOR CRUCIATE LIGAMENT INJURIES IN ATHLETES;ASTHMA;ATRIAL FIBRILLATION;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CHOLESTEROL-LOWERING TREATMENT;CHRONIC CEREBRAL HYPOPERFUSION-RELATED NEURODEGENERATIVE DISEASES;COLORECTAL CANCER RESEARCH AND TREATMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER","14;6;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CERITINIB;EGFR MUTATIONS;CLINICAL ENDPOINT;T790M;EXPANDED ACCESS;OSIMERTINIB;REFRACTORY (PLANETARY SCIENCE);TREATMENT GUIDELINES;ALK INHIBITOR;PEMETREXED;REGIMEN;DISCONTINUATION;PROGRESSION-FREE SURVIVAL;TAXANE;AFATINIB;ANAPLASTIC LARGE-CELL LYMPHOMA;ANTIRETROVIRAL THERAPY;BIOMARKER ANALYSIS;BIOMARKERS FOR IMMUNOTHERAPY;BRAIN METASTASES","7;7;6;6;5;5;5;5;4;4;4;3;3;3;2;2;2;2;2;2","LUNG CANCER;CELL LUNG;NON-SMALL CELL;EXPANDED ACCESS;CANCER NSCLC;ACCESS PROGRAMME;COHORT STUDY;PATIENTS PTS;TYROSINE KINASE;ADVANCED NSCLC;ADVANCED SQUAMOUS;BREAST CANCER;CANCER PATIENTS;CERITINIB VERSUS;ITALIAN NIVOLUMAB;NSCLC PATIENTS;PHASE II;PROGRAMME EAP;SQUAMOUS NSCLC;ACCESS PROGRAM;ADVANCED NON-SMALL;AUTOMATIC WHITE;BONE METASTASES;CNS RESPONSE;CONSENSUS DOCUMENT;EGFR WT;ELDERLY PATIENTS;FIRST-LINE CERITINIB;HIGH-GRADE NEUROENDOCRINE;HYPERINTENSITIES SEGMENTATION","12;9;8;7;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","ADVERSE EVENTS;LUNG CANCER;RESPONSE RATE;BRISTOL-MYERS SQUIBB;DISEASE CONTROL;NSCLC PATIENTS;CONTROL RATE;PROGRESSION-FREE SURVIVAL;MEDIAN FOLLOW-UP;SAFETY PROFILE;VERSUS CHEMOTHERAPY;WMH VOLUME;CNS METASTASES;CNS RESPONSE;COMPLETE RESPONSE;BRAIN METASTASES;CLINICAL TRIAL;LONG-ACTING PASIREOTIDE;PARTIAL RESPONSE;ADMINISTERED INTRAVENOUSLY;AQP OVEREXPRESSION;CELL LUNG;CHEST PAIN;COMMON TERMINOLOGY;EGFR MUTATION;IIIBSTAGE IV;KRAS MUTATION;NIVOLUMAB MGKG;PRIOR SYSTEMIC;STAGE III","18;15;14;13;13;12;11;11;10;10;10;10;9;9;9;8;8;8;8;7;7;7;7;7;7;7;7;7;7;7",32,0.34,5.2,6.25,1.5,2,1,6.75,0,0,3,7.25,0,1,5.5,0,3,1,2.5,3.25,3,0,0,63,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,4.42,765.71,20.87,8,0.33,68.92,0,0,5,1,7,0,1,10,0,16,8,0,0,0,0,0,0,23,1,0,24,0,0,0,0,0,0,0,0,0,"United States;Italy;Denmark;Germany","8;4;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY","22;15;9;3;2;2;2;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;CARDIOVASCULAR;LUNG;BRAIN DISORDERS;HEART DISEASE;HEMATOLOGY;PREVENTION;LUNG CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;PEDIATRIC;ACQUIRED COGNITIVE IMPAIRMENT;AGING;BEHAVIORAL AND SOCIAL SCIENCE;CHILDHOOD LEUKEMIA;MENTAL HEALTH;NEUROSCIENCES","22;12;12;7;7;6;6;5;5;5;5;4;3;3;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;INFECTION;MENTAL HEALTH;NEUROLOGICAL;RESPIRATORY;STROKE","10;5;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","15;2;2;1;1","LUNG CANCER;LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER","5;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","5;1;1;1",1,6958896,535299.69,8,13,7,1,26,66912.4615384615,1.38987563544562,"AZIENDA OSPEDALIERA DI PERUGIA;CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX;IMPERIAL COLLEGE LONDON;KING'S COLLEGE LONDON;MEDICAL UNIVERSITY OF GRAZ;NORTH DENMARK REGION;UNIVERSITY HOSPITAL HEIDELBERG;UNIVERSITY HOSPITAL WÜRZBURG;UNIVERSITY OF BIRMINGHAM;UNIVERSITY OF BORDEAUX;UNIVERSITY OF LIVERPOOL;UNIVERSITY OF WÜRZBURG;VALL D'HEBRON HOSPITAL UNIVERSITARI","1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES","1;1;1","BRAIN DISORDERS;CARDIOVASCULAR;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;HEART DISEASE;NEUROSCIENCES;PREVENTION;STROKE","1;1;1;1;1;1;1;1;1","STROKE","1",NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,3,"PUBLIC LIBRARY OF SCIENCE","3","32 BIOMEDICAL AND CLINICAL SCIENCES;52 PSYCHOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;5202 BIOLOGICAL PSYCHOLOGY","3;2;1;1;1;1","BRAIN DISORDERS;CLINICAL RESEARCH;MENTAL HEALTH;NEURODEGENERATIVE;NEUROSCIENCES;PARKINSON'S DISEASE;SCHIZOPHRENIA;SERIOUS MENTAL ILLNESS","1;1;1;1;1;1;1;1","NEUROLOGICAL;MENTAL HEALTH","2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BIOMEDICAL","1","BASIC SCIENCE","1","BRAIN TUMOR","1",NA,NA
"AOU_PERUGIA",2018,90,15.1333333333333,2.36666666666667,0.288888888888889,0.211111111111111,0.322222222222222,1.73170731707317,1.3,1.11764705882353,1.31818181818182,0.577777777777778,0,58,16,3,6,0.64,0.18,0.03,0.07,26.09,0.855141977394408,8.77726218097446,0.388888888888889,0.955555555555556,0.463,0.529,0.502,0.495,"RITA CHIARI;BIAGIO RICCIUTI;GIULIO METRO;DIANA GIANNARELLI;PAOLO CALABRESI;ROSS A. SOO;BENJAMIN SOLOMON;FABIANA LETIZIA CECERE;MARIA BASSANELLI;VIENNA LUDOVINI;ALICE T. SHAW;GUIDO BELLEZZA;SARA BAGLIVO;HOLGER THURM;PAOLO EUSEBI;PAOLA SARCHIELLI;JILL S. CLANCY;FRANCESCO GROSSI;TODD M. BAUER;GIUSEPPE VITTORIO DE SOCIO","24;7;7;7;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4","RITA CHIARI;GIULIO METRO;PAOLO CALABRESI;GUIDO BELLEZZA;DIANA GIANNARELLI;ANNIBALE DONINI;VIENNA LUDOVINI;SARA BAGLIVO;BIAGIO RICCIUTI;PAOLO EUSEBI;ELISABETTA MARINO;LUIGINA GRAZIOSI;PAOLA SARCHIELLI;ANGELO SIDONI;STEFANO MINISTRINI;MARIA ANASTASIA RICCI;LAURA RASERO;BENIAMINO ADDEY;NICOLA RAMACCIATI;ALFONSO CAMPANILE","1.86;0.88;0.76;0.73;0.67;0.56;0.56;0.54;0.53;0.52;0.5;0.5;0.5;0.48;0.43;0.43;0.42;0.42;0.42;0.42","RITA CHIARI;BIAGIO RICCIUTI;GIULIO METRO;PAOLO CALABRESI;VIENNA LUDOVINI;GUIDO BELLEZZA;SARA BAGLIVO;PAOLO EUSEBI;PAOLA SARCHIELLI;GIUSEPPE VITTORIO DE SOCIO;ANDREA DE GIGLIO;SUSANNA ESPOSITO;STEFANO MINISTRINI;MICHELE ROMOLI;R. TARDUCCI;GIUSEPPE AMBROSIO;ANGELO SIDONI;ANNIBALE DONINI;MARTA BRAMBILLA;IOSIEF ABRAHA","24;7;7;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3","RITA CHIARI;GIULIO METRO;PAOLO CALABRESI;GUIDO BELLEZZA;ANNIBALE DONINI;VIENNA LUDOVINI;SARA BAGLIVO;BIAGIO RICCIUTI;PAOLO EUSEBI;ELISABETTA MARINO;LUIGINA GRAZIOSI;PAOLA SARCHIELLI;ANGELO SIDONI;STEFANO MINISTRINI;MARIA ANASTASIA RICCI;BENIAMINO ADDEY;NICOLA RAMACCIATI;ALFONSO CAMPANILE;ANDREA CECCAGNOLI;MICHELE ROMOLI","1.86;0.88;0.76;0.73;0.56;0.56;0.54;0.53;0.52;0.5;0.5;0.5;0.48;0.43;0.43;0.42;0.42;0.42;0.42;0.41","RITA CHIARI;ALICE T. SHAW;BENJAMIN SOLOMON;JILL S. CLANCY;ROSS A. SOO;GREGORY J. RIELY;HOLGER THURM;TODD M. BAUER;ANTONELLO ABBATTISTA;GERSON PELTZ;BENJAMIN BESSE;D. ROSS CAMIDGE;ENRIQUETA FELIP;SAI‐HONG IGNATIUS OU;SHIRISH M. GADGEEL;ENG HUAT TAN;ALESSANDRA BEARZ;CHIA‐CHI LIN;JEAN-FRANÇOIS MARTINI;JOSEPH CHEN","821;712;712;701;699;695;695;695;690;690;684;684;684;684;684;673;667;667;667;656","RITA CHIARI;GIUSEPPE VITTORIO DE SOCIO;ANNA MENGONI;CINZIA ZUCHI;ERBERTO CARLUCCIO;GIANFRANCO ALUNNI;GIULIANA BARDELLI;GIUSEPPE AMBROSIO;PAOLO BIAGIOLI;ROSANNA LAUCIELLO;STEFANO COIRO;ANDREA CECCAGNOLI;BENIAMINO ADDEY;NICOLA RAMACCIATI;PAOLO EUSEBI;PAOLO CALABRESI;GIUSEPPE QUINTALIANI;FEDERICO PAOLINI PAOLETTI;MICHELE ROMOLI;NICOLA TAMBASCO","821;202;161;161;161;161;161;161;161;161;161;139;139;139;129;123;119;88;88;88","RITA CHIARI;GIULIO METRO;BIAGIO RICCIUTI;SARA BAGLIVO;VIENNA LUDOVINI;PAOLO EUSEBI;GIUSEPPE VITTORIO DE SOCIO;CLAUDIO CAVALLINI;PAOLA SARCHIELLI;R. TARDUCCI;ANNIBALE DONINI;MAURIZIO CANIGLIA;PAOLO CALABRESI;ALFONSO CAMPANILE;ANDREA CECCAGNOLI;ANDREA DE GIGLIO;ANDREA MANCINI;ANNAMARIA SIGGILLINO;BENIAMINO ADDEY;CINZIA COSTA","24;7;7;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;ENGINEERING;MATHEMATICS;SOCIOLOGY;BUSINESS;CHEMISTRY;GEOGRAPHY;MATERIALS SCIENCE;PHILOSOPHY","88;19;9;9;5;4;4;3;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;RADIOLOGY;CANCER RESEARCH;CARDIOLOGY;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;IMMUNOLOGY;BIOCHEMISTRY;OPTICS;NURSING;PEDIATRICS;PSYCHIATRY;NEUROSCIENCE;DATABASE;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;PHYSICAL THERAPY;STATISTICS","70;26;24;18;17;12;12;10;10;9;8;7;6;6;5;5;5;4;3;3;3;3;3;3","CANCER;LUNG CANCER;GENE;CHEMOTHERAPY;COHORT;DISEASE;POPULATION;ADVERSE EFFECT;CONFIDENCE INTERVAL;CLINICAL TRIAL;DIABETES MELLITUS;RADIATION THERAPY;TRANSPLANTATION;HEART FAILURE;INCIDENCE (GEOMETRY);LUNG;MAGNETIC RESONANCE IMAGING;MYOCARDIAL INFARCTION;OBESITY;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;RETROSPECTIVE COHORT STUDY","25;22;14;10;10;9;9;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4","MALIGNANT PLEURAL EFFUSION;ADENOCARCINOMA;MUTATION;IMMUNOTHERAPY;CLINICAL ENDPOINT;EPIDERMAL GROWTH FACTOR RECEPTOR;HAZARD RATIO;PHENOTYPE;BREAST CANCER;CHROMOSOME;COLORECTAL CANCER;DIAGNOSIS CODE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;TYPE 2 DIABETES;TYROSINE-KINASE INHIBITOR;WEIGHT LOSS;CHRONIC KIDNEY FAILURE;CYCLOPHOSPHAMIDE;EMERGENCY NURSING;FLUID-ATTENUATED INVERSION RECOVERY;G PROTEIN-COUPLED BILE ACID RECEPTOR;GENE EXPRESSION;HUMAN FACTORS AND ERGONOMICS;INJURY PREVENTION;MYOCLONIC EPILEPSY;NEUTROPENIA;PARKINSON'S DISEASE;QUALITY ASSURANCE;SUICIDE PREVENTION;TOLERABILITY;TYROSINE KINASE;VIRAL LOAD;WILCOXON SIGNED-RANK TEST","9;8;7;6;5;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CRIZOTINIB;ANAPLASTIC LYMPHOMA KINASE;ROS1;GEFITINIB;NIVOLUMAB;ANTIRETROVIRAL THERAPY;ERLOTINIB;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;GASTRIC BYPASS;KRAS;LEVODOPA;LOSS FUNCTION;MISSENSE MUTATION;POINT MUTATION;WORKPLACE VIOLENCE;ACUTE AORTIC SYNDROME;ACUTE LYMPHOCYTIC LEUKEMIA;AORTIC RUPTURE;BREAST CARCINOMA;BUSULFAN;COMPOUND HETEROZYGOSITY;CYCLIC NEUTROPENIA;CYTOGENETICS;DABIGATRAN;DIFFUSING CAPACITY;DUCTAL CARCINOMA;DYSKINESIA;ENDOVASCULAR ANEURYSM REPAIR;EPITHELIAL–MESENCHYMAL TRANSITION;EXOME SEQUENCING;FORAMEN OVALE (HEART);FRAMESHIFT MUTATION;GASTRIC ADENOCARCINOMA;GERMLINE MUTATION;GLYCATED HEMOGLOBIN;GONADOTROPIN-RELEASING HORMONE;GP41;HEREDITARY SPASTIC PARAPLEGIA;HETEROPLASMY;HETEROZYGOTE ADVANTAGE;IN SITU HYBRIDIZATION;INDOLEAMINE 2,3-DIOXYGENASE;INSULIN GLARGINE;LASER CAPTURE MICRODISSECTION;LUNG CANCER STAGING;MEN1;MICROARRAY;MIGRAINE WITH AURA;MORBID OBESITY;NINTEDANIB;NON-MENDELIAN INHERITANCE;NUCLEOTIDE EXCISION REPAIR;ONCOGENE;PENETRANCE;PREDIABETES;RENAL SINUS;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;STEATOHEPATITIS;TAMOXIFEN;TOTAL BODY IRRADIATION;TRANSFER RNA;VERBAL ABUSE;WEIGHT MANAGEMENT","8;6;6;4;4;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;ITALY;ADULT;AGED;LUNG NEOPLASMS;TREATMENT OUTCOME;CARCINOMA, NON-SMALL-CELL LUNG;HIV INFECTIONS;RENAL INSUFFICIENCY, CHRONIC;MUTATION;CHILD;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;AORTIC DISEASES;HYPERTENSION","46;42;40;33;26;23;22;17;16;14;12;12;12;11;8;8;7;7;7;7","ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER IMMUNOTHERAPY;ACCURACY OF CLINICAL CODING IN HEALTHCARE DATA;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND TREATMENT OF BONE FRACTURES;GASTRIC CANCER RESEARCH AND TREATMENT;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;WORKPLACE BULLYING AND HARASSMENT IN PROFESSIONAL ENVIRONMENTS;ACUTE MYELOID LEUKEMIA;ANALYSIS OF GENE INTERACTION NETWORKS;AORTIC ATHEROSCLEROTIC DISEASE AND EMBOLIC EVENTS;ATRIAL FIBRILLATION;BREAST PATHOLOGY AND IMAGING TECHNIQUES;COLORECTAL CANCER RESEARCH AND TREATMENT;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE","14;4;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","ALK INHIBITORS;CLINICAL ENDPOINT;ALK INHIBITOR;NON-SMALL CELL LUNG CANCER;BIOMARKER ANALYSIS;CROSS-SECTIONAL STUDY;DIAGNOSIS CODE;HEMATOPOIETIC CELL TRANSPLANTATION;MAGNETIC RESONANCE IMAGING;REGIMEN;STROKE (ENGINE);TREATMENT;ANTIRETROVIRAL THERAPY;CHRONIC KIDNEY FAILURE;CHRONIC RENAL FAILURE;CLINICAL CODING;CODING ACCURACY;DIETARY MANAGEMENT;DOLUTEGRAVIR;EGFR MUTATIONS","5;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","LUNG CANCER;CELL LUNG;NON-SMALL CELL;CANCER NSCLC;ADVANCED NON-SMALL;NON-SMALL-CELL LUNG;CELL TRANSPLANTATION;ITALIAN NATIONAL;PATIENTS PTS;STEM CELL;ADMINISTRATIVE HEALTHCARE;CANCER ICD--CM;GASTRIC CANCER;HEALTHCARE DATABASES;ICD--CM CODES;ACCURACY STUDY;ACID RECEPTOR;ADVERSE EVENTS;ANAPLASTIC LYMPHOMA;ATRIAL FIBRILLATION;BILE ACID;BREAST CANCER;CANCER PATIENTS;CANCER TREATED;CELL LINES;CLINICAL SCANNER;DEATH PD-;DIAGNOSTIC ACCURACY;DOMAIN MUTATIONS;EMERGENCY NURSES","18;10;10;7;5;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;HONORARIA MEMBERSHIP;HR CI;HR CI-;ADVISORY BOARD;LUNG CANCER;RESEARCH FUNDING;ADVANCED NSCLC;ALK IHC;MO CI-;BRISTOL-MYERS SQUIBB;HONORARIA SPEAKERS;MEDIAN AGE;MEDIAN FOLLOW-UP;ROS MUT;BREAST CANCER;CI- PLT;CLINICAL OUTCOMES;FREE SURVIVAL;NSCLC PATIENTS;PFIZER NOVARTIS;SURVIVAL OS;UMBRIA CI;ADMINISTRATIVE DATABASES;DE NOVO;HONORARIA PFIZER;JANSSEN HONORARIA;MEDIAN OS","37;37;26;21;17;14;13;13;11;10;10;10;9;9;9;9;8;7;7;7;7;7;7;7;7;6;6;6;6;6",26,0.29,5.8,7.75,1.25,1,0,5,2.75,0,1.75,10.25,1,0,9,0,1,1.25,4.5,5.5,5,0,0,97.75,97.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,4.74,1055.06,15.97,9,0.47,95.79,0,1,4,0,6,0,0,8,0,14,5,0,0,0,0,0,0,16,3,0,19,0,0,0,0,0,0,0,0,0,"United States;Italy;Germany","3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","19;12;7;3;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;PATIENT SAFETY;PREVENTION;RARE DISEASES;PEDIATRIC;BIOENGINEERING;BREAST CANCER;COMPLEMENTARY AND INTEGRATIVE HEALTH;LUNG;NEURODEGENERATIVE;ORPHAN DRUG;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;STEM CELL RESEARCH;AGING;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE","17;11;9;5;5;4;4;3;2;2;2;2;2;2;2;2;2;1;1;1","CANCER;EYE;METABOLIC AND ENDOCRINE;RESPIRATORY;SKIN","9;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.3 MANAGEMENT AND DECISION MAKING","11;2;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;ENDOMETRIAL CANCER;LUNG CANCER;OVARIAN CANCER","3;2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.6 COMPLEMENTARY AND ALTERNATIVE TREATMENT APPROACHES","7;2;2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PERUGIA",2019,94,14.0212765957447,2,0.191489361702128,0.148936170212766,0.24468085106383,1.504,1.125,1.07692307692308,1.15,0.574468085106383,0,40,30,6,5,0.43,0.32,0.06,0.05,27.13,1.1155893140519,8.11111111111113,0.404255319148936,0.968085106382979,0.392,0.46,0.496,0.367,"RITA CHIARI;GIULIO METRO;GIUSEPPE AMBROSIO;PAOLO EUSEBI;ROSS A. SOO;ADRIANA CARINO;SILVIA MARCHIANÒ;BENJAMIN SOLOMON;ELEONORA DISTRUTTI;STEFANO FIORUCCI;MICHELE BIAGIOLI;ANGELO DELMONTE;ALICE T. SHAW;CHIARA FIORUCCI;HOLGER THURM;DOMENICO GALETTA;BENJAMIN BESSE;BIAGIO RICCIUTI;TODD M. BAUER;PATRIZIA RICCI","14;7;6;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4","GIUSEPPE AMBROSIO;RITA CHIARI;GIULIO METRO;ADOLFO AITA;GIANPAOLO REBOLDI;FABIO ANGELI;FRANCESCO NOTARISTEFANO;PAOLO EUSEBI;SUSANNA ESPOSITO;ADRIANA CARINO;SILVIA MARCHIANÒ;ELEONORA DISTRUTTI;STEFANO FIORUCCI;MICHELE BIAGIOLI;CHIARA FIORUCCI;MIRKO BERTOZZI;MAURIZIO ZIZZO;GIOVANNI MARTINO;STEFANO ASCANI;MAGDA ZANELLI","1.06;0.8;0.62;0.51;0.51;0.51;0.5;0.48;0.48;0.45;0.45;0.45;0.45;0.45;0.45;0.41;0.38;0.38;0.38;0.38","RITA CHIARI;GIULIO METRO;GIUSEPPE AMBROSIO;ELEONORA DISTRUTTI;BIAGIO RICCIUTI;IOSIEF ABRAHA;VIENNA LUDOVINI;SARA BAGLIVO;SUSANNA ESPOSITO;MIRKO BERTOZZI;MASSIMO E. DOTTORINI;GIOVANNI MARTINO;GIUSEPPE VITTORIO DE SOCIO;FABIO ANGELI;PAOLO CALABRESI;FAUSTO ROILA;SIMONETTA TESORO;OLIVIA MINELLI;CRISTINA TRANFAGLIA;NICOLA ALBI","14;7;6;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2","GIUSEPPE AMBROSIO;RITA CHIARI;GIULIO METRO;FABIO ANGELI;FRANCESCO NOTARISTEFANO;SUSANNA ESPOSITO;ELEONORA DISTRUTTI;MIRKO BERTOZZI;GIOVANNI MARTINO;IOSIEF ABRAHA;BIAGIO RICCIUTI;VIENNA LUDOVINI;SARA BAGLIVO;PAOLO CALABRESI;A PIERANGELI;S. CORSI;ANDREA LELI;DANIELE CASTELLANI;MAURIZIO CANIGLIA;MARIA TERESA PAGANELLI","1.06;0.8;0.62;0.51;0.5;0.48;0.45;0.41;0.38;0.3;0.3;0.28;0.28;0.28;0.25;0.25;0.25;0.25;0.25;0.25","RITA CHIARI;ALICE T. SHAW;BENJAMIN SOLOMON;ROSS A. SOO;SAI‐HONG IGNATIUS OU;ANTONELLO ABBATTISTA;BENJAMIN BESSE;CHIA‐CHI LIN;HOLGER THURM;TODD M. BAUER;GREGORY J. RIELY;JEAN‐FRANÇOIS MARTINI;STEVEN KAO;JILL S. CLANCY;SHERRY LI;ENRIQUETA FELIP;D. ROSS CAMIDGE;SHIRISH M. GADGEEL;MIYAKO SATOUCHI;GERSON PELTZ","976;616;616;616;615;613;613;613;613;613;612;612;612;600;597;332;329;329;328;285","RITA CHIARI;ELEONORA DISTRUTTI;GIOVANNI GAMBELUNGHE;GIULIO METRO;GIUSEPPE AMBROSIO;BIAGIO RICCIUTI;R. VALECCHI;MICHELE BISACCIA;IOSIEF ABRAHA;ANNA MENGONI;CINZIA ZUCHI;ERBERTO CARLUCCIO;GIANFRANCO ALUNNI;GIULIANA BARDELLI;PAOLO BIAGIOLI;ROSANNA LAUCIELLO;ALFREDO VILLA;SARA BAGLIVO;VIENNA LUDOVINI;MASSIMO LENTI","976;173;163;155;103;100;99;74;71;69;69;69;69;69;69;69;58;56;56;55","RITA CHIARI;GIULIO METRO;ELEONORA DISTRUTTI;GIUSEPPE AMBROSIO;SARA BAGLIVO;VIENNA LUDOVINI;IOSIEF ABRAHA;BIAGIO RICCIUTI;GIOVANNI MARTINO;GIUSEPPE VITTORIO DE SOCIO;MASSIMO E. DOTTORINI;MIRKO BERTOZZI;ALFREDO VILLA;CRISTINA TRANFAGLIA;DANIELA FRANCISCI;ELISABETTA SCHIAROLI;FABIO ANGELI;FAUSTO ROILA;LEONARDO FLENGHI;LUCIO SARPI","14;7;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;SOCIOLOGY;MATHEMATICS;ECONOMICS;PHILOSOPHY;BUSINESS;GEOGRAPHY;GEOLOGY;POLITICAL SCIENCE","92;23;11;8;7;7;6;6;5;3;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GENETICS;RADIOLOGY;BIOCHEMISTRY;PEDIATRICS;ENDOCRINOLOGY;GASTROENTEROLOGY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PSYCHIATRY;INTENSIVE CARE MEDICINE;ANESTHESIA;CARDIOLOGY;DEMOGRAPHY;DERMATOLOGY;PALEONTOLOGY","72;30;25;20;13;13;11;10;9;9;8;8;8;8;7;6;6;6;6;6","CANCER;DISEASE;LUNG CANCER;GENE;CHEMOTHERAPY;COHORT;POPULATION;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;CLINICAL TRIAL;HEART FAILURE;MAGNETIC RESONANCE IMAGING;TRANSPLANTATION;ADVERSE EFFECT;ALTERNATIVE MEDICINE;BIOMARKER;DIABETES MELLITUS;EPILEPSY;HEALTH CARE;INCIDENCE (GEOMETRY);LYMPHOMA;MYOCARDIAL INFARCTION;RECEPTOR","18;17;16;13;10;8;8;8;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4","ADENOCARCINOMA;CLINICAL ENDPOINT;EPIDERMAL GROWTH FACTOR RECEPTOR;GENOTYPE;HAZARD RATIO;MALIGNANT PLEURAL EFFUSION;CISPLATIN;DEMENTIA;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOTHERAPY;MULTICENTER STUDY;TRANSCRIPTION FACTOR;ADALIMUMAB;AORTIC ANEURYSM;BREAST CANCER;COLORECTAL CANCER;CROHN'S DISEASE;DIAGNOSIS CODE;DIFFUSE LARGE B-CELL LYMPHOMA;DYSLIPIDEMIA;EJECTION FRACTION;FATTY LIVER;GENE EXPRESSION;INFLAMMATORY BOWEL DISEASE;MUTATION;NEURORADIOLOGY;PHASES OF CLINICAL RESEARCH;PSORIATIC ARTHRITIS;SALVAGE THERAPY;TOLERABILITY;TYROSINE-KINASE INHIBITOR","6;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CRIZOTINIB;GEFITINIB;ROS1;ANAPLASTIC LYMPHOMA KINASE;COGNITIVE DECLINE;ERLOTINIB;GENOTYPING;IMMUNE CHECKPOINT;NUCLEAR RECEPTOR;PEMBROLIZUMAB;TRANSCRIPTOME;USTEKINUMAB;AGGRESSIVE LYMPHOMA;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;ARYL HYDROCARBON RECEPTOR;BASAL INSULIN;CARBOPLATIN;CEREBRAL AMYLOID ANGIOPATHY;CLINICAL PHENOTYPE;CXCR4;CYP2C9;CYP3A4;DEMENTIA WITH LEWY BODIES;ENDOVASCULAR ANEURYSM REPAIR;FGF19;GENE EXPRESSION PROFILING;GENE MUTATION;GENOTYPE-PHENOTYPE DISTINCTION;IMIPENEM;INSULIN GLARGINE;KRAS;LONG NON-CODING RNA;MICAFUNGIN;NATURAL KILLER T CELL;NINTEDANIB;NON-SMALL CELL LUNG CANCER (NSCLC);OBETICHOLIC ACID;OBINUTUZUMAB;OXFORD KNEE SCORE;PEMETREXED;PERCUTANEOUS ETHANOL INJECTION;PRENATAL DIAGNOSIS;RESPIRATORY RATE;RIVAROXABAN;RUBELLA;SANGER SEQUENCING;SPECKLE TRACKING ECHOCARDIOGRAPHY;SPLENIC DISEASE;STEATOHEPATITIS;SUPRAGLOTTIC AIRWAY;SYNAPTIC VESICLE;SYNKINESIS;THORACIC AORTIC ANEURYSM;TOTAL BODY IRRADIATION;VANCOMYCIN;VENTRICULAR HYPERTROPHY;VON WILLEBRAND DISEASE","4;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;CARCINOMA, NON-SMALL-CELL LUNG;ITALY;LUNG NEOPLASMS;MIDDLE AGED;AGED;ADULT;TREATMENT OUTCOME;ALZHEIMER DISEASE;BIOMARKERS;CARDIOVASCULAR DISEASES;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;BRAIN NEOPLASMS;PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;YOUNG ADULT;COGNITIVE DYSFUNCTION","55;42;40;37;28;28;28;27;25;24;15;14;12;12;11;11;11;11;11;10","ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;CANCER IMMUNOTHERAPY;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;ACCURACY OF CLINICAL CODING IN HEALTHCARE DATA;APPLICATION OF 3D PRINTING IN MEDICAL ANATOMY EDUCATION;ATRIAL FIBRILLATION;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CANCER OF UNKNOWN PRIMARY SITE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;CLASSIFICATION AND TREATMENT OF HISTIOCYTIC DISORDERS;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS AND MANAGEMENT OF DRY EYE DISEASE","11;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;NON-SMALL CELL LUNG CANCER;ALK INHIBITOR;ALK INHIBITORS;BIOMARKER ANALYSIS;NEUROIMAGING;REGIMEN;STROKE (ENGINE);TOLERABILITY;VENOUS THROMBOEMBOLISM;ANEURYSM SCREENING;BIOMARKERS FOR IMMUNOTHERAPY;COGNITIVE DECLINE;CONCOMITANT;CROSS-SECTIONAL STUDY;DEEP VEIN THROMBOSIS;DIAGNOSIS;DIAGNOSIS CODE;DYSLIPIDEMIA;EGFR MUTATIONS","5;5;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","LUNG CANCER;CELL LUNG;NON-SMALL CELL;NON-SMALL-CELL LUNG;ALZHEIMERS DISEASE;II STUDY;PATIENTS TREATED;PHASE II;ADMINISTRATIVE DATABASES;CANCER NSCLC;CARDIAC DEATH;NSCLC PATIENTS;PHASE III;ADVANCED NON-SMALL;ADVANCED NON-SMALL-CELL;ATRIAL FIBRILLATION;BOWEL DISEASE;CANCER PATIENTS;CELL TRANSPLANTATION;CEREBROSPINAL FLUID;CLINICAL OUTCOMES;COGNITIVE IMPAIRMENT;CONCOMITANT PSORIASIS;CROSS-SECTIONAL STUDY;DISEASE PATIENTS;HEALTHCARE ADMINISTRATIVE;HEART FAILURE;IG-IBD STUDY;IMPAIRMENT PATIENTS;INFLAMMATORY BOWEL","13;7;6;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADVISORY CONSULTANCY;HAZARD RATIO;HR CI;LUNG CANCER;NKT CELLS;CONDITIONING REGIMEN;PROGRESSION-FREE SURVIVAL;STEM CELL;ALK MUTATIONS;BOEHRINGER INGELHEIM;RESPONSE RATE;SD PLT;BLOOD PRESSURE;CANCER NSCLC;HOMOZYGOUS ΒΒ;LEFT VENTRICULAR;SURVIVAL PFS;THERMAL ABLATION;ACTIVITY SD;ADOPTIVE TRANSFER;CELL LUNG;COPD PATIENTS;GPBAR AGONISM;HEMATOPOIETIC STEM;LONGITUDINAL STRAIN;LV SYSTOLIC;MEDIAN AGE;PATIENTS TREATED;PROBE DRUG;RATIO SD","28;16;16;14;14;10;10;10;9;9;9;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6",46,0.49,9.44,6,1,0,0,1,4,0,1,7.75,1,0,7.5,1,1,2,7.75,6,4,0,0,63.75,63.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,4.77,723.69,21.85,14,0.54,105.08,0,1,3,0,11,0,2,9,0,18,8,0,0,0,0,0,0,25,0,1,26,0,0,0,0,0,0,0,0,0,"United States;United Kingdom;Denmark;Italy;Japan;France;Germany","10;4;2;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3107 MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","25;13;11;4;3;3;3;2;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;AGING;BRAIN DISORDERS;NEURODEGENERATIVE;NEUROSCIENCES;PEDIATRIC;PREVENTION;LUNG;LUNG CANCER;ORPHAN DRUG;PATIENT SAFETY;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BEHAVIORAL AND SOCIAL SCIENCE;CARDIOVASCULAR","22;16;14;9;7;5;5;5;5;4;4;3;3;3;3;2;2;2;2;2","CANCER;NEUROLOGICAL;EYE;CARDIOVASCULAR;INFECTION;MENTAL HEALTH;SKIN;STROKE","11;3;2;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);6.2 CELLULAR AND GENE THERAPIES","21;2;1;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;COLON AND RECTAL CANCER;MELANOMA;MYELOMA;NOT SITE-SPECIFIC CANCER;PROSTATE CANCER","4;3;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","9;2;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS","6;2","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;44 HUMAN SOCIETY;4407 POLICY AND ADMINISTRATION;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;40 ENGINEERING;4007 CONTROL ENGINEERING, MECHATRONICS AND ROBOTICS;51 PHYSICAL SCIENCES","6;5;3;3;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BEHAVIORAL AND SOCIAL SCIENCE;CANCER;CARDIOVASCULAR;DEPRESSION;HEALTH SERVICES;HEART DISEASE;LUNG;LUNG CANCER;MENTAL HEALTH;NEURODEGENERATIVE;NEUROSCIENCES;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;SPINAL CORD INJURY;TRAUMATIC HEAD AND SPINE INJURY","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;CANCER;MENTAL HEALTH;NEUROLOGICAL","4;1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","1;1","CLINICAL;HEALTH SERVICES & SYSTEMS","2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","5;1;1","LUNG CANCER","1",NA,NA
"AOU_PERUGIA",2020,99,15.050505050505,1.85858585858586,0.141414141414141,0.262626262626263,0.181818181818182,1.76923076923077,1,1.36842105263158,1.125,0.606060606060606,0,38,35,9,5,0.38,0.35,0.09,0.05,18.73,0.743188018104941,8.57971014492754,0.212121212121212,0.98989898989899,0.46,0.47,0.47,0.436,"GIULIO METRO;GIUSEPPE AMBROSIO;FAUSTO ROILA;PAOLO EUSEBI;GIAN LUIGI NICOLOSI;GIUSEPPE LUIGI BANNA;ADRIANA CARINO;SILVIA MARCHIANÒ;GIUSEPPE VITTORIO DE SOCIO;ELEONORA DISTRUTTI;STEFANO FIORUCCI;MICHELE BIAGIOLI;ALFREDO ADDEO;ANDREA SONAGLIONI;MICHELE LOMBARDO;ROSALINDA ROSELLI;DIEGO SIGNORELLI;CRISTINA DI GIORGIO;LUCILLA PARNETTI;DOMENICO GALETTA","11;11;8;6;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5","GIUSEPPE AMBROSIO;GIAN LUIGI NICOLOSI;ANDREA SONAGLIONI;MICHELE LOMBARDO;GIULIO METRO;CLAUDIO ANZÀ;NICOLA RAMACCIATI;GIUSEPPE VITTORIO DE SOCIO;GIAN DOMENICO GIUSTI;FAUSTO ROILA;SARA BAGLIVO;ADRIANA CARINO;SILVIA MARCHIANÒ;ELEONORA DISTRUTTI;STEFANO FIORUCCI;MICHELE BIAGIOLI;PAOLO EUSEBI;STEFANO ASCANI;LUIGI MECCARIELLO;MICHELE BISACCIA","1.64;1.02;1.02;1.02;0.81;0.69;0.67;0.63;0.61;0.54;0.53;0.52;0.52;0.52;0.52;0.52;0.52;0.5;0.46;0.46","GIULIO METRO;GIUSEPPE AMBROSIO;FAUSTO ROILA;PAOLO EUSEBI;GIUSEPPE VITTORIO DE SOCIO;ELEONORA DISTRUTTI;DANIELA FRANCISCI;STEFANO ASCANI;VIENNA LUDOVINI;SARA BAGLIVO;ANTONELLA MENCACCI;GIOVANNI MARTINO;STEFANIA TROIANI;CYNTHIA ARISTEI;PIERO FLORIDI;MICHELE BISACCIA;MARCO BANINI;P CHIARINI;MICHELE ROMOLI;RAFFAELE MANTA","11;11;8;6;6;6;5;5;5;5;4;4;4;4;4;4;4;3;3;3","GIUSEPPE AMBROSIO;GIULIO METRO;NICOLA RAMACCIATI;GIUSEPPE VITTORIO DE SOCIO;GIAN DOMENICO GIUSTI;FAUSTO ROILA;SARA BAGLIVO;ELEONORA DISTRUTTI;PAOLO EUSEBI;STEFANO ASCANI;MICHELE BISACCIA;GIOVANNI MARTINO;RAFFAELE MANTA;VIENNA LUDOVINI;MARIA TERESA PAGANELLI;CYNTHIA ARISTEI;DANIELA FRANCISCI;STEFANIA TROIANI;BRUNANGELO FALINI;LORENZO BRUNETTI","1.64;0.81;0.67;0.63;0.61;0.54;0.53;0.52;0.52;0.5;0.46;0.45;0.45;0.44;0.39;0.38;0.35;0.35;0.33;0.33","DANIELA FRANCISCI;RAFFAELE SCALA;GIULIO METRO;AGNESE VERZURI;AGOSTINO OGNIBENE;AGOSTINO RIVA;ALESSANDRA VERGORI;ALESSANDRO BRUSELLES;ALFONSO TREZZA;ALFREDO BRUSCO;ALICE DONATI;ANDREA ANTINORI;ANDREA CIOLFI;ANDREA COSSARIZZA;ANDREA TOMMASI;ANNA CANACCINI;ANNALAURA TORELLA;ANNARITA GILIBERTI;ANTONELLA D’ARMINIO MONFORTE;ARIANNA EMILIOZZI","393;339;260;252;252;252;252;252;252;252;252;252;252;252;252;252;252;252;252;252","DANIELA FRANCISCI;GIULIO METRO;ELISABETTA SCHIAROLI;ELEONORA DISTRUTTI;GIUSEPPE AMBROSIO;FABIO GORI;MARCO BANINI;FAUSTO ROILA;GIUSEPPE VITTORIO DE SOCIO;PAOLO GROFF;STEFANIA TROIANI;PIERO FLORIDI;BRUNANGELO FALINI;LORENZO BRUNETTI;MARIA PAOLA MARTELLI;ERBERTO CARLUCCIO;ISABELLA TRITTO;LAURA CERQUIGLINI;VIENNA LUDOVINI;MICHELE ROMOLI","282;260;252;192;175;158;129;108;102;91;73;72;54;54;54;45;45;42;40;37","GIULIO METRO;GIUSEPPE AMBROSIO;FAUSTO ROILA;ELEONORA DISTRUTTI;GIUSEPPE VITTORIO DE SOCIO;SARA BAGLIVO;VIENNA LUDOVINI;MARCO BANINI;MICHELE BISACCIA;STEFANIA TROIANI;DANIELA FRANCISCI;GIOVANNI MARTINO;MARIA TERESA PAGANELLI;P CHIARINI;PIERO FLORIDI;RAFFAELE MANTA;ANTONELLA MENCACCI;CARMEN MOLICA;ERBERTO CARLUCCIO;FABIO GORI","11;8;8;6;5;5;5;4;4;4;3;3;3;3;3;3;2;2;2;2","MEDICINE;BIOLOGY;MATHEMATICS;PSYCHOLOGY;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;PHYSICS;ECONOMICS;PHILOSOPHY;MATERIALS SCIENCE;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;GEOGRAPHY","94;31;8;8;6;5;5;5;4;4;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;IMMUNOLOGY;PATHOLOGY;CARDIOLOGY;CANCER RESEARCH;PEDIATRICS;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;BIOCHEMISTRY;PSYCHIATRY;RADIOLOGY;FAMILY MEDICINE;NEUROSCIENCE;PHYSICAL THERAPY;VIROLOGY;ENDOCRINOLOGY;NUCLEAR MEDICINE;PALEONTOLOGY","69;26;20;17;17;15;13;12;11;10;10;9;9;8;6;6;6;6;5;5;5","CANCER;LUNG CANCER;DISEASE;GENE;CONFIDENCE INTERVAL;CHEMOTHERAPY;HEART FAILURE;POPULATION;COHORT;PROPORTIONAL HAZARDS MODEL;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;EPIDEMIOLOGY;IMMUNE SYSTEM;MAGNETIC RESONANCE IMAGING;MULTIVARIATE ANALYSIS;OUTBREAK;RECEPTOR;CLINICAL TRIAL;INFLAMMATION;LYMPHOMA;MYOCARDIAL INFARCTION;RADIATION THERAPY;RETROSPECTIVE COHORT STUDY","18;16;13;12;10;9;9;9;8;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4","INFECTIOUS DISEASE (MEDICAL SPECIALTY);IMMUNOTHERAPY;CLINICAL ENDPOINT;HAZARD RATIO;2019-20 CORONAVIRUS OUTBREAK;EJECTION FRACTION;EPIDERMAL GROWTH FACTOR RECEPTOR;BREAST CANCER;COLORECTAL CANCER;DIFFUSION MRI;MUTATION;VIRAL LOAD;ADENOCARCINOMA;AGONIST;CARDIOTOXICITY;DIAGNOSIS CODE;DIASTOLE;DRUGGABILITY;GERMLINE;GESTATION;HEALTHCARE COST AND UTILIZATION PROJECT;INJURY PREVENTION;INSULIN RESISTANCE;LIQUID BIOPSY;LOG-RANK TEST;MALIGNANT PLEURAL EFFUSION;METASTASIS;NEURORADIOLOGY;NEUTROPHIL TO LYMPHOCYTE RATIO;PARKINSON'S DISEASE;PERFORATION;PERFORMANCE STATUS;PROGRESSION-FREE SURVIVAL;RADIOSURGERY;RNA;TEMOZOLOMIDE;TRANSCRIPTION FACTOR;VAGINAL DELIVERY;VITAMIN D DEFICIENCY","10;9;7;7;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;GEFITINIB;PD-L1;ANAPLASTIC LYMPHOMA KINASE;ANTIRETROVIRAL THERAPY;NUCLEAR RECEPTOR;OBETICHOLIC ACID;TRACTOGRAPHY;ADIPOKINE;AUTODOCK;BELL'S PALSY;BIFIDOBACTERIUM;CANCER IMMUNOTHERAPY;CEBPA;CHEMOKINE RECEPTOR;CHILD ABUSE;CIRCULATING TUMOR CELL;CRIZOTINIB;CROSSOVER STUDY;CYP8B1;DIGITAL POLYMERASE CHAIN REACTION;DOPPLER ECHOCARDIOGRAPHY;DOPPLER IMAGING;EICOSANOID;ENTEROCOCCUS FAECALIS;ERLOTINIB;FRACTIONAL ANISOTROPY;GLOBAL DEVELOPMENTAL DELAY;HEART FAILURE WITH PRESERVED EJECTION FRACTION;HOMEOSTATIC MODEL ASSESSMENT;IMMUNE CHECKPOINT;INJURY SEVERITY SCORE;INTRACRANIAL ARTERIOVENOUS MALFORMATIONS;KARYOTYPE;KRAS;LAMIVUDINE;LARYNGEAL MASKS;LOCKED NUCLEIC ACID;MACE;MEK INHIBITOR;MODIFIED RANKIN SCALE;OLIGODENDROGLIOMA;OSTEOPENIA;OSWESTRY DISABILITY INDEX;OXALIPLATIN;PARADOXICAL EMBOLISM;POINT MUTATION;SECONDARY HYPERPARATHYROIDISM;SPECKLE TRACKING ECHOCARDIOGRAPHY;STEM CELL NICHE;STROKE VOLUME;SUPRAGLOTTIC AIRWAY;SØRENSEN–DICE COEFFICIENT;TELOMERASE REVERSE TRANSCRIPTASE;TOBRAMYCIN;TRAMETINIB;TRASTUZUMAB;UTERINE ARTERY;VANCOMYCIN;WEIGHT CHANGE;WORKPLACE VIOLENCE;ZAFIRLUKAST","10;7;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ITALY;ADULT;CARCINOMA, NON-SMALL-CELL LUNG;LUNG NEOPLASMS;BRAIN NEOPLASMS;AGED, 80 AND OVER;GLIOBLASTOMA;STROKE;RECEPTORS, G-PROTEIN-COUPLED;B7-H1 ANTIGEN;LEUKEMIA, MYELOID, ACUTE;THROMBOSIS;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES","56;42;28;26;25;24;22;20;20;19;14;12;10;10;9;8;8;8;7;7","CANCER IMMUNOTHERAPY;ADVANCEMENTS IN LUNG CANCER RESEARCH;CORONAVIRUS DISEASE 2019;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;CARDIOTOXICITY OF CANCER TREATMENTS;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;GLIOMAS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;LYMPHOID NEOPLASMS;MINIMALLY INVASIVE REPAIR OF PECTUS EXCAVATUM;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;OPERATIVE MANAGEMENT OF PELVIC FRACTURES;ACUTE MYELOID LEUKEMIA;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;ANALYSIS OF GENE INTERACTION NETWORKS;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE","7;6;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1","CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;CORONAVIRUS;BIOMARKERS FOR IMMUNOTHERAPY;ECHOCARDIOGRAPHY;MEDICAL RECORD;PD-1 AND PD-L1;REGIMEN;SMALL-CELL LUNG CANCER;STROKE (ENGINE);TREATMENT;TREATMENT GUIDELINES;BETACORONAVIRUS;BIOMARKER ANALYSIS;CARDIAC IMAGING;CARDIOTOXICITY;CARDIOVASCULAR RISK ASSESSMENT;CHEST WALL DEFORMITIES;CONCOMITANT;CORONA VIRUS","7;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","LUNG CANCER;CANCER PATIENTS;CELL LUNG;NON-SMALL CELL;BILE ACID;FIRST-LINE PEMBROLIZUMAB;NON-SMALL-CELL LUNG;ACID RECEPTOR;ADVANCED NSCLC;AMYGDALAR NUCLEI;BREAST MILK;DTI TRACTOGRAPHY;FINGERTIP CROSS-LOCALIZATION;FRONT-LINE PEMBROLIZUMAB;GLIOBLASTOMA PATIENTS;HEALTHCARE ADMINISTRATIVE;HIPPOCAMPAL SUBFIELDS;INFANT FORMULAS;ITALIAN MULTICENTER;MULTICENTER STUDY;MYOCARDIAL INFARCTION;MYOCARDIAL STRAIN;NSCLC PATIENTS;OBSERVATIONAL STUDY;OLFACTORY TRACT;PARKINSONS DISEASE;PD-L EXPRESSION;PECTUS EXCAVATUM;PERFORMANCE STATUS;PRELIMINARY RESULTS","11;6;6;6;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","REGGIO EMILIA;LUNG CANCER;UNIT AZIENDA;NSCLC PATIENTS;BREAST MILK;CANCER NSCLC;INFLUENZA VACCINATION;AZIENDA UNITÀ;DI REGGIO;LOCALE-IRCCS DI;SANITARIA LOCALE-IRCCS;UNITÀ SANITARIA;ADVISORY COMMITTEES;ARTERIOVENOUS FISTULAS;AZIENDA OSPEDALIERA;CELL LUNG;DURAL ARTERIOVENOUS;ENTITYS BOARD;EYE DROPS;HR CI;NON-SMALL CELL;PD-L EXPRESSION;SPEAKERS BUREAU;ASPLENIC PATIENTS;CD CD;CURRENT SMOKERS;EMILIA REGGIO;HUMAN BREAST;MEDICAL CHARTS;PATHOLOGY UNIT","18;17;14;11;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6",54,0.55,5.64,5,1,1,0,2,1,1,1,6,1,0,5,0,1,1,2,3.75,2.75,0,0,42.75,42.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,4.85,611.9,20.41,14,0.7,88.5,0,0,3,0,7,0,1,9,0,12,8,0,0,0,0,0,0,19,1,0,20,0,0,0,0,0,0,0,0,0,"Italy;Denmark;Japan;United Kingdom;United States","7;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3210 NUTRITION AND DIETETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","20;9;9;3;3;3;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;PATIENT SAFETY;GENETICS;LYMPHOMA;INFECTIOUS DISEASES;LUNG;BIOMEDICAL IMAGING;DIABETES;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HUMAN GENOME;LUNG CANCER;NEURODEGENERATIVE;PEDIATRIC;PREVENTION;TRANSPLANTATION","18;11;11;10;6;6;4;4;3;3;2;2;2;2;2;2;2;2;2;2","CANCER;INFECTION;NEUROLOGICAL;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;SKIN","9;2;2;1;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","13;2;2;1;1;1","LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER;BREAST CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;HODGKIN'S DISEASE;OVARIAN CANCER","4;3;2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","9;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS","19;1","32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;3202 CLINICAL SCIENCES;44 HUMAN SOCIETY;4407 POLICY AND ADMINISTRATION;31 BIOLOGICAL SCIENCES;4007 CONTROL ENGINEERING, MECHATRONICS AND ROBOTICS;42 HEALTH SCIENCES;51 PHYSICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;4013 GEOMATIC ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS","18;6;4;4;4;3;3;2;2;1;1;1;1;1;1;1","BRAIN DISORDERS;CLINICAL RESEARCH;AGING;CANCER;HEALTH SERVICES;LUNG;LUNG CANCER;NEUROSCIENCES;STROKE","2;2;1;1;1;1;1;1;1","STROKE;CANCER","2;1","8.1 ORGANISATION AND DELIVERY OF SERVICES","1","BIOMEDICAL;CLINICAL","1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","10;3","COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;LUNG CANCER;STOMACH CANCER","1;1;1;1",NA,NA
"AOU_PERUGIA",2021,103,22.0776699029126,1.83495145631068,0.155339805825243,0.194174757281553,0.213592233009709,1.43511450381679,1,1.17647058823529,1.04761904761905,0.689320388349515,0,51,24,4,9,0.5,0.23,0.04,0.09,13.44,0.871353649058446,8.42857142857142,0.407766990291262,0.990291262135922,0.401,0.349,0.364,0.379,"RITA CHIARI;GIULIO METRO;ALAIN GELIBTER;FRANCESCO GROSSI;GIUSEPPE VITTORIO DE SOCIO;ALEX FRIEDLAENDER;ALESSIO CORTELLINI;ALFREDO ADDEO;STEFANO ASCANI;ALESSANDRO DE TOMA;GIAMPIERO PORZIO;DIEGO SIGNORELLI;RAFFAELE GIUSTI;ROSSANA BERARDI;CORRADO FICORELLA;FABRIZIO CITARELLA;GIOVANNI MARTINO;GIUSEPPE LUIGI BANNA;MARCO FILETTI;MICHELE DE TURSI","8;8;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5","NICOLA RAMACCIATI;STEFANO ASCANI;RAFFAELE MANTA;GIUSEPPE AMBROSIO;NICOLA NANTE;ALESSANDRA CARTOCCI;FRANCESCO BAZZURRI;GIANMARCO TROIANO;GIAN LUIGI NICOLOSI;ANDREA SONAGLIONI;MICHELE LOMBARDO;GIAN FRANCO GENSINI;STEFANO PASQUINO;FRANCESCA SANGUEDOLCE;MAURIZIO ZIZZO;MAGDA ZANELLI;GIOVANNI MARTINO;ALESSIO GILI;GIUSEPPE VITTORIO DE SOCIO;ELEONORA DISTRUTTI","0.59;0.56;0.55;0.54;0.5;0.5;0.5;0.5;0.49;0.49;0.49;0.49;0.48;0.46;0.46;0.46;0.43;0.41;0.4;0.4","RITA CHIARI;GIULIO METRO;GIUSEPPE VITTORIO DE SOCIO;STEFANO ASCANI;GIOVANNI MARTINO;VIENNA LUDOVINI;PAOLO SPORTOLETTI;ELISABETTA TORLONE;RAFFAELE MANTA;FRANCESCO PUMA;GIUSEPPE AMBROSIO;DANIELA FRANCISCI;ELEONORA DISTRUTTI;BRUNANGELO FALINI;BARBARA LUCIANI PASQUA;ANGELO SIDONI;ELISABETTA SCHIAROLI;NICOLA RAMACCIATI;LEONARDO FLENGHI;STEFANO PASQUINO","8;8;6;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","NICOLA RAMACCIATI;STEFANO ASCANI;RAFFAELE MANTA;GIUSEPPE AMBROSIO;FRANCESCO BAZZURRI;STEFANO PASQUINO;GIOVANNI MARTINO;GIUSEPPE VITTORIO DE SOCIO;ELEONORA DISTRUTTI;FEDERICO CRUSCO;VIENNA LUDOVINI;STEFANIA TROIANI;GIULIO METRO;ANGELO SIDONI;MARIA GRAZIA CELANI;TERESA ANNA CANTISANI;CARLA CAPONI;GIAN DOMENICO GIUSTI;MAURIZIO RADICIONI;DAVIDE DI LAZZARO","0.59;0.56;0.55;0.54;0.5;0.48;0.43;0.4;0.4;0.33;0.32;0.31;0.3;0.28;0.25;0.25;0.25;0.25;0.25;0.25","DANIELA FRANCISCI;ANTONELLA D’ARMINIO MONFORTE;STEFANO RUSCONI;ELISABETTA SCHIAROLI;MATTEO SIANO;AGOSTINO RIVA;AGNESE VERZURI;AGOSTINO OGNIBENE;ALESSANDRA VERGORI;ALICE DONATI;ANDREA ANTINORI;ANDREA COSSARIZZA;ANNA CANACCINI;ANNA MARIA PINTO;ANNARITA GILIBERTI;ARIANNA EMILIOZZI;ARIANNA GABRIELI;BARBARA ROSSETTI;BRUNO FREDIANI;CESIRA NENCIONI","373;294;274;266;257;256;232;232;232;232;232;232;232;232;232;232;232;232;232;232","DANIELA FRANCISCI;FRANCESCO PACIOSI;ELISABETTA SCHIAROLI;GIULIO METRO;BARBARA LUCIANI PASQUA;ELEONORA DISTRUTTI;ANGELO GIACOMUCCI;PAOLO SPORTOLETTI;STELVIO BALLANTI;GIUSEPPE VITTORIO DE SOCIO;PIER GIORGIO SCOTTON;GIUSEPPE AMBROSIO;EDOARDO DE ROBERTIS;BRUNANGELO FALINI;ENRICO TIACCI;MARIA PAOLA MARTELLI;MARIA CRISTINA PAGLIACCI;SAURO BISCOTTO;ALESSIA TABARRINI;BARBARA BIGERNA","232;232;175;169;110;84;81;74;72;70;57;46;45;43;43;43;41;41;40;40","GIULIO METRO;VIENNA LUDOVINI;GIUSEPPE VITTORIO DE SOCIO;GIUSEPPE AMBROSIO;PAOLO SPORTOLETTI;RAFFAELE MANTA;ELEONORA DISTRUTTI;LEONARDO FLENGHI;BARBARA LUCIANI PASQUA;RITA CHIARI;STEFANO ASCANI;ANGELO GIACOMUCCI;BARBARA BIFARINI;BRUNANGELO FALINI;DANIELA FRANCISCI;ELENA MASTRODICASA;ENRICO TIACCI;FEDERICO CRUSCO;FRANCESCA ROMANA TOFANETTI;FRANCESCO ARCIONI","8;5;5;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PSYCHOLOGY;CHEMISTRY;POLITICAL SCIENCE;ENGINEERING;MATHEMATICS;PHYSICS;SOCIOLOGY;BUSINESS;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;GEOGRAPHY","98;29;10;10;9;6;4;4;4;4;2;2;2;2;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;GENETICS;IMMUNOLOGY;PSYCHIATRY;CANCER RESEARCH;CARDIOLOGY;BIOCHEMISTRY;FAMILY MEDICINE;GASTROENTEROLOGY;PEDIATRICS;RADIOLOGY;INTENSIVE CARE MEDICINE;NURSING;ENDOCRINOLOGY;LAW;EMERGENCY MEDICINE;ENVIRONMENTAL HEALTH;NEUROSCIENCE;PHARMACOLOGY;PHYSICAL THERAPY","76;24;22;20;16;16;13;12;12;11;10;8;8;8;7;7;6;6;4;4;4;4;4","CANCER;GENE;DISEASE;LUNG CANCER;CHEMOTHERAPY;RANDOMIZED CONTROLLED TRIAL;COHORT;RETROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;CONFIDENCE INTERVAL;LUNG;LYMPHOMA;PROSPECTIVE COHORT STUDY;ANTIBODY;COHORT STUDY;DIABETES MELLITUS;HEART FAILURE;IMMUNOHISTOCHEMISTRY;INTENSIVE CARE UNIT;LEUKEMIA;MEDLINE;MYOCARDIAL INFARCTION;OBSERVATIONAL STUDY;POPULATION;PROPORTIONAL HAZARDS MODEL;QUALITY OF LIFE (HEALTHCARE);RECEPTOR;REGIMEN","25;17;16;11;10;9;8;8;6;6;6;6;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","IMMUNOTHERAPY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);HAZARD RATIO;PROGRESSION-FREE SURVIVAL;CLINICAL ENDPOINT;COLORECTAL CANCER;GENE EXPRESSION;EJECTION FRACTION;GASTRECTOMY;MUTATION;TRANSCRIPTION FACTOR;ADENOCARCINOMA;ANAPLASTIC LARGE-CELL LYMPHOMA;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CHROMOSOME;CHRONIC LYMPHOCYTIC LEUKEMIA;CORONARY ANGIOGRAPHY;CYCLOPHOSPHAMIDE;DEMENTIA;DIASTOLE;ESOPHAGEAL CANCER;ESOPHAGEAL STENT;EXON;FATTY LIVER;GESTATION;HISTONE;LAPAROSCOPIC SURGERY;METASTASIS;MULTICENTER STUDY;NEUTROPENIA;NUCLEOPHOSMIN;PERCUTANEOUS CORONARY INTERVENTION;PHENOTYPE;RANDOMIZATION;SPINAL CORD INJURY;VIRAL LOAD;WEIGHT LOSS","9;7;6;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;ANTIRETROVIRAL THERAPY;GESTATIONAL DIABETES;HISTONE DEACETYLASE;KARYOTYPE;NIVOLUMAB;NUCLEAR RECEPTOR;PD-L1;RIGHT CORONARY ARTERY;VINCRISTINE;AMPA RECEPTOR;ANDROGEN RECEPTOR;ARYL HYDROCARBON RECEPTOR;ATYPICAL ANTIPSYCHOTIC;AUTOIMMUNE ENCEPHALITIS;BIVALIRUDIN;BRCA MUTATION;CARBOPLATIN;CARFILZOMIB;COCHRANE COLLABORATION;COGNITIVE DECLINE;COLONOSCOPY;CYP8B1;DNA MICROARRAY;ELECTRICAL CARDIOVERSION;ENDOVASCULAR ANEURYSM REPAIR;EPITHELIAL OVARIAN CANCER;FEBRILE NEUTROPENIA;GENE MUTATION;IBRUTINIB;KRAS;LOSS FUNCTION;MICROARRAY;MONOCLONAL;MYB;NON-SMALL CELL LUNG CANCER (NSCLC);NONALCOHOLIC FATTY LIVER DISEASE;OBETICHOLIC ACID;OPPORTUNISTIC INFECTION;PERIPHERAL T-CELL LYMPHOMA;PERMISSIVENESS;POLY ADP RIBOSE POLYMERASE;PRIMARY TUMOR;PROLYMPHOCYTIC LEUKEMIA;PYRAZINAMIDE;RIFABUTIN;RIVAROXABAN;RUXOLITINIB;SENTINEL LYMPH NODE;SENTINEL NODE;STEATOHEPATITIS;THYMIDYLATE SYNTHASE;TOLL-LIKE RECEPTOR;TRANSCRIPTOME;VASO-OCCLUSIVE CRISIS;WEIGHT CHANGE","7;6;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;MALE;FEMALE;LUNG NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;AGED;COVID-19;MIDDLE AGED;RETROSPECTIVE STUDIES;ITALY;SARS-COV-2;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;PROSPECTIVE STUDIES;TREATMENT OUTCOME;ADULT;AGED, 80 AND OVER;DEGLUTITION DISORDERS;ESOPHAGEAL STENOSIS","53;49;26;25;23;22;20;17;15;14;12;10;9;9;9;7;6;6;6;6","CANCER IMMUNOTHERAPY;ESOPHAGEAL INTERVENTION TECHNIQUES;CORONAVIRUS DISEASE 2019;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF KAWASAKI DISEASE;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;IMPACT OF GESTATIONAL DIABETES MELLITUS ON PREGNANCY;KIDNEY TRANSPLANTATION;MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;ROLE OF HISTONE DEACETYLASES IN CELLULAR REGULATION;ROLE OF LONG NONCODING RNAS IN CANCER AND DEVELOPMENT;SHARED DECISION MAKING IN HEALTHCARE;WORKPLACE BULLYING AND HARASSMENT IN PROFESSIONAL ENVIRONMENTS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA","7;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","PROGRESSION-FREE SURVIVAL;CLINICAL ENDPOINT;PANDEMIC;PD-1 AND PD-L1;REGIMEN;TREATMENT;BIOMARKERS FOR IMMUNOTHERAPY;DELPHI METHOD;ECHOCARDIOGRAPHY;LEFT VENTRICULAR FUNCTION;MANTLE CELL LYMPHOMA;RENAL REPLACEMENT THERAPY;TUMOR STAGING;ACUTE KIDNEY INJURY;ANAPLASTIC LARGE-CELL LYMPHOMA;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CLINICAL CHARACTERISTICS;CONCOMITANT;CONCORDANCE;CORONARY ARTERY ABNORMALITIES","5;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","LUNG CANCER;ITALIAN SOCIETY;MULTICENTER STUDY;CELL LUNG;COVID- PANDEMIC;EMERGENCY DEPARTMENT;NON-SMALL CELL;NON-SMALL-CELL LUNG;OBSERVATIONAL STUDY;PD-L EXPRESSION;RECEIVING FIRST-LINE;ABERRANT CYTOPLASMIC;ACUTE KIDNEY;BASED RECOMMENDATIONS;CARE UNIT;CLINICAL TRIALS;CONVALESCENT PLASMA;CORONARY ARTERY;COVID- DISEASE;DEPARTMENT PRESENTATIONS;ELDERLY PATIENTS;EVIDENCE BASED;FIRSTLINE IMMUNOTHERAPY;GASTRIC CANCER;GESTATIONAL DIABETES;IMPROVEMENTSTHE STRONG;INTENSIVE CARE;KIDNEY INJURY;LIFE-THREATENING COVID-;LYMPHOBLASTIC LEUKEMIA","10;5;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;ACCOMODATIONS EXPENSES;TRAVEL ACCOMODATIONS;HR CI;LUNG CANCER;PD-L EXPRESSION;SURVIVAL OS;LECTURE FEE;NSCLC PATIENTS;PATIENTS UNDERGOING;BLOOD SAMPLES;CELL LINES;SURVIVAL PFS;ANTIBODY CLONES;CD CELLS;CORONARY ARTERY;HEALTHCARE-MANAGED VOCS;PRONE POSITION;ADVISORY BOARD;AWAKE PRONE;CONSULTANCY HONORARIA;CONSULTANCY MEMBERSHIP;DEEP LEARNING;GASTRIC CANCER;INTENSIVE CARE;LUNG ADENOCARCINOMA;MEDIAN AGE;MONTHS PFS","46;46;16;14;14;13;11;11;10;9;9;9;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6",52,0.5,6.89,10,1,1.25,0,3,1,1,1,11.25,1,1,9,0,1,2,4.5,6,4.5,0,0,32.25,32.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,3.61,829.42,26.27,18,0.58,75.48,0,1,7,0,11,0,0,12,0,24,7,0,0,0,0,0,0,29,2,0,31,0,0,0,0,0,0,0,0,0,"United States;Italy;Hungary;Japan","6;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY","30;13;12;8;3;3;2;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;LUNG;PATIENT SAFETY;PEDIATRIC;PEDIATRIC CANCER;AGING;CHILDHOOD LEUKEMIA;PREVENTION;BIOENGINEERING;LUNG CANCER;LYMPHOMA;REGENERATIVE MEDICINE;STEM CELL RESEARCH;TRANSPLANTATION;VACCINE RELATED;ACUTE RESPIRATORY DISTRESS SYNDROME","27;20;15;15;13;8;5;5;5;4;4;4;3;3;3;3;3;3;3;2","CANCER;CARDIOVASCULAR;RESPIRATORY;INFECTION;BLOOD;EYE;NEUROLOGICAL;SKIN","12;3;3;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","20;3;2;1;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;MELANOMA;HODGKIN'S DISEASE;MYELOMA;OVARIAN CANCER","10;4;3;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","13;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,"FRONTIERS;SPRINGER NATURE;ZENODO","9;4;2","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;34 CHEMICAL SCIENCES;3202 CLINICAL SCIENCES","24;18;6;6;6;2;2;1","CANCER;DIGESTIVE DISEASES;GENETICS;RARE DISEASES;DRUG ABUSE (NIDA ONLY);SUBSTANCE MISUSE;CARDIOVASCULAR;CLINICAL RESEARCH;KIDNEY DISEASE","6;6;6;6;2;2;1;1;1","CANCER;CARDIOVASCULAR;RENAL AND UROGENITAL","6;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","6;6","CLINICAL","7","CLINICAL MEDICINE AND SCIENCE","11","STOMACH CANCER","6","3 GOOD HEALTH AND WELL BEING","1"
"AOU_PERUGIA",2022,85,19.9882352941176,1.95294117647059,0.152941176470588,0.141176470588235,0.152941176470588,1.36363636363636,0.928571428571429,1.09090909090909,0.928571428571429,0.635294117647059,0,34,14,12,5,0.4,0.16,0.14,0.06,8.24,0.922535097474853,7.47239263803681,0.388235294117647,0.964705882352941,0.426,0.427,0.393,0.427,"GIULIO METRO;ELEONORA DISTRUTTI;STEFANO FIORUCCI;MICHELE BIAGIOLI;SILVIA MARCHIANÒ;ROSALINDA ROSELLI;CRISTINA DI GIORGIO;RAFFAELE MANTA;MARTINA BORDONI;ANGELA ZAMPELLA;DANILO CASTELLANI;ANNA MARIA MOSCONI;GIAN DOMENICO GIUSTI;RACHELE BELLINI;FEDERICO CAPPUZZO;GINEVRA URBANI;CLAUDIO ZAMAGNI;MARIA CHIARA MONTI;ANTONIO PIERINI;PAOLO GROFF","9;7;7;7;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3","ELEONORA DISTRUTTI;STEFANO FIORUCCI;MICHELE BIAGIOLI;RAFFAELE MANTA;GIAN DOMENICO GIUSTI;SILVIA MARCHIANÒ;DANILO CASTELLANI;GIULIO METRO;ANGELA ZAMPELLA;UGO GERMANI;ROSALINDA ROSELLI;CRISTINA DI GIORGIO;MARTINA BORDONI;RAFFAELLA COLOMBATTI;LAURIE DEBONNETT;FRANCESCO ARCIONI;ALESSIO GILI;NICOLA RAMACCIATI;GINEVRA URBANI;RACHELE BELLINI","0.82;0.82;0.82;0.7;0.63;0.62;0.56;0.55;0.5;0.43;0.42;0.42;0.42;0.38;0.38;0.38;0.34;0.34;0.34;0.3","GIULIO METRO;ELEONORA DISTRUTTI;RAFFAELE MANTA;DANILO CASTELLANI;ANNA MARIA MOSCONI;GIAN DOMENICO GIUSTI;ANTONIO PIERINI;PAOLO GROFF;CYNTHIA ARISTEI;UGO GERMANI;PAOLO SPORTOLETTI;MARIA PAOLA MARTELLI;FRANCESCO ARCIONI;BRUNANGELO FALINI;ILENIA CORBELLI;MATTEO D’AMMANDO;ANGELO BONAITI;ANGELO BRUNORI;LOREDANA RUGGERI;NICOLA RAMACCIATI","9;7;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","ELEONORA DISTRUTTI;RAFFAELE MANTA;GIAN DOMENICO GIUSTI;DANILO CASTELLANI;GIULIO METRO;UGO GERMANI;FRANCESCO ARCIONI;NICOLA RAMACCIATI;ANGELO BRUNORI;PAOLO GROFF;MATTEO D’AMMANDO;CLAUDIO CAVALLINI;ANGELO PISANI;ELISA PIERINI;ANNA MARIA MOSCONI;GIUSEPPE AMBROSIO;S. TORRISI;ANTONIO BRUNORI;ANGELO BONAITI;NICCOLÒ METELLI","0.82;0.7;0.63;0.56;0.55;0.43;0.38;0.34;0.29;0.29;0.27;0.27;0.25;0.2;0.2;0.2;0.2;0.2;0.18;0.18","ELEONORA DISTRUTTI;MICHELE BIAGIOLI;STEFANO FIORUCCI;ANGELA ZAMPELLA;GIULIO METRO;ANDREA CORTEGIANI;ANTONINO GIARRATANO;MARIACHIARA IPPOLITO;NICOLAS GIRARD;MARTIN RECK;ALFREDO ADDEO;ALONA ZER;ANTONIO CALLES;FRANK ABOUBAKAR NANA;JAIR BAR;KRISTOF CUPPENS;LYNN DECOSTER;MAXIMILIAN J. HOCHMAIR;MOR MOSKOVITZ;NIR PELED","89;89;89;81;81;76;76;76;74;72;60;60;60;60;60;60;60;60;60;60","ELEONORA DISTRUTTI;GIULIO METRO;PAOLO GROFF;STEFANO DE VUONO;LUCIO CRINÓ;MICHELA BONCOMPAGNI;ANNA MARIA MOSCONI;G. METRO;GIAN DOMENICO GIUSTI;CARMEN CALVELLO;CINZIA COSTA;ALFREDO VILLA;BONIN CECILIA;PAOLO VERDECCHIA;PERANDINI ALESSIO;SAVERIO ARENA;MARIA GIULIA BERIOLI;MARIA PAOLA MARTELLI;CYNTHIA ARISTEI;ELISABETTA PERRUCCI","89;81;59;58;39;38;35;32;22;21;21;20;19;19;19;19;18;18;17;17","GIULIO METRO;ELEONORA DISTRUTTI;RAFFAELE MANTA;ANNA MARIA MOSCONI;DANILO CASTELLANI;GIAN DOMENICO GIUSTI;PAOLO GROFF;UGO GERMANI;ALFREDO VILLA;ANGELO BONAITI;CLAUDIO CAVALLINI;GIUSEPPE VITTORIO DE SOCIO;LEONARDO FLENGHI;MATTEO D’AMMANDO;NICCOLÒ METELLI;PAOLO SPORTOLETTI;SARA BAGLIVO;STEFANO DE VUONO;VIENNA LUDOVINI;A. CHIAPPINIELLO","9;7;5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;SOCIOLOGY;BUSINESS;ENVIRONMENTAL SCIENCE;PHILOSOPHY;POLITICAL SCIENCE","80;21;11;8;6;4;3;3;3;2;2;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;IMMUNOLOGY;BIOCHEMISTRY;PATHOLOGY;CANCER RESEARCH;GENETICS;RADIOLOGY;CARDIOLOGY;GASTROENTEROLOGY;PEDIATRICS;ENDOCRINOLOGY;VIROLOGY;CELL BIOLOGY;FAMILY MEDICINE;OPTICS;INTENSIVE CARE MEDICINE;NEUROSCIENCE;NURSING;PHARMACOLOGY;PSYCHIATRY","62;24;22;13;12;11;10;10;10;9;9;8;6;6;5;5;5;4;4;4;4;4","CANCER;DISEASE;GENE;CHEMOTHERAPY;ADVERSE EFFECT;CLINICAL TRIAL;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;CONFIDENCE INTERVAL;COHORT;INCIDENCE (GEOMETRY);OUTBREAK;EMERGENCY DEPARTMENT;LEUKEMIA;LYMPHOMA;BONE MARROW;COMORBIDITY;DISCONTINUATION;ENDOSCOPY;HEALTH CARE;IMMUNE SYSTEM;INFLAMMATION;MYOCARDIAL INFARCTION;ODDS RATIO;POPULATION;PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;RECEPTOR;RETROSPECTIVE COHORT STUDY;THROMBOSIS","23;17;14;11;9;9;9;8;7;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;BEVACIZUMAB;EPIDERMAL GROWTH FACTOR RECEPTOR;PROGRESSION-FREE SURVIVAL;ADENOCARCINOMA;OVARIAN CANCER;POLYMERASE;2019-20 CORONAVIRUS OUTBREAK;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;COLORECTAL CANCER;G PROTEIN-COUPLED BILE ACID RECEPTOR;HAZARD RATIO;IMMUNOTHERAPY;PHASES OF CLINICAL RESEARCH;SICKLE CELL ANEMIA;TOLERABILITY;TRANSCRIPTION FACTOR;CUMULATIVE INCIDENCE;DISEASE BURDEN;DOCETAXEL;ENDOSCOPIC MUCOSAL RESECTION;FRACTION OF INSPIRED OXYGEN;GRAFT-VERSUS-HOST DISEASE;HAEMATOPOIESIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MALIGNANT PLEURAL EFFUSION;PANCREATIC CANCER;PERFORATION;PLACEBO;T CELL","10;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);ERLOTINIB;POLY ADP RIBOSE POLYMERASE;BRCA MUTATION;ROS1;VASO-OCCLUSIVE CRISIS;CARBOPLATIN;CHEMOIMMUNOTHERAPY;CRIZOTINIB;GEFITINIB;NIVOLUMAB;NUCLEAR RECEPTOR;PEMETREXED;ACCESSORY PATHWAY;ADOPTIVE CELL TRANSFER;ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA;ANTIRETROVIRAL THERAPY;BENDAMUSTINE;BRENTUXIMAB VEDOTIN;CHRONIC LEUKEMIA;COLONOSCOPY;CORONARY STEAL;CORONARY VASOSPASM;DASATINIB;DEBULKING;DNA METHYLATION;DONOR LYMPHOCYTE INFUSION;GERMLINE MUTATION;GLUCOSE HOMEOSTASIS;HEMATOPOIETIC CELL;HISTONE DEACETYLASE;HYPOCAPNIA;KARYOTYPE;KRAS;LEUKEMIA INHIBITORY FACTOR;MACE;MIGRAINE WITH AURA;MITOCHONDRIAL DISEASE;MITOCHONDRIAL ENCEPHALOMYOPATHY;MITOCHONDRIAL MYOPATHY;MYOCARDIAL BRIDGE;NILOTINIB;PEMBROLIZUMAB;PRIMARY TUMOR;REVERSE TRANSCRIPTASE;RIVAROXABAN;STEATOHEPATITIS;SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS;SYSTEMIC THERAPY;THYMOCYTE;TRABECTEDIN;UNDERWEIGHT;VENETOCLAX","10;5;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;COVID-19;FEMALE;LUNG NEOPLASMS;RETROSPECTIVE STUDIES;VENOUS THROMBOEMBOLISM;AGED;CARCINOMA, NON-SMALL-CELL LUNG;COLORECTAL NEOPLASMS;COVID-19 VACCINES;HIV INFECTIONS;MALE;RECEPTORS, G-PROTEIN-COUPLED;SARS-COV-2;BILE ACIDS AND SALTS;MIDDLE AGED;NEOPLASM RECURRENCE, LOCAL;PROSPECTIVE STUDIES;PROTEIN KINASE INHIBITORS","48;36;25;10;10;9;9;7;7;7;7;7;7;7;7;6;6;6;6;6","ADVANCEMENTS IN LUNG CANCER RESEARCH;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;HEMATOPOIETIC STEM CELL BIOLOGY;HYPERSENSITIVITY REACTIONS TO DRUGS AND MEDICATIONS;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;LYMPHOID NEOPLASMS;ACUTE MYELOID LEUKEMIA;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;BREASTFEEDING: EPIDEMIOLOGY, MECHANISMS, AND HEALTH OUTCOMES;CANCER IMMUNOTHERAPY;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CHALLENGES IN MEDICAL WASTE MANAGEMENT DURING COVID-19 PANDEMIC;CLINICAL CHARACTERISTICS AND MANAGEMENT OF SARCOIDOSIS;COMPUTATIONAL METHODS IN DRUG DISCOVERY;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS","10;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;EGFR MUTATIONS;PROGRESSION-FREE SURVIVAL;OLAPARIB;OSIMERTINIB;PANDEMIC;T790M;2019-20 CORONAVIRUS OUTBREAK;BRCA MUTATION;DIAGNOSIS;DISCONTINUATION;REGIMEN;TOLERABILITY;VASO-OCCLUSIVE CRISIS;ANTIRETROVIRAL THERAPY;CARBOPLATIN;CHEMOIMMUNOTHERAPY;COHEN'S KAPPA;COMBINATION THERAPIES;CUMULATIVE INCIDENCE","6;5;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2","LUNG CANCER;ACCESS PROGRAM;CELL LUNG;MANAGED ACCESS;NON-SMALL CELL;CELL DISEASE;CELL TRANSPLANTATION;DISEASE SCD;OVARIAN CANCER;PHASE II;PHASE III;PROGRAM MAP;SICKLE CELL;VASO-OCCLUSIVE CRISES;ACID RECEPTOR;ADVANCED OVARIAN;ANTIRETROVIRAL THERAPY;ARTERY DISSECTION;BASELINE DISEASE;BILE ACID;BLOOD PRESSURE;BURDEN TREATED;CERVICAL ARTERY;CHRONIC LYMPHOCYTIC;CLINICAL PRACTICE;DISEASE BURDEN;EGFR MUTATIONS;III PAOLA-ENGOT-OV;LYMPHOCYTIC LEUKEMIA;MAINTENANCE OLAPARIB","5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HEALTHCARE-MANAGED VOCS;BREAST CANCER;ADVERSE EVENTS;CRIZANLIZUMAB TREATMENT;MEDIAN AGE;PROGRESSION-FREE SURVIVAL;PAIN RELIEF;SEIZURE FREQUENCY;VISUAL STIMULATION;VOC-RELATED PAIN;BONE MARROW;CONFIDENCE INTERVAL;RADIATION THERAPY;SCD-RELATED COMPLICATIONS;STATISTICALLY SIGNIFICANT;Þ BEVACIZUMAB;ARR CI;BASELINE PERIOD;DETECTION RATE;LAPAROSCOPIC SURGERY;LUNG CANCER;MAINTENANCE THERAPY;MDOR MONTHS;MEDIAN FOLLOW-UP;MPFS MONTHS;NK CELLS;RESPONSE RATE;SIGNIFICANT DIFFERENCE;SURVIVAL PFS;TREATING PHYSICIAN","10;9;8;8;8;8;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5",43,0.51,5.42,6.5,1,1.25,0,1,0,1,0,7.5,0,0,6,1,0,1.25,6,5,2,0,0,19,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,3.75,575.22,23.93,18,0.64,68.82,2,4,3,0,10,0,0,9,0,21,7,0,0,0,0,0,0,28,0,0,28,0,0,0,0,0,0,0,0,0,"United States;Italy;Belgium;Japan;Switzerland","7;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES","27;15;15;3;2;2;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;LUNG;ORPHAN DRUG;LYMPHOMA;PEDIATRIC;CARDIOVASCULAR;LUNG CANCER;PREVENTION;STEM CELL RESEARCH;AGING;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BRAIN DISORDERS;CHILDHOOD LEUKEMIA;EMERGENCY CARE","27;17;16;11;8;6;5;5;4;4;3;3;3;3;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;INJURIES AND ACCIDENTS;METABOLIC AND ENDOCRINE;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;SKIN","15;3;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.4 SURVEILLANCE AND DISTRIBUTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;8.1 ORGANISATION AND DELIVERY OF SERVICES","20;5;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;MELANOMA;LUNG CANCER;BLOOD CANCER;BREAST CANCER;HODGKIN'S DISEASE;LIVER CANCER;MYELOMA","6;6;4;3;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","12;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,"FRONTIERS;SPRINGER NATURE;TAYLOR & FRANCIS GROUP","2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES","6;4;3;2;2;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;GENETICS;LUNG;LUNG CANCER;RARE DISEASES;DIABETES;PEDIATRIC;PREVENTION","3;2;2;2;2;2;2;1;1;1","CANCER;METABOLIC AND ENDOCRINE","2;1","6.1 PHARMACEUTICALS","1","CLINICAL","2","CLINICAL MEDICINE AND SCIENCE","3","LUNG CANCER;NOT SITE-SPECIFIC CANCER","2;1","3 GOOD HEALTH AND WELL BEING","1"
"AOU_PERUGIA",2023,65,17.1230769230769,2.15384615384615,0.169230769230769,0.138461538461538,0.138461538461538,1.44329896907216,0.916666666666667,0.9,0.9,0.707692307692308,0,28,12,6,2,0.43,0.18,0.09,0.03,4.98,1.13723789194929,6.61052631578948,0.338461538461538,0.969230769230769,0.413,0.305,0.207,0.289,"GINEVRA URBANI;CRISTINA DI GIORGIO;CARMEN MASSA;GIULIO METRO;SILVIA MARCHIANÒ;MARIA CHIARA MONTI;MARTINA BORDONI;ANNIBALE DONINI;ELEONORA DISTRUTTI;STEFANO FIORUCCI;MICHELE BIAGIOLI;ANGELA ZAMPELLA;ELVA MORRETTA;RACHELE BELLINI;CRISTINA MECUCCI;STEFANO MANCIN;LUIGINA GRAZIOSI;DESIRÈE ANDREOLI;ROSALINDA ROSELLI;DANIELA MIANI","5;5;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;3;3","STEFANO MANCIN;DESIRÈE ANDREOLI;NICOLA RAMACCIATI;ILARIA LEONE DE MAGISTRIS;MAURIZIO PACIARONI;PAOLO VERDECCHIA;STEFANO COIRO;FABIO ANGELI;RICCARDO PARACINO;BEATRICE MAZZOLENI;EMANUELA MORENGHI;GIULIO METRO;FANNY SOEKELAND;GIUSEPPE MURDOLO;ENRICO CIERI;GIAN DOMENICO GIUSTI;ELISABETTA METLICHIN;MARCO SGUANCI;ALESSIO GILI;LUIGINA GRAZIOSI","0.68;0.68;0.53;0.5;0.5;0.48;0.48;0.48;0.38;0.37;0.37;0.35;0.34;0.34;0.34;0.33;0.33;0.31;0.31;0.3","GIULIO METRO;ANNIBALE DONINI;ELEONORA DISTRUTTI;CRISTINA MECUCCI;LUIGINA GRAZIOSI;DESIRÈE ANDREOLI;DANIELA MIANI;GIUSEPPE MURDOLO;ANNA MARIA MOSCONI;MICHELE CORREALE;ALESSANDRA VILLANI;ELENA PERUZZI;FILIPPO M. SARULLO;MARTINA MANDARANO;CLAUDIO BILATO;LUCA DEGLI ESPOSTI;MASSIMO IACOVIELLO;LEONARDO FLENGHI;ENRICO CIERI;ANDREA PASSANTINO","5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","DESIRÈE ANDREOLI;ILARIA LEONE DE MAGISTRIS;MAURIZIO PACIARONI;PAOLO VERDECCHIA;STEFANO COIRO;RICCARDO PARACINO;GIULIO METRO;GIUSEPPE MURDOLO;ENRICO CIERI;GIAN DOMENICO GIUSTI;LUIGINA GRAZIOSI;ELEONORA DISTRUTTI;FABRIZIO MANCINI;ANNIBALE DONINI;CRISTINA MECUCCI;MARCO LUPATTELLI;STEFANO ASCANI;VALERIA MITRO;DANIELA MIANI;ANNALISA SANTUCCI","0.68;0.5;0.5;0.48;0.48;0.38;0.35;0.34;0.34;0.33;0.3;0.26;0.25;0.23;0.23;0.22;0.21;0.2;0.2;0.2","ANNA MARIA MOSCONI;CLAIRE CROPET;DOMENICA LORUSSO;DOMINIK DENSCHLAG;IGNACE VERGOTE;JOHANNA MÄENPÄÄ;NICOLETTA COLOMBO;PHILIPP HARTER;ÉRIC PUJADE-LAURAINE;CHRISTIAN MARTH;A. LORTHOLARY;ALEXANDER BURGES;ALEXANDRA LÉARY;ANTONIO GONZÁLEZ‐MARTÍN;AYŞE BALAT;BENOÎT YOU;C. LEFEUVRE-PLESSE;CORALINE DUBOT;EVA MARIA GUERRA ALÍA;FRÉDÈRIC SELLE","116;116;116;116;116;116;116;116;116;103;99;99;99;99;99;99;99;99;99;99","ANNA MARIA MOSCONI;ELEONORA DISTRUTTI;ILARIA CAPOLSINI;LEONARDO FLENGHI;DESIRÈE ANDREOLI;FRANCESCO GAGGIA;GIUSEPPE MURDOLO;MARIA PAOLA MARTELLI;SOFIA SCIABOLACCI;V. CARDINALI;ANNA MARINA LIBERATI;ANTÓNIO GALZERANO;EDOARDO DE ROBERTIS;GIACOMO DE GIROLAMO;MATTEO BELLUCCI;CRISTIANA VERMIGLI;GIUSEPPE VITTORIO DE SOCIO;CYNTHIA ARISTEI;ELEONORA BIANCHINI;MAURIZIO CANIGLIA","116;45;17;17;15;15;15;13;13;13;12;12;12;12;12;11;11;9;8;6","ELEONORA DISTRUTTI;GIULIO METRO;DESIRÈE ANDREOLI;LUIGINA GRAZIOSI;GIUSEPPE MURDOLO;ANNA MARIA MOSCONI;LEONARDO FLENGHI;ERBERTO CARLUCCIO;ANNA MARINA LIBERATI;CLAUDIO CAVALLINI;CRISTIANA VERMIGLI;FRANCESCO GAGGIA;GIUSEPPE VITTORIO DE SOCIO;MAURIZIO CANIGLIA;RICCARDO PARACINO;STEFANO COIRO;ANDREA SANTUCCI;ANTÓNIO GALZERANO;BARBARA CRESCENZI;BENEDETTA DELLA TORRE","5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;PHILOSOPHY;ENGINEERING;PSYCHOLOGY;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;SOCIOLOGY","63;20;7;7;5;5;4;4;3;3;3;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;BIOCHEMISTRY;PATHOLOGY;SURGERY;CARDIOLOGY;IMMUNOLOGY;CANCER RESEARCH;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GENETICS;GASTROENTEROLOGY;NURSING;PHARMACOLOGY;EPISTEMOLOGY;INTENSIVE CARE MEDICINE;PALEONTOLOGY;PEDIATRICS;PHYSICAL THERAPY;RADIOLOGY","53;19;12;12;10;9;9;8;8;8;8;7;5;5;4;4;4;4;4;4","CANCER;GENE;CHEMOTHERAPY;COHORT;DISEASE;LYMPHOMA;POPULATION;PROSPECTIVE COHORT STUDY;ADVERSE EFFECT;LEUKEMIA;RETROSPECTIVE COHORT STUDY;STEM CELL;DIABETES MELLITUS;HEALTH CARE;HEART FAILURE;LUNG CANCER;TRANSPLANTATION;ALTERNATIVE MEDICINE;ANTIBODY;BLOOD PRESSURE;BONE MARROW;CLINICAL TRIAL;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);QUALITY (PHILOSOPHY);RECEPTOR;TOXICITY","14;12;10;7;7;7;7;7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","EJECTION FRACTION;RITUXIMAB;TRANSCRIPTION FACTOR;COLORECTAL CANCER;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;OVARIAN CANCER;TOLERABILITY;VALSARTAN;B CELL;BEVACIZUMAB;CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL ENDPOINT;CYCLOPHOSPHAMIDE;DIFFUSE LARGE B-CELL LYMPHOMA;FATTY LIVER;G PROTEIN-COUPLED BILE ACID RECEPTOR;GENE EXPRESSION;HAEMATOPOIESIS;HEALTH PROFESSIONALS;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INTERLEUKIN 6;MUTATION;MYELOFIBROSIS;NEUTROPENIA;POLYMERASE","4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","NUCLEAR RECEPTOR;SACUBITRIL;SACUBITRIL, VALSARTAN;CORONAVIRUS DISEASE 2019 (COVID-19);LEUKEMIA INHIBITORY FACTOR;POLY ADP RIBOSE POLYMERASE;VENETOCLAX;4-HYDROXYNONENAL;ANTIRETROVIRAL THERAPY;BLASTOID;BONE MARROW FAILURE;BUSULFAN;CALCITONIN GENE-RELATED PEPTIDE;CAROTID STENTING;DNA METHYLATION;FEBRILE NEUTROPENIA;FIBROBLAST GROWTH FACTOR RECEPTOR;FIBROBLAST GROWTH FACTOR RECEPTOR 2;FIBROBLAST GROWTH FACTOR RECEPTOR 3;FLUDARABINE;FOLLICLE-STIMULATING HORMONE;GASTRO-;GERMINAL CENTER;GERMLINE MUTATION;GLUCOSE HOMEOSTASIS;HEART FAILURE WITH PRESERVED EJECTION FRACTION;HISTONE DEACETYLASE;IBRUTINIB;IDH1;IGHV@;IPILIMUMAB;KARYOTYPE;KRAS;MARGINAL ZONE;MEGAKARYOCYTE;METASTATIC BREAST CANCER;MONOCLONAL;MYELOPROLIFERATIVE NEOPLASM;NEUROEPITHELIAL CELL;NIVOLUMAB;NONALCOHOLIC FATTY LIVER DISEASE;ROS1;STEATOHEPATITIS;TAUROURSODEOXYCHOLIC ACID;THIOTEPA;TRANSCRIPTOME;VINCRISTINE","3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;RETROSPECTIVE STUDIES;BRAIN NEOPLASMS;HIV INFECTIONS;NON-ALCOHOLIC FATTY LIVER DISEASE;RECEPTORS, G-PROTEIN-COUPLED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FEMALE;TREATMENT OUTCOME;ADULT;AGED;ANIMALS;DIABETES MELLITUS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;LEUKEMIA, MYELOID, ACUTE;MALE;OVARIAN NEOPLASMS;PROSPECTIVE STUDIES;ANTI-HIV AGENTS","34;30;8;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;3","LYMPHOID NEOPLASMS;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF HEART FAILURE;GASTRIC CANCER RESEARCH AND TREATMENT;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;ACUTE MYELOID LEUKEMIA;GLIOMAS;MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER;QUALITY OF NURSING DOCUMENTATION AND EVALUATION APPROACHES;AIRBORNE TRANSMISSION OF RESPIRATORY VIRUSES;ATRIAL FIBRILLATION;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLESTEROL-LOWERING TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;CONTENT VALIDITY IN EDUCATIONAL TECHNOLOGY AND HEALTH RESEARCH;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EFFICACY AND RESISTANCE IN CML TREATMENT","5;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;EVIDENCE-BASED PRACTICE;FARNESOID X RECEPTOR;SACUBITRIL;SACUBITRIL, VALSARTAN;TOLERABILITY;BIG DATA IN NURSING;CLINICAL ENDPOINT;CONCORDANCE;GASTRIC CANCER;HEALTH PROFESSIONALS;INTERQUARTILE RANGE;MANTLE CELL LYMPHOMA;MEDICATION ADHERENCE;MEDICATION PERSISTENCE;METASTATIC GASTRIC CANCER;NURSING EDUCATION;OLAPARIB;PLATINUM-SENSITIVE OVARIAN CANCER;RITUXIMAB THERAPY","3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GASTRIC CANCER;EJECTION FRACTION;HEART FAILURE;OVARIAN CANCER;PAOLA-ENGOT-OV TRIAL;REALIT STUDY;ADVANCED OVARIAN;BILE ACID;CELL LYMPHOMA;CLINICAL PRACTICE;FACTOR RECEPTOR;FONDAZIONE ITALIANA;HEALTHCARE PROFESSIONALS;III PAOLA-ENGOT-OV;INHIBITORY FACTOR;ITALIANA LINFOMI;LEUKEMIA INHIBITORY;LUNG CANCER;NURSING STUDENTS;PATIENTS PTS;PHASE III;PRACTICE GUIDELINES;REDUCED EJECTION;ACID RECEPTOR;ACID SIGNALING;ACTIVE LEARNING;ACUTE LEUKEMIA;ACUTE MYELOID;ADIPOGENIC DIFFERENTIATION;ADIPOSE PRECURSOR","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","PLT COUNT;NIO NPS;BILE ACID;CLINICAL PRACTICE;EJECTION FRACTION;GASTRIC CANCER;MEDIAN FOLLOW-UP;ADVERSE EVENTS;HR CI;NURSING STUDENTS;OVARIAN CANCER;ACTIVE TEACHING;ACUTE MYELOID;APOE-- MICE;BONE MARROW;CANCER PATIENTS;CLINICAL NUTRITION;CLINICALLY MEANINGFUL;FATTY LIVER;HEART FAILURE;LIVER DISEASE;NONALCOHOLIC FATTY;REDUCED EJECTION;SPORE TRAP;SUBTOXIC DOSES;SURVIVAL PFS;TARGET DOSE;-YEAR NA;ADVANCED OVARIAN;BILE ACIDS","11;10;9;9;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4",27,0.42,7.4,7,1,1,0,2.25,0,0,0,7.5,0,0,4.5,0,0,1,2.5,8.5,2,0,0,9.5,9.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2.69,271.08,16.46,0,0,34.54,0,0,4,0,3,0,1,5,0,9,4,0,0,0,0,0,0,12,0,1,13,0,0,0,0,0,0,0,0,0,"Italy;United States;Japan;Netherlands;United Kingdom","2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","12;8;6;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;AGING;LUNG;LUNG CANCER;PATIENT SAFETY;RARE DISEASES;HEMATOLOGY;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);ARTHRITIS;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE;BIOENGINEERING;BRAIN DISORDERS;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;DEMENTIA","13;10;7;4;4;3;3;3;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;EYE;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;RESPIRATORY;SKIN","6;1;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","10;2;1;1","LUNG CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER","3;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,"FRONTIERS","3","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY","6;2;2;1;1;1;1","CANCER;PREVENTION;BIODEFENSE;BREAST CANCER;CLINICAL RESEARCH;EMERGING INFECTIOUS DISEASES;GENETIC TESTING;GENETICS;HEMATOLOGY;HIV/AIDS;INFECTIOUS DISEASES;LUNG;LYMPHOMA;PNEUMONIA;RARE DISEASES;VACCINE RELATED","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2","BIOMEDICAL","2","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","1;1;1","BREAST CANCER;HODGKIN'S DISEASE;NON-HODGKIN'S LYMPHOMA","1;1;1",NA,NA
"AOU_PERUGIA",2024,69,17.768115942029,2.15942028985507,0.217391304347826,0.159420289855072,0.246376811594203,1.33035714285714,1.07142857142857,1.22222222222222,1.13333333333333,0.623188405797101,0,32,13,8,4,0.46,0.19,0.12,0.06,0.9,0.940197201779345,5.33493589743589,0.304347826086957,0.956521739130435,0.451,0.289,0.414,0.27,"GIULIO METRO;RICCARDO PARACINO;ELEONORA GARIAZZO;FRANCESCO NOTARISTEFANO;RICCARDO ANTONIO RICCIUTI;FABRIZIO MANCINI;PIERFRANCESCO DE DOMENICO;GIANLUCA ZINGARINI;DIEGO CORTINOVIS;FEDERICA PESCE;PAOLO VERDECCHIA;CLAUDIO CAVALLINI;ANDREA DE GIGLIO;FABIO ANGELI;MANUEL FRESCHINI;UMBERTO VITOLO;ILARIA CASETTA;FRANCESCO RASPAGLIESI;SARA GALIMBERTI;GAETANO CIMINO","8;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","GIULIO METRO;RICCARDO PARACINO;ELEONORA GARIAZZO;ANDREA DE GIGLIO;FABIO ANGELI;NICOLA RAMACCIATI;GIAN DOMENICO GIUSTI;PIERFRANCESCO DE DOMENICO;MAURO DOBRAN;PAOLO VERDECCHIA;ALESSANDRO DI FEDERICO;GIANPAOLO REBOLDI;ROSA CURCIO;PATRIZIA MORETTI;ALFONSO TORTORELLA;VERONICA RASPA;RICCARDO ALCIDI;GIULIA MENCULINI;GIACOMO PUCCI;ALESSIA XHAFERRI","0.86;0.75;0.63;0.61;0.61;0.58;0.58;0.55;0.45;0.42;0.36;0.36;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33","GIULIO METRO;RICCARDO PARACINO;ELEONORA GARIAZZO;FRANCESCO NOTARISTEFANO;FABRIZIO MANCINI;GIANLUCA ZINGARINI;FEDERICA PESCE;PAOLO VERDECCHIA;CLAUDIO CAVALLINI;MANUEL FRESCHINI;GAETANO CIMINO;MATTEO D’AMMANDO;MAURIZIO PACIARONI;CRISTIANA VERMIGLI;VERONICA RASPA;RAFFAELE MANTA;ANNA MARIA MOSCONI;GIAN DOMENICO GIUSTI;ELEONORA DISTRUTTI;VALERIA CARDINALI","8;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","GIULIO METRO;RICCARDO PARACINO;ELEONORA GARIAZZO;GIAN DOMENICO GIUSTI;PAOLO VERDECCHIA;VERONICA RASPA;GIACOMO PUCCI;FABRIZIO MANCINI;MATTEO MARIA OTTAVIANI;FRANCESCO ARCIONI;PAOLO VERDECCHIA;FRANCESCO NOTARISTEFANO;GIANLUCA ZINGARINI;FEDERICA PESCE;CLAUDIO CAVALLINI;MANUEL FRESCHINI;DANIELA FRUTTINI;CARLO CAGINI;TOMMASO BONIFAZI;FRANCESCO DELLA LENA","0.86;0.75;0.63;0.58;0.42;0.33;0.33;0.32;0.3;0.27;0.25;0.24;0.24;0.24;0.24;0.24;0.2;0.2;0.2;0.2","FABIO ANGELI;GIANPAOLO REBOLDI;PAOLO VERDECCHIA;ALESSIA SCATENA;ANTONIO VOLPE;BENEDETTA RAGGHIANTI;CARLOTTA GAUNA;CESARE MIRANDA;CORRADO BORDIERI;CRISTIANA VERMIGLI;FRANCESCO ROMEO;L. MONGE;LUIGI UCCIOLI;MATTEO MONAMI;RODOLFO TRAMONTA;ANNA MARINA LIBERATI;ANNARITA CONCONI;FRANCESCA MALLAMACI;UMBERTO VITOLO;AGOSTINO VIRDIS","13;13;13;10;10;10;10;10;10;10;10;10;10;10;10;9;9;9;9;8","PAOLO VERDECCHIA;CRISTIANA VERMIGLI;ELEONORA BIANCHINI;FRANCESCO GAGGIA;GIUSEPPE MURDOLO;ANNA MARINA LIBERATI;ELEONORA DISTRUTTI;GIULIO METRO;LUIGINA GRAZIOSI;MAURIZIO PACIARONI;NICOLA NATALIZI;ELEONORA GARIAZZO;FLAVIO FALCINELLI;ROCCO SCLAFANI;SILVIA COSTABILE;ANNA MARIA MOSCONI;DILETTA BARTOLINI;KETTY SAVINO;ROBERTA LA STARZA;TERESA ANNA CANTISANI","13;10;8;8;8;6;5;5;5;5;5;3;3;3;3;2;2;2;2;2","GIULIO METRO;ELEONORA GARIAZZO;PAOLO VERDECCHIA;ANNA MARIA MOSCONI;CRISTIANA VERMIGLI;ELEONORA DISTRUTTI;MAURIZIO PACIARONI;ROCCO SCLAFANI;ANNA MARINA LIBERATI;CARLO CAGINI;CARLO PALLOTTO;DANIELA FRUTTINI;DILETTA BARTOLINI;ELEONORA BIANCHINI;FLAVIO FALCINELLI;FRANCESCO DELLA LENA;FRANCESCO GAGGIA;GIACOMO ISERNIA;GIUSEPPE MURDOLO;KETTY SAVINO","8;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;PHYSICS;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY;GEOLOGY;BUSINESS;ECONOMICS;GEOGRAPHY;PHILOSOPHY;SOCIOLOGY","64;19;6;6;6;6;5;4;3;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;INTENSIVE CARE MEDICINE;CARDIOLOGY;IMMUNOLOGY;CANCER RESEARCH;RADIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;PHYSICAL THERAPY;LAW;MECHANICAL ENGINEERING;PALEONTOLOGY;PATHOLOGY;PHYSICAL MEDICINE AND REHABILITATION;PSYCHIATRY;STATISTICS;VIROLOGY","43;17;16;11;9;8;8;7;7;5;5;5;4;4;4;4;4;4;4;4","CANCER;DISEASE;GENE;CHEMOTHERAPY;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;CLINICAL TRIAL;MEDLINE;OBSERVATIONAL STUDY;POPULATION;ADVERSE EFFECT;ANTIBODY;BLOOD PRESSURE;HEART FAILURE;LYMPHOMA;OUTBREAK;PERCUTANEOUS;RECEPTOR;STROKE (ENGINE)","14;11;10;8;8;8;5;4;4;4;4;3;3;3;3;3;3;3;3;3","CLINICAL ENDPOINT;IMMUNOTHERAPY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INTRACEREBRAL HEMORRHAGE;OVARIAN CANCER;2019-20 CORONAVIRUS OUTBREAK;CHROMOSOME;CISPLATIN;DIABETIC FOOT;DIFFUSE LARGE B-CELL LYMPHOMA;EJECTION FRACTION;FIXATION (POPULATION GENETICS);HAEMATOPOIESIS;HAZARD RATIO;ISCHEMIC STROKE;MULTICENTER STUDY;MUTATION;PERCUTANEOUS CORONARY INTERVENTION;PROGENITOR CELL;PROGRESSION-FREE SURVIVAL","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);CARBOPLATIN;NIVOLUMAB;ANEUPLOIDY;BRCA MUTATION;CHEMOIMMUNOTHERAPY;CXCR4;DIABETES TREATMENT;DNA METHYLATION;DOUBLE NEGATIVE;ERLOTINIB;EZH2;FRACTIONAL FLOW RESERVE;GASTRIC BYPASS;GERMINAL CENTER;HEMATOPOIETIC STEM CELL;IDH1;INFLAMMATORY BOWEL DISEASES;INTRAOPERATIVE RADIOTHERAPY;INVERSE AGONIST;KARYOTYPE;LEUKEMIA INHIBITORY FACTOR;LYMPHOPOIESIS;MASTECTOMY;MISSENSE MUTATION;MODIFIED RANKIN SCALE;OPISTHORCHIS VIVERRINI;PEMETREXED;POLY ADP RIBOSE POLYMERASE;POMALIDOMIDE;PRAZIQUANTEL;PREMATURE RUPTURE OF MEMBRANES;PRENATAL DIAGNOSIS;PROGENITOR;RAR-RELATED ORPHAN RECEPTOR GAMMA;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SACUBITRIL;SACUBITRIL, VALSARTAN;STREPTOCOCCUS AGALACTIAE;TARGET LESION;THYMOCYTE;TRABECTEDIN;TRAMETINIB;VASO-OCCLUSIVE CRISIS;VEMURAFENIB","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;ADULT;AGED;MIDDLE AGED;AGED, 80 AND OVER;TREATMENT OUTCOME;CARCINOMA, NON-SMALL-CELL LUNG;ERBB RECEPTORS;LUNG NEOPLASMS;RETROSPECTIVE STUDIES;MUTATION;ANIMALS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;NEOPLASM RECURRENCE, LOCAL;PRACTICE GUIDELINES AS TOPIC;PROSPECTIVE STUDIES","44;25;11;10;9;9;9;7;6;5;5;5;5;4;3;3;3;3;3;3","ADVANCEMENTS IN LUNG CANCER RESEARCH;LYMPHOID NEOPLASMS;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GLOBAL IMPACT OF HELMINTH INFECTIONS AND CONTROL STRATEGIES;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;PREVENTION AND MANAGEMENT OF DIABETIC FOOT ULCERS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANTERIOR CRUCIATE LIGAMENT INJURIES IN ATHLETES;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CORONAVIRUS DISEASE 2019 RESEARCH;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;DIAGNOSIS AND MANAGEMENT OF CARPAL TUNNEL SYNDROME;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIFFUSION MAGNETIC RESONANCE IMAGING;EATING DISORDERS AND BODY IMAGE CONCERNS","7;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","NON-SMALL CELL LUNG CANCER;CLINICAL ENDPOINT;STROKE (ENGINE);TREATMENT;TREATMENT GUIDELINES;2019-20 CORONAVIRUS OUTBREAK;CARBOPLATIN;DELPHI METHOD;EGFR MUTATIONS;FOOT ULCERS;HYPERTENSION;IDENTIFICATION (BIOLOGY);INTRACRANIAL HYPOTENSION;INTRATUMOR HETEROGENEITY;LEFT VENTRICULAR FUNCTION;MYOCARDIAL REVASCULARIZATION;PROGRESSION-FREE SURVIVAL;SINGLE CENTER;ACUTE MYELOID LEUKEMIA;ACUTE PANCREATITIS","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","LUNG CANCER;CELL LUNG;NON-SMALL CELL;DIABETIC FOOT;INTRACEREBRAL HEMORRHAGE;OVARIAN CANCER;FOOT SYNDROME;FOOT ULCERS;ITALIAN GUIDELINES;MULTICENTRIC STUDY;NONSMALL CELL;SINGLE-CENTER STUDY;STAGE III;TRIGLYCERIDE-GLUCOSE INDEX;ACID SPHINGOMYELINASE;ACIDS SERVE;ACQUISITION PLAN;ACUTE MYELOID;ADULT OBESITY;ADULT PATIENTS;ADVANCED NONSMALL;ADVANCED OVARIAN;ADVANCED RET;ADVERSE LIMB;AGALACTIAE SWAB;AGE ESTIMATION;AIRO ITALIAN;ALK-POSITIVE NON-SMALL;ALL-CAUSE DEATH;ALLOWING MAINTENANCE","7;6;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BRAF VE;PHYSICAL ACTIVITY;INTENSIVE CARE;SPONTANEOUS VENTILATION;ARTERIAL HYPERTENSION;BILE ACIDS;CANCER NSCLC;LUNG CANCER;STAGE III;ARTICUNO STUDY;BONE MARROW;CARE UNIT;CLINICAL PRACTICE;CONDUCTION SYSTEM;CV MORTALITY;ESTATE COSTS;FEMOROPOPLITEAL TLR;HARBORING UEGFR;HYBRID PROCEDURES;INTRACEREBRAL HEMORRHAGE;MAJOR UEGFR;MAXILLOFACIAL SURGERY;MUT NSCLC;NSCLC HARBORING;PATIENTS TREATED;SURFACE ECG;VENTRICULAR LEAD;ABSTRACT INTRODUCTION;ACID SPHINGOMYELINASE;ADVANCED BRAF","8;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,4,226.67,2.7,0,0,62.67,0,0,1,0,1,0,0,1,0,2,1,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Switzerland;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","3;3;1;1","CANCER;CLINICAL RESEARCH;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;AGING;GENETICS;LUNG;LUNG CANCER;ORPHAN DRUG;STEM CELL RESEARCH;TRANSPLANTATION","3;3;3;2;2;2;1;1;1;1;1;1;1","CANCER","3","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","2;1","NON-HODGKIN'S LYMPHOMA;LUNG CANCER","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
